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RAD MODULATION OF THE L-TYPE CALCIUM CHANNEL CONFERS 
SYSTOLIC ADVANTAGE IN THE HEART 
 
 
Heart failure is a major public health problem and a leading cause of mortality. 
This clinical condition affects populations of all ages, and is the result of various 
cardiomyopathies.  Almost half of these patients suffer specifically from heart failure 
with reduced ejection fraction; these hearts have decreased performance due to a failure 
of the heart to contract with sufficient force to meet demand. While there are therapies 
available to increase contractility, none of these enhance contraction without also further 
promoting pathological signaling and remodeling. 
Under normal physiological conditions, the body elevates cardiac output through 
the fight-or-flight response. This response activates -adrenergic receptors (-AR) at the 
level of individual cardiomyocytes, which leads to enhanced calcium handling in order to 
increase contraction.  One of the major targets of -AR downstream signaling is the L-
type calcium channel (LTCC).  The influx of calcium through the LTCC (ICa,L) provides 
the trigger for calcium induced calcium release from the sarcoplasmic reticulum in order 
to produce a contraction; LTCC activity is significantly increased when -ARs are 
activated.  However, -ARs are chronically activated in heart failure, leading to 
pathological remodeling and further development of heart failure. This has served as a 
foundation to establish dogma that increasing ICa,L in a manner that reflects -AR 
activation necessarily promotes pathology. Because -AR signaling is a principle 
physiological mechanism to increase cardiac output, understanding this pathway and how 
to increase calcium safely is critical to successfully treating heart failure.  Discovering a 
mechanism to increase cardiac output downstream of -AR signaling would be ideal so 
as to preserve the fight-or-flight response while also boosting cardiac performance in 
order to meet demand. 
The mechanism by which LTCC activity is increased under -AR signaling, 
known as modulation, has been a major focus of study for many years; however, it 
remains unknown.  The LTCC is a heteromultimeric protein complex, and is inhibited by 
an endogenous small monomeric GTPase called Rad. Studies in heterologous expression 
systems show overexpression of Rad blocks calcium current through the LTCC; absence 
of Rad yields a significant increase in calcium current. Whole-body Rad knock out mouse 
models demonstrate calcium current that mirrors calcium current stimulated by -AR 
signaling; however, this also promoted significant growth of the heart. To investigate the 
effect of Rad deletion without contributions from non-cardiac tissue, a cardiomyocyte-
restricted inducible Rad knock out mouse model was created. The work of this 
     
 
dissertation utilizes this mouse to better understand the mechanism by which Rad inhibits 
the LTCC by studying the effects on channel function, cellular calcium handling, and 
overall cardiac structure and function in the absence of Rad. 
Using an array of methods and techniques, the studies in this dissertation establish 
Rad as a critical target of the LTCC to respond to -AR stimulation.  When Rad is 
depleted specifically from cardiomyocytes, ICa,L is increased in a safe, stable manner that 
mirrors LTCC modulation, both in sinoatrial node and in the ventricle.  This regulation is 
governed specifically by the C-terminus of Rad.  Elevated ICa,L in the absence of Rad 
promotes enhanced calcium handling and increased cardiac output without progression to 
heart failure, and occurs independently of  -AR activation.  Enhanced calcium cycling in 
the absence of Rad is balanced by accelerated inactivation of the LTCC so as to promote 
positive inotropy without instigating arrhythmogenesis.  This allows for cardiac 
protection under conditions of pressure-overload induced heart failure.  In summary, the 
work of this dissertation supports Rad deletion specifically from cardiomyocytes as an 
ideal positive inotrope for heart failure treatment due to the novel mechanism to increase 
ICa,L in a manner that preserves structure, function, and the fight-or-flight response within 
the heart. 
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CHAPTER 1.  INTRODUCTION 
1.1 Significance 
The incidence of heart failure (HF) is steadily increasing, with projections putting 
heart failure as the leading cause of mortality and morbidity in developed countries by the 
year 2030 [1, 2]. Many cardiovascular disorders, including atherosclerosis, 
cardiomyopathy, and hypertension, result in the development of HF. Of these patients, 
~45% suffer from HF with reduced ejection fraction (HFrEF).  HFrEF results in a 
decrease in cardiac performance due to a failure of the heart to contract with sufficient 
force to meet demand; this is soon followed by problems in other organ systems, such as 
neurohormonal, circulatory, and renal systems [3, 4]. Current therapies are limited to 
increasing survival and reducing symptoms, but are accompanied by side effects and 
ultimately fail to increase systolic function or inhibit HF progression [3-5].  
Cardiac contractility is governed by calcium cycling within individual 
cardiomyocytes.  During a cardiac action potential, calcium enters the cell via voltage-
gated calcium channels, specifically L-type calcium channels (LTCC).  This calcium 
triggers calcium release from the sarcoplasmic reticulum (SR), raising cytosolic calcium 
concentration ~ten-fold to activate muscle contraction. Upon relaxation, calcium is either 
taken back up into the SR via SERCA2a (Sarco/endoplasmic reticulum calcium ATPase) 
or extruded from the cell via the Na+/Ca2+ exchanger (NCX) [3, 4, 6]. In HF, calcium 
transients are depressed, resulting in decreased contractile function,[6, 7].  Logically, it 
would follow that a treatment for HF would therefore be to increase calcium within the 




cardiac contractility by increasing sympathetic drive and activating the -adrenergic 
receptor (-AR) signaling cascade.  However, chronic stimulation of this cascade triggers 
pathological remodeling of the heart, thereby promoting the development of HF ([4, 6, 8, 
9]. Studies focusing on the utilization of positive inotropes have proven to be acutely 
effective, but chronically induce further damage on the heart by initiating hypertrophic 
signaling and triggering arrhythmias [5-7, 9, 10]. It has therefore become dogma that 
increasing calcium within a cardiomyocyte directly causes pathology and ultimately 
results in HF. 
Many studies have focused on the SR, [3-5, 7] the pathways associated with -AR 
signaling [8, 11], or certain components of the LTCC complex [12-15] as potential 
therapeutic targets for HF; unfortunately, they have yet to find a target that increases 
contraction without instigating more pathology as a side effect.  A recent new potential 
therapeutic target that has emerged is Rad, a small monomeric GTPase that serves as an 
endogenous inhibitor to the LTCC [16-24].  The studies of this dissertation focus 
primarily on the mechanism by which the absence of Rad confers systolic advantage on 
the heart independently of -AR signaling, thereby preserving the cardiac response to 
autonomic input without pathological structural remodeling. 
-AR stimulation is the principle physiological mechanism whereby contractility 
and cardiac output is increased; the guiding principle for treating heart failure, and this 
dissertation, is that enhancing systolic function exclusive of adrenergic activation is safe 




1.2 L-Type Calcium Channels 
1.2.1 Voltage Gated Calcium Channels 
Voltage-gated calcium channels (VGCC) are found in all excitable cells; these 
channels support longer depolarizing responses because they can maintain inward 
current, and also are the only link between non-electrical components and excitation [25, 
26].  Calcium entering via VGCCs serves as an elemental secondary messenger that 
initiates numerous intracellular events, including contraction [25, 27-31]. Signal 
transduction via VGCCs differs depending on cell type, thereby requiring different 
molecular subtypes of channels to have unique physiological, pharmacological and 
regulatory properties [25, 28]. VGCCs were first differentiated based on activation 
threshold, classified as either low-voltage-activated (LVA) or high-voltage-activated 
(HVA) [25, 28, 29].  Calcium channels are also large heteromeric proteins and are 
categorized based on structure of the complex [29].  The first purified calcium channel 
was isolated from skeletal muscle and comprised of five components: 1 (170 kDa), 2 
(150 kDa),  (52 kDa),  (17-25 kDa), and  (32 kDa) in an approximately stoichiometric 
ratio (Figure 1.1A; [28-30].  This complex was also termed the dihydropyridine receptor 
for its sensitivity to 1,4-dihydropyridines (DHPs); because 1 was identified as the 
subunit of the complex that bound DHPs, it was established that it was the pore-forming 
subunit [29]. As of now, there are 10 different 1 subunits that have been discovered and 
all exhibit distinct functions (Figure 1.1B,C).  These include L-type, P/Q-type, N-type, 
R-type, and T-type calcium channels [25, 28, 29]. HVA channels that were sensitive to 
DHPs were identified as ‘long-lasting’ or L-type channels because of slow voltage 




28]; these channels form the CaV1 family  [25, 28, 29, 32, 33]. CaV1.1 expression is 
restricted to skeletal muscle, while CaV1.4 expression is restricted to the retina [29]. 
CaV1.2 and CaV1.3 are found in many different excitable cell types with both often 
expressed in the same cell [29], such as adrenal chromaffin cells, neurons, and sinoatrial 
and atrial cardiomyocytes [29].  The remainder of this chapter will focus primarily on 
CaV1.2 and its role in cardiac function.  
1.2.2 Structure of the L-type Calcium Channel 
1.2.2.1 The pore-forming subunit: 1C 
The 1 subunit that comprises CaV1.2 is encoded by the gene cacna1c [34]. The 
1 subunit is approximately 2000 amino acid residues and is organized into four repeated 
domains (I-IV) that each contain six transmembrane segments (S1-S6) and a membrane-
associated loop between transmembrane segments S5 and S6 (Figure 1.2; [29, 35]. The 
domains are connected by intracellular loops linking domain I-II, domain II-III, and 
domain III-IV [36], and end in NH2- and COOH-terminal intracellular segments [34]. In 
each domain, S1-S4 segments form a voltage-sensing domain [37], with S4 being the 
primary ‘voltage sensor’ for activation [25, 28, 29]. In every third position within the 
helix of the S4 are positively charged Arg or Lys that sense depolarization of the 
membrane [37].  Changes in the electric field of the membrane cause the S4 segment to 
rotate outwards, thereby changing the conformation of the channel to open the pore [25, 
28]. The S5 and S6 segments and the associated loop form the pore lining of the channels 
[25, 28, 29, 38]. The external portion contains a pair of glutamate residues within the 




inner pore is formed by the S6 segments and contains the receptor sites for antagonist, 
pore-blocking drugs specific for L-type calcium channels [25, 28, 29, 38]. Though a 
structural model of the CaV1.2 pore has been suggested [39], a detailed three-dimensional 
structure of calcium channels is not known [25, 28]. For clarity and consistency, the 
remainder of the dissertation will refer to CaV1.2 simply as LTCC (L-type calcium 
channel). 
1.2.2.2 CaV subunit 
A requirement for normal LTCC function is the auxiliary CaVβ subunit [40]. 
There are four distinct genes that encode four subfamilies of CaVβ (β1-β4), each of which 
regulate LTCC differently [29, 40]. Each consist of a core region, composed of two 
highly conserved regions homologous to the SRC homology 3 (SH3) and guanylate 
kinase (GK) domains; these are joined together by the HOOK region [25, 40].  CaVβ 
binds to the 1 subunit in a 1:1 stoichiometric fashion with high affinity to a single site 
within the α-interaction domain (AID), the first half of the cytoplasmic linker connecting 
domains I and II of the 1 subunit (Figure 1.2; [25, 28, 40, 41]. The AID forms an α-
helix that binds tightly to a groove within the GK domain of CaVβ, and is critical for 
CaVβ regulation of calcium channels [25, 40].  The GK domain of CaVβ also contains the 
interaction sites for other proteins that regulate channel function, such as RGK GTPases 
[20, 40]. The interaction between CaVβ and LTCC is crucial for normal channel function, 
and modulates channel activity [25, 28, 40, 41], which will be further discussed in the 
next section. 




The LTCC complex also contains the α2δ subunit (Figure 1.1A).  α2 and δ are 
produced from a single gene and proteolytically cleaved to form separate proteins but still 
attached via a disulfide bond [25, 29, 40, 42]. There are also four distinct genes that 
encode α2δ (α2δ1-4), that correspond to specific tissues, with α2δ1 highly expressed in 
skeletal muscle [42, 43].  The δ peptide of the subunit anchors the subunit to the 
extracellular membrane via a glycosylphosphatidylinositol linker [41, 42]. The main 
function of α2δ is to increase calcium channel expression and retention within the 
membrane, and contributes minorly to channel gating properties [25, 28, 29, 40, 42].  
1.2.2.4  subunit 
The  subunit of LTCC complex is a glycoprotein that has four transmembrane 
segments and intracellular amino and carboxy termini (Figure 1.1A) [25, 28, 41]. There 
are eight different genes that encode  subunits that all have diverse functions, depending 
on the tissue in which they are expressed, though the function of each subunit is not fully 
known [41]. Of these eight genes, only CaV1 and CaV6 are considered to be a subunit of 
voltage-gated calcium channels [34]. In regards to calcium channel function,  subunits 
primarily contribute to voltage dependence of activation and inactivation in a small but 
significant manner [25, 28, 41, 44]. Although CaV1 was found in skeletal muscle, it 
appears there are no CaV subunits expressed in the heart [13]. 
1.2.2.5 Calmodulin 
A critical protein that associates with the LTCC complex is a ubiquitous calcium-




terminus of the 1 subunit within the EF hand, pre-IQ, and IQ regions and serves as a key 
regulator of channel function and targeting LTCC to the cell surface (Figure 1.2; [45-47].  
For every channel, there is one CaM molecule in association [48, 49]. Each molecule of 
CaM is composed of two lobes, each made of two EF hands [49].  The N-terminal lobe 
acts as a ‘global’ calcium sensor for the channel, sensing an elevation of calcium within 
the couplon or junction; the C-terminal lobe acts as a ‘local’ calcium sensor, triggering 
regulatory signaling of the channel based on calcium flowing through individual channels 
[49]. Specific interactions within the IQ domain and the two lobes cause different 
calcium-dependent regulatory processes to occur within the channel [46], which will be 
discussed in the next section.      
1.2.3 Function of the L-type Calcium Channel 
1.2.3.1 Excitation Contraction Coupling 
Calcium is a critical intracellular second messenger that initiates multiple signaling 
pathways within the cell [5, 6].  In a cardiomyocyte, the membrane is depolarized in 
response to an action potential and LTCCs open to provide an influx of calcium needed for 
excitation contraction coupling [6].  LTCCs also maintain membrane depolarization during 
the plateau phase of the cardiac action potential [44]. Because alterations in calcium influx 
affect action potential duration and refractory period duration, the LTCC contributes to 
electrical balance that allows contraction and relaxation of the myocardium [44, 50].      
LTCCs are expressed within the transverse tubules of the membrane in close 
proximity (~12-20 nm) to ryanodine receptors (RyR2) so that the calcium influx from the 




(SR) [6, 45].  This provides the necessary elevation in cytosolic calcium to activate 
myofilaments and generate contractile activity [6, 51]. At the junction between plasma 
membrane and the sarcoplasmic reticulum, ~25 LTCCs and ~100 individual RyR2 form a 
unit known as the couplon [51].  Couplons are spaced between 1-2 µm away from each 
other so that neighboring couplons can activate calcium release synchronously and provide 
a unified contraction within the entire cardiomyocyte [6, 51].  
There is also a subset of LTCCs that are expressed within the caveolae of 
ventricular myocytes, a type of lipid raft that create small invaginations within the plasma 
membrane and characterized by the expression of caveolin-3 [45]. The fraction of LTCCs 
found in the caveolae range depending on species, but it is estimated that in mice, ~50% of 
LTCCs are found in the caveolae; the mechanisms by which LTCCs are sorted either to 
transverse tubules versus caveolae remain unknown [45].  It is unclear whether LTCCS 
that exist in the caveolae contribute to excitation contraction coupling within the entire 
cardiomyocyte, or rather in a more localized fashion [45].  However, studies have shown 
these channels play a critical role in NFAT signaling and β2-adrenergic signaling [52, 53]. 
Because cardiac LTCCs are expressed in multiple microdomains within the plasma 
membrane and play a major role in critical signaling pathways within the cardiomyocyte, 
channel activity is tightly regulated to prevent cellular and cardiac dysfunction [45].  
1.2.3.2 Activation of the L-type Calcium Channel 
The activation of a channel occurs via charge movement in four domains, with a resulting 
‘concerted’ step of opening the pore [54]. Modifications in activation could occur due to 




activate once the membrane has depolarized to about -30 mV [46].  Gating charge 
movement is governed by the S4 segments within each domain, though the specific 
segment contributions is unclear. One study suggests S4 from domain I and domain III 
determine the voltage dependence of channel opening and channel closing, while all four 
voltage sensors contribute to stabilizing the channel in an open state [55]; a different study 
observed that S4 segments from domain II and III played a major role in activation, while 
domain I only played a minor role [37].  The cooperative step of opening the pore results 
from the interaction between the S4 segments in domain I, II, and III with the S6 segment 
in all four domains [55]. The specific S6 segments that contribute to activation of the LTCC 
still remain undetermined, though studies suggest the binding of CaVβ to the AID induces 
a conformational change between the S6 of domain I and the linker between domain I and 
II that contributes to activation [34, 56]. CaVβ causes a hyperpolarized shift in voltage 
dependence of activation, ~10-15 mV, accelerates activation, and increases the open 
probability of the channel when present in the complex  [40, 41].  
An emerging hypothesis is that individual LTCCs can activate additional channels 
in close proximity through physical tethers between their C-terminal tails [57-59].  When 
multiple channels are adjoined, the resulting clusters coordinate activity to open 
synchronously to provide a larger calcium influx, thereby causing a larger calcium release 
from the SR [57, 58]. The clustering is dictated by calcium complexing with CaM [58]. 
When one channel opens during an action potential, the resulting calcium sparklet1 induces 
binding between calcium and CaM; this promotes the physical interaction between the C-
 





termini of the open channel and a neighboring LTCCs [57, 58].  As more channels 
physically interact as more calcium flows in, clusters form; once individual channels begin 
to inactivate, coupled channels begin to disassemble and activity decreases [58].  Some 
channels remain clustered, forming a ‘molecular memory’ and instant increases in calcium 
influx upon subsequent action potentials [58]. This mechanism of cooperativity is 
hypothesized to be a way that LTCCs are regulated, either during β-adrenergic receptor 
stimulation or during facilitation [58, 59].  These regulatory processes will be discussed 
later. 
1.2.3.3 Inactivation of the L-type Calcium Channel 
Inactivation of the LTCC is a key regulatory mechanism to concomitantly control 
action potential plateau duration and levels of intracellular calcium [46].  During 
depolarization, calcium current (ICa,L) decays in a non-exponential fashion but is divided 
into two components; investigators have described this complex process by fitting a double 
exponential function to the data [34, 60]. These studies have yielded a fast component and 
a slow component with time constants of 10 ms and 90 ms, respectively [34, 50, 60-63]. 
ICa,L decay occurs by two distinct processes: calcium dependent inactivation (CDI) and 
voltage dependent inactivation (VDI) [64, 65].  
CDI is hypothesized to dominate the early, fast component of ICa,L [60, 66]. Calcium 
induced inactivation was first proposed by Eckert and Tillotson; their experiments 
illustrated that the depression of calcium currents seemed to be based on a calcium 
dependent mechanism [67]. It is now known that this is dictated by calcium directly 




conformational change to induce rapid inactivation [45, 48, 49, 68-72].  For LTCC, the C-
lobe of CaM is responsible for the rapid phase of CDI [45, 48, 49, 68-72]; the N-lobe of 
CaM contributes minimally to CDI [72]. CaM binds to the IQ motif on the C-terminus of 
LTCC α1C, specifically amino acids 1624-1635; disruption of this region abolished CDI 
[34, 49, 72].  Amino acid 1624 of this region is isoleucine, and is required for CaM binding; 
studies in heterologous expression systems demonstrated that the mutation I1624A 
decreased the affinity of CaM binding and abrogated CDI [34, 49]. Two other elements 
that are essential for CDI are CaVβ and a rigid IS6-AID linker; mutations that disrupted the 
α-helix of IS6-AID linker or that disrupted CaVβ binding to CaVα1 both drastically slowed 
CDI [41, 73].  The source of calcium to induce CDI can be from the sarcoplasmic reticulum 
(SR) or from entry through the LTCC [45, 48, 49, 66, 68-72]. Calcium released from the 
SR is thought to control CDI in the initial phase of the action potential, and calcium 
entering through the channel is suggested to control CDI in the remainder of the action 
potential [66].  
It is generally accepted that the late, slow component of ICa,L decay is dominated 
by VDI [60, 66]; however, some studies claim that VDI contributes to both components 
but is dampened when calcium influx increases [60, 74-76]. Early studies demonstrated 
that inactivation of the LTCC occurred independent of ion permeation, and displayed a 
monotonic dependency on membrane potential [77-79]. Many of these experiments used 
barium as the charge carrier in order to isolate inactivation dependent on calcium [34, 77] 
[78, 79]. The mechanism by which VDI occurs remains controversial. Key players 
involved in the mechanism include: the S4 segments of α1, the cytosolic ends of the S6 




AID of LTCC, and CaVβ [34, 55, 67, 80]. One hypothesis has been that all four S4 segments 
contribute to a global conformational change to induce inactivation, though specific roles 
of each segment remain unknown [55] [80]. Other studies have suggested that the 
interaction between CaVβ and the AID modifies VDI and CDI through a conformational 
change between the S6 of domain I and the linker between domain I and II so that the linker 
occludes the channel pore; indeed, the presence of CaVβ in the complex shifts voltage 
dependence of inactivation more negative and increases the rate of inactivation, though this 
is dependent on isoform [25, 28, 34, 40, 41]. Depending on which isoform of CaVβ is part 
of the complex, the different isoforms of the  subunit also induce a hyperpolarizing shift 
in VDI [41]. A recent study argued that the linker between domain I and II does not occlude 
the pore; rather inactivation is based on a displacement of the AID and the S6 of domain I 
towards the pore axis, initiating closure [67].  Though much is known about the major 
contributors to VDI and CDI, the molecular mechanisms by which LTCC inactivation is 
governed remains elusive.  
1.2.3.4 L-type Calcium Channel Regulation by Facilitation 
Changes in the stimulation frequency can regulate LTCC activity that either 
decreases or increases macroscopic calcium current through a mechanism known as 
facilitation [81-87]. This mechanism is critical to cardiac function because it regulates 
calcium influx at fast heart rates [34, 88]. Early studies demonstrated that in response to 
repetitive channel activation or a strong pre-pulse to positive potentials resulted in an 
increase in ICa,L amplitude [85, 86].   The conclusion was this was governed in a voltage-




calcium was replaced with barium [87]. Facilitation was also blocked by BAPTA, a fast 
calcium chelator, but was unaffected by EGTA, a slower calcium buffer, which indicated 
that the mechanism of facilitation is calcium-dependent and localized to the calcium 
channel [34, 82, 84]. It was then established that facilitation was mediated by CaM and 
CaMKII (Calmodulin Kinase II) [34, 81, 82, 84]. Recent studies have shown that inhibiting 
CaM or CaMKII results in blocking CDF; CaMKIIδ-knock out mouse displayed reduced 
CDF [34, 88].  It is known that the IQ motif is required for CDF to occur [89]. The proposed 
phosphorylation sites for CaMKII on the α1 subunit are S1512 and S1570, though alanine 
mutations of these sites do not completely abolish CDF [90]. T500 on CaVβ is also a 
phosphorylation site for CaMKII, but deletion of this site did not affect CDF at all [91]. It 
has also been suggested that CDF is dependent on channel clustering [58].  When channels 
couple together to form a cluster, the entire population of channels within the cluster 
activate together to amplify influx during high-frequency stimulation, thereby potentially 
demonstrating a CaMKII-independent mechanism of facilitation [58]. While much is 
known about this regulatory process, the molecular mechanisms by which the LTCC is 
facilitated remains elusive.  
1.2.3.5  Modulation of the L-type Calcium Channel 
During the fight-or-flight response, LTCC activity is enhanced by β-adrenergic 
receptor (β-AR) stimulation to increase contractility [25, 28, 92-95]. This form of 
regulation has been defined as LTCC modulation and is the most thoroughly studied LTCC 
regulatory mechanism [25, 28]. Voltage-clamp experiments first described that addition of 




that translated to increased plateau height and duration of the action potential [94, 95]. 
Later studies demonstrated these effects were mediated by cAMP and of cAMP-dependent 
protein kinase; direct injection of cAMP or the catalytic subunit of cAMP-dependent 
protein kinase yielded ICa identical to ICa treated with adrenaline or norepinephrine [94, 96-
100]. While cAMP can be increased due to activation of multiple receptors, LTCC 
modulation occurs specifically through the signaling downstream of β-AR stimulation 
[101].  cAMP localized to the t-tubule and caveole compartments of the cardiomyocyte has 
been shown to be the critical microdomain for β-AR stimulation, compared to cAMP in 
the cytosolic compartments [101, 102]. It has now known that the pathway includes the 
following cascade: β-AR stimulation, activation of adenylyl cyclase, increase in cAMP, 
activation of PKA and phosphorylation of the LTCC [103]. Upon activation of β-ARs, ICa,L 
increases significantly, voltage dependent activation is shifted to hyperpolarized potentials, 
and CDI is enhanced; the overall result is a gain of LTCC function [103]. 
Studies in Chinese hamster ovary cells first revealed that modulation of the LTCC 
required the activation of the cAMP-dependent protein kinase A (PKA;  [28, 104, 105]. 
Phosphorylation of LTCC by PKA results in a two- to four-fold increase in ICa,L in the cell, 
and was long thought to be the main mechanism of LTCC modulation [28, 31, 106-109].  
Ser1928, Ser1700, and Thr1704 on α1C and Ser459, Ser478, and Ser479 on CaVβ were all 
eligible to be the critical site or sites needed for LTCC modulation; however, single 
mutations of each site did not eliminate LTCC modulation [91, 110, 111]. When all of the 
serines and threonines were mutated at the same time in vivo, treatment with isoproterenol 




substitutions at Ser1700 and Thr1704 in transgenic mice markedly decreased basal and 
modulated ICa,L [107, 108, 113].  
LTCCs can undergo proteolytic cleavage at the distal C-terminus (dCT), resulting 
in increased channel activity [114]. The C-terminus of LTCC contains Ser1928, suggesting 
that the dCT was the major substrate of PKA-mediated regulation [114].  Expressing a 
truncated channel and the dCT in non-muscle cells demonstrated that the dCT is still bound 
to the channel non-covalently and serves as an auto-inhibitor to the channel [114].  Within 
the C-terminus of the LTCC lies a modified-leucine zipper that interacts with A-kinase 
anchoring protein-15 (AKAP15), a scaffolding protein that anchors PKA to the LTCC [31, 
108].  The interaction between the dCT, AKAP15, and PKA is essential for modulation; 
disruption of the interaction ablates LTCC response to activation of cAMP via forskolin 
[108, 114, 115]. In the absence of dCT, the effects of modulation by PKA were more 
prominent [116].  However, disruption of the substrate recognition site within the C-
terminus for proteolytic cleave by calpain-like proteases did not affect LTCC modulation 
[112].  The importance of phosphorylation of the LTCC in regards to modulation remains 
inconclusive due to inconsistent results from both cell lines and animal models; this 
suggests that modulation may require key protein-protein interactions in order to enhance 
LTCC activity [31, 109]. 
CaVβ has been shown to be a critical component of modulation for the LTCC [31, 
40, 41, 109]. It was originally thought that the main role of CaVβ was to traffic channels to 
the membrane and modulated LTCC activity through phosphorylation [25, 28, 40, 41, 91]. 
However, disruption of the phosphorylation sites did not affect modulation [91].  A study 




demonstrated that the AID-CaVβ interaction was essential for modulation, not trafficking; 
without CaVβ, channels did not respond to β-adrenergic stimulation [117]. When flexibility 
is introduced to the domain I-II linker that connects the AID to the pore, current parallels 
channels that cannot bind CaVβ, further suggesting that the coupling between CaVβ and the 
AID is crucial for modulation [118]. CaVβ also tightly binds to a 700 kDa protein termed 
“ahnak” [103, 119].  When bound to CaVβ, Ahnak represses ICa,L; repression is relieved by 
PKA phosphorylation [103, 119]. However, transgenic mice that were Ahnak-deficient 
showed intact β-AR responsiveness, demonstrating Ahnak is not critical to LTCC 
modulation [120]. CaVβ also bind to RGK proteins, which serve as endogenous inhibitors 
of the LTCC and potential targets of PKA phosphorylation [17, 103].  This will be further 
discussed in the next section, as well as explored through the studies described in this 
dissertation.    
Another proposed mechanism of LTCC modulation is channel clustering [31, 59]. 
Functional channels that reside in the transverse tubules of a cardiomyocyte can form 
clusters to enhance calcium influx [58, 59]. In response to β-AR stimulation, cAMP levels 
increase in the transverse tubule microdomain, and channels cluster together to form 
‘super-clusters’ that have enhanced physical interactions between LTCC C-termini and 
amplification of calcium influx to the level of modulated channels [59].  This could be due 
to a ‘reserve’ population of channels that could be mobilized specifically in response to β-
AR stimulation to form the ‘super-clusters’ and enhance ICa,L [59]. However, clustering 
does not necessarily explain the hyperpolarized shift in activation seen in modulated 
LTCCs.  It is also unclear which element within the complex response to PKA 




between CaM on neighboring LTCCs [59].  Therefore, clustering may be a supportive 
component to enhanced ICa,L, it does not appear to be the underlying mechanism for 
modulation. Though many studies have focused on β-AR stimulation and its regulation of 
the LTCC, a conclusive mechanism for modulation remains undetermined [31]. 
1.2.4 Role of the L-type Calcium Channel in Cardiac Pathophysiology 
 
Because of the central role that LTCC and ICa,L plays in normal cardiac function, 
disruption of either structure or function of the LTCC contributes to electrical and 
mechanical dysfunction within the cardiomyocyte [45].  Alterations in channel function 
contribute to numerous cardiovascular diseases; understanding how the LTCC is modified 
in various pathological states will potentially uncover new therapeutic targets and agents 
to treat these diseases [121].  
1.2.4.1 Arrhythmias 
Cardiac arrhythmias are generally categorized into two major groups: 
enhanced/abnormal impulse generation (also known as focal activity) and conductance 
disturbances (also known as reentry) [122, 123]. Enhanced focal activity promotes the 
spontaneous generation of action potentials, due to disease conditions, such as in heart 
failure (HF), that cause the membrane to rest at more depolarized potentials [122].  The 
most common causes of enhanced focal activity are: early afterdepolarizations (EADs) that 
occur before full repolarization of the action potential and delayed afterdepolarizations 
(DADs) that occur after full repolarization [122]. Reentry occurs when a group of cells or 




activate while the rest of the tissue is in the refractory period, creating reciprocating 
tachycardia [123]. Arrhythmias can also occur due to mutations within calcium-handling 
proteins that cause dysfunctional calcium channels, transports, or related proteins [122]. In 
this section, arrhythmias specifically associate with the LTCC will be discussed.  
1.2.4.2 Early After Depolarizations 
EADs instigate local focal activity by depolarizing neighboring tissue that then 
promotes ventricular tachyarrhythmias associated with HF and long QT syndrome (LQTS) 
[122, 123]. These events typically occur during bradycardia under conditions of reduced 
repolarization reserve, either due to significantly decreased outward current or enhanced 
inward currents [61, 63, 122, 123].  One major contributor to EAD production is 
reactivation of the LTCC during phase 2 or phase 3 of the action potential, leading to 
excessive prolongation of the action potential [122]. Other ionic currents contribute to EAD 
formation, but inward current such as ICa,L is required for EADs to propagate [63].  LTCCs 
can reactivate when steady-state activation and inactivation overlap, known as the window 
current, between -40 and 0 mV [62, 63, 124, 125].  In many cardiac pathological conditions 
that are at high risk for ventricular tachycardia or ventricular fibrillation (ex. activation of 
CaMKII, Timothy Syndrome, Long QT Syndrome), the rate of ICa,L inactivation can be 
slowed significantly, thereby generating an increase in late inward depolarizing current 
[61-63]. This creates a pool of LTCCs that never inactivate [61-63]. Three possibilities to 
treat EADs include: 1) shift ICa,L steady-state activation in the depolarizing direction by < 
5 mV; 2) shifting steady-state inactivation in the hyperpolarzing direction by <5 mV; or 3) 




of ICa,L to reduce window current without reducing peak ICa,L; this is a major downfall to 
traditional treatments like verapamil or nifedipine [62]. Indeed, reducing peak ICa,L is not 
needed to suppress EAD formation, but rather only decreasing the late, arrhythomogenic 
component of ICa,L [62, 63]. This way, excitation contraction coupling and overall 
contractility is unaffected.  One drug of promise that seems to decrease the late ICa,L without 
affecting peak ICa,L is roscovitine, cyclin-dependent kinase inhibitor that is part of a new 
class of drug known as ‘gate modifiers’ [62, 63, 126-130]. 
1.2.4.3 Timothy Syndrome 
Genetic mutations in the C-terminus of LTCC, either G402S or G406R, revealed a 
novel arrhythmia syndrome that was termed Timothy Syndrome (TS; [131, 132]. Because 
LTCC is expressed in multiple tissues, this syndrome disrupts multiple organ systems [131, 
132].  In the original 1992 study, children affected by the mutation displayed varying 
severity in symptoms, such as 60% of patients had autism, 50% had cavities in their teeth, 
and 36% suffered from hypoglycemia [131].  However, 100% of patients had QT 
prolongation, 71% had ventricular tachyarrhythmia and 94% had bradycardia; arrhythmias 
were the deadliest for these children, with 12 of 17 children dying due to arrhythmic 
episodes [131]. The mutations in the channel causes almost complete loss of inactivation, 
thereby delaying repolarization of the action potential, prolonging QT interval, and 
increasing the risk of spontaneous, abnormal secondary depolarizations, arrhythmias and 
sudden death [131-133].   A single mutation of G406R induces the classical TS by 
disrupting voltage dependent inactivation [121]. When both mutations are present, TS is 




disrupting calcium-dependent inactivation, with G406R causing more serious disruption 
[134]. Therapies available include: i) verapamil, a calcium channel blocker, decreases the 
number of ventricular fibrillation episodes but does not shorten QT interval and is not 
handled well by many TS patients [126, 135]; ii) mexiletine is a class IB antiarrhythmic 
drug used to shorten QT interval, but does not demonstrate any significant effect on LTCC 
[126, 136]; iii) Nifedipine, a dihydropyridine calcium channel antagonist, normalized VDI 
kinetics, but can alter calcium transients that could affect activation of the slow-activating 
potassium current [63, 126, 127, 137, 138]; iv) Roscovitine is a cyclin-dependent kinase 
inhibitor that dampens ICa,L amplitude, slows activation, enhances inactivation, and 
normalizes the calcium influx during an action potential, but has been found to block 
voltage-gated potassium channels, including HERG [126-130]. Though the underlying 
mechanism of TS still remains unknown, much has been discovered about the role of 
calcium channel function in regards to other cardiac pathology, such as Long QT 
syndrome; this has provided new technologies and avenues for potential therapeutics that 
not only applies to TS but also arrhythmias in general [126].  
1.2.4.4 Brugada Syndrome 
Brugada Syndrome is characterized by elevation of the ST segment of the ECG, 
followed by a negative T wave [139, 140]. While this syndrome is typically associated with 
mutations within the NaV1.5 complex, Brugada Syndrome 3 and 4 are caused by mutations 
in α1C (A39V, G490R, E1115K, R1880Q, V2014I, D2130N, E1829_Q1833, C1873Y, and 
E850del), CaVβ (S481L), and α2δ (S709N, D550Y, Q917H) of the LTCC, respectively  




display shortened QT intervals in addition to elevation of ST and a negative T wave [141]. 
This is because all of these mutations result in a significant decrease in ICa,L [141, 142]. For 
A39V, current was decreased due to dysfunctional channel trafficking to the membrane; 
G490R displayed normal trafficking so may affect open probability of the channels within 
the membrane [141].  E1115K reduced single channel conductance without changing 
gating [142, 143].  V2014I dampened peak current density and shifted half-inactivation 
voltage to more negative potentials [142].  E1829_Q1833 yielded almost complete 
suppression of ICa,L [142, 143]. For CaVβ, S481L is located near the binding domain for 
CaVβ- α1C, thereby potentially interfering with that association in order to lead to a decrease 
in ICa,L [142]. The changes in calcium channel surface expression or activity remain 
unknown for mutations in the α2δ subunit [142, 143]. Available treatments for Brugada 
Syndrome include implantable cardioverter-defibrillators and ventricular fibrillation 
suppression drugs, such as quinidine, denopamine, or cilostazol, and ventricular ablation; 
however, the multiple side effects that accompany any form of treatment demonstrate the 
need for refined treatment [144].  
1.2.4.5  Heart Failure 
Heart failure (HF) is a leading cause of mortality, and is defined as any abnormality 
in cardiac structure or function that results in the failure of the heart to meet the metabolic 
demands of the body [1, 2, 5, 122]. Heart failure with reduced ejection fraction, or systolic 
heart failure, is caused by reduced contractility due to alterations in cellular calcium 
handling [5, 122, 145]. ICa,L remains unchanged or decreases in HF, potentially due to 




HF through two key mechanisms: cardiac hypertrophy and chronic -AR stimulation [5, 
45, 52, 145-147].  
 Cardiac Hypertrophy 
Increases in calcium influx under pathological conditions trigger activation of 
pathological hypertrophy and HF [52, 145-147]. Intracellular calcium binding to CaM 
activates calcineurin, a serine-threonine protein phosphatase that mediates nuclear factor 
of activated T cells (NFAT) and myocyte enhancer factor 2 (MEF2) [146, 147].  
Dephosphorylation of NFAT and MEF2 by calcineurin causes activation of transcription 
of hypertrophic response genes [146]. The source of calcium to activate calcineurin is 
thought to be the LTCC [52, 145, 148].  Early studies first hypothesized this when 
overexpression of either LTCC or CaV resulted in significant cardiac hypertrophy and 
heart failure in a range of a few weeks to a few months [12, 146, 149]. Indeed, calcium 
channel antagonists prevented cardiac hypertrophy [146, 150, 151]. It was therefore 
hypothesized that the LTCC provided the ‘hypertrophic’ calcium necessary to induce 
hypertrophy [146, 148].  It was then discovered that LTCCs that reside specifically in the 
microdomain of caveolin-3 provide the calcium required to induce activation of the 
calcineurin-NFAT pathway [52]. However, a follow-up study by the same group could not 
replicate these findings in a pressure-overload induced heart failure mouse model [152].  
This indicated that cardiac hypertrophy was not solely due to the activation of 
calcineurin/NFAT [152, 153]. 
Another major calcium-dependent hypertrophic signaling pathway is the calcium-




in experimental models of hypertrophy as well as patients with heart failure; CaMKII is 
activated by the binding of calcium to CaM [153, 154]. Under pathological conditions, 
CaMKII activity is upregulated and contributes to defective excitation-contraction 
coupling and excitation transcription coupling in mechanisms that favor pathological 
hypertrophy, such as activation of MEF2 [147, 154]. Indeed, transgenic mice 
overexpressing specific isoforms of CaMKII resulted in hypertrophy and HF; mice 
depleted of other isoforms of CaMKII demonstrated resistance to pathological remodeling 
[154]. One source of activation of CaMKII is the LTCC [153]. Several studies have 
demonstrated that increased ICa,L in response to -AR stimulation facilitates CaMKII 
activity [119, 153, 154]. Increased influx through caveolae LTCC has also been shown to 
induce activation of CaMKII [153]. Classical treatment of heart failure with reduced 
ejection fraction has included positive inotropic agents in order to increase cardiac 
performance; however, agents that increase ICa,L induce long-term maladaptive effects, 
partly due to CaMKII-induced cardiac remodeling [5].  Understanding the role of 
microdomain-specific signaling in regards to the LTCC, CaMKII, and calcineurin could 
provide selective inhibitory targets that can better improve systolic function without 
instigating pathological remodeling [5, 153]. 
 Loss of -Adrenergic Receptor Stimulation 
In order to increase contractility, a failing heart is under persistent adrenergic 
activation [156]. In heart failure, the LTCC becomes less responsive to PKA 
phosphorylation resulting in reduced contractility and a diminished fight-or-flight response 




hyperphosphorylation of the LTCC, thereby increasing the availability and open 
probability of the channels, but limits the response to -AR agonists [103, 157, 158]. The 
increase in function leads to an increase in calcium influx, which in turn promotes the 
hypertrophic signaling pathways described above [5, 103, 119, 147, 153, 154].  Heart 
failure also promotes disruption of transverse tubule structure, thereby disrupting LTCC 
regulation [103, 159, 160]. Dislocation of LTCCs from transverse tubules disrupts highly 
localized regulation of the LTCC by -ARs [103, 159, 160]. Because of all these major 
effects on the LTCC in regards to chronic -AR stimulation, the hypothesis is that the 
LTCC plays a central role in the altered calcium handling seen in HF [157]. Current 
therapies for HF include -blockers in order to prevent further structural and functional 
damage to the heart; however, these drugs do not address the critical issue of diminished 
contractility [156]. These treatments also can only serve a small population of patients 
suffering from HF, depending on their stage of HF and the presence of comorbidities [156].  
A potentially successful treatment for HF would be a positive inotrope that increases ICa,L 
downstream of -ARs in a domain-specific manner so as not to activate hypertrophic 
pathways but increases cardiac performance [5, 153]. 
1.3 Rad 
1.3.1 RGK Proteins 
RGK proteins are a subfamily of small Ras-related G proteins that bind to CaV. In 
over-expression systems, all tested RGK proteins profoundly inhibit all CaV1 and CaV2 
channels [17, 20]. There are four members: Rad, Gem, Rem, and Rem2 [20]. Rad (Ras 




overexpressed in skeletal and cardiac muscle of patients with type II diabetes [161]. Gem 
was the next member of the family identified in human peripheral blood T cells as a 
mitogen-induced gene and hypothesized to participate in receptor-mediated signal 
transduction [162]. Rem was then identified based on cloning using a degenerate PCR 
strategy based on structural similarity to Rad and Gem, and found to be expressed in 
skeletal and cardiac muscle, lung and kidney [163]. Rem2 was the last member to be 
discovered in neuronal tissue [164]. The common structure of all RGK proteins includes: 
conserved Rad-related core domain, series of nonconservative amino acid substitutions 
within regions involved in guanine nucleotide binding and hydrolysis, conserved polybasic 
C-terminal extension, and a large N-terminal extension relative to other Ras family proteins 
[17].  The C-terminus extension of RGK proteins lacks the CAAX (Cysteine, Aliphatic, 
Aliphatic, X is any amino acid) prenylation motif that is common to many Ras superfamily 
proteins, and directs the proteins to anchor to the membrane; instead, the C-terminus 
contains basic and hydrophic residues to target the plasma membrane [20]. RGK proteins 
have been implicated in numerous functions in different cell types, including cell shape 
remodeling, apoptosis of cardiomyocytes, synapse development, and neuronal 
proliferation [20].  This section and the remainder of the chapter will focus on Rad, and the 
physiological significance of Rad within the LTCC complex and overall cardiac function. 
1.3.2 Structure of Rad 
Rad is expressed in excitable and non-excitable tissues, and exists as a monomer, 
containing five -helices (A1-A5) and one large -sheet, comprised of two extended anti-
parallel -strands (B2, B3) and five extended parallel -strands (B3, B1, B4-B6) [20, 165-




147-153), and loop A3-B5 [165]. Unlike other small GTPases in the Ras family, the crystal 
structures of switch I and II in Rad are disordered, suggesting conformational flexibility 
within these regions; however, it must be noted that these structures do not include the N- 
and C-terminal extensions [165, 173]. This flexibility potentially allows optimal shape 
complementarity between Rad and the GK domain of CaVβ; the residues on Rad required 
for CaVβ association are Arg208 and His237 [166, 174]. The C-terminus of Rad contains 
crucial binding sites for localization and function; CaM binds to the C-terminus of Rad in 
the region of residues 278-297 in a calcium dependent manner [175]. CaM, along with 14-
3-3 proteins, contribute to the localization of Rad [176].  14-3-3 proteins are involved in 
various signaling pathways, and associate with Rad in a phosphorylation-dependent 
manner, specifically at Ser39 and Ser301[166, 176]. The C-terminus of Rad also includes 
a region that can bind to negatively charged phospholipids in the plasma membrane, such 
as PI(3,4,5)P3 and PI (4,5)P2; when the plasma membrane is depleted of PI (4,5)P2, Rad 
was unable to target to the plasma membrane [92, 177]. Rad also serves as a substrate for 
multiple kinases, including PKA (Ser272, Ser301), PKC, CaMKII (Ser273, Ser299) and 
casein kinase II that could serve as critical modulators of Rad function [92, 166, 175]. 
1.3.3 Function of Rad 
When first identified in type II diabetic patients, Rad was hypothesized to be an 
inhibitory Ras GTPase that increased activity as a compensatory response in muscle when 
patients became insulin resistant [161]. Rad was then overexpressed in skeletal muscle and 
adipocyte cell lines to assess the contribution of Rad to insulin-mediated signaling and 
found to be a negative regulator of glucose uptake [178]. β-tropomyosin was also shown 




suggested that Rad was involved in skeletal muscle motor function and cytoskeletal 
organization [178, 179]. Following this study, Gem was reported to act as an inhibitor of 
high voltage-activated calcium channels through a direction interaction with the β-subunit 
[16]. This prompted the investigation of the role of Rad in regards to calcium channel 
inhibition in HEK cells; coexpression of wild-type Rad with LTCC and CaVβ2a resulted in 
complete inhibition of detectable ionic current through direct interaction with CaVβ [17].  
Inhibition of ICa,L by Rad also required the expression of the C-terminal tail [17]. This 
finding was accompanied by multiple studies of human heart failure: one study 
demonstrated that a nonsynonymous single-nucleotide polymorphism within the Rad gene 
(RadQ66P) was found in patients with congestive heart failure [180]; myocardium collected 
from end-stage heart failure patients displayed significantly decreased protein levels of Rad 
[23, 181]. Because of these studies, Rad was hypothesized to play a central role in cellular 
calcium homeostasis. 
Loss of function of Rad, either through overexpression of a dominant suppressive 
mutant of Rad (S105N) or via RNAi-mediated knockdown, yielded an increase in ICa,L, 
calcium transients, and contractility; these results were accompanied by action potential 
prolongation, QT prolongation and ventricular arrhythmias [182]. However, this mutant 
may not represent a dominant-negative protein; biochemical studies of Rad S105N reported 
this mutant may be a non-native protein that fails to bind nucleotide or exhibit only partial 
occupancy of the nucleotide, despite the site being equivalent to the known dominant 
negative mutation in Ras (S17N)[173]. The pathology seen in response to increased ICa,L 
from the suppression of Rad could have been due to activated CaMKII; Rad-/- mice 




overload [181].  However, that particular study did not report the effects of Rad deletion 
on myocardial function; indeed, the same group also reported Rad was a critical negative 
regulator of vascular lesion formation [181]. Assessment of the effect of Rad-/- on cardiac 
function demonstrated significantly elevated systolic function in response to enhanced 
calcium handling and increased calcium current; interestingly, ICa,L, calcium handling and 
cardiac function that phenocopied β-AR stimulation [21, 23]. This was supported by the 
report of a large, sustained decrease in Rad in neonatal cardiac myocytes that were exposed 
to the adrenergic agonist phenylephrine [181]. However, Rad had also been reported to 
selectively negate β-AR signaling in regards to ICa,L; Rad knockdown to 30% of normal 
expression did not block the increase in current in response to isoproterenol  [183]. Taken 
together, these varying results presented a complex cardiac phenotype that could include 
noncardiac influences, thereby making interpretation of the mechanism by which Rad 
regulates the LTCC confusing.   
Impaired calcium handling within cardiomyocytes contributes to the loss of 
contractility in heart failure [6, 51, 147].  Current positive inotropes can be used acutely, 
but trigger pathological signaling when used long-term [5]. Because Rad protein 
expression is decreased in patients with heart failure, the small GTPase emerged as a 
potential therapeutic target to increase positive inotropy [21, 23, 181]. Indeed, Rad-/- 
displayed elevated cardiac function and preserved cardiac output with aging [22].  Under 
conditions of acute myocardial infarction, Rad-/- reduced mortality, contractile dysfunction, 
and scar development independent of preserving tissue viability, possibly by mediating an 
inflammatory response within the heart [184].  However, Rad deficiency promotes cardiac 




It therefore remains unclear as to whether the down regulation of Rad in the context of 
heart failure is more of a pathological or compensatory response.  
1.4 Working Hypothesis 
It is well established that Rad is critical to regulation of the LTCC [166].  However, 
the resulting cardiac phenotype in Rad-/- models is puzzling due to the potential 
contributions of Rad deletion in noncardiac cell types obscuring the positive inotropic 
effects on the heart. Another level of complexity is the contradicting effects of β-AR 
stimulation on LTCC function with and without Rad present in the complex; these studies 
support Rad playing a critical role in PKA-mediated modulation of the LTCC but the 
mechanism remains unclear. Rad also seems to play a critical role in the cardiac response 
to heart failure, but the underlying mechanism to which this role belongs, pathological or 
compensatory, has yet to be determined.   
The main objective of this dissertation is test the hypothesis that the deletion of Rad 
solely from cardiomyocytes provides a safe, stable target to increase positive inotropy 
downstream of β-AR signaling. Myocardial-specific deletion of Rad increases ICa,L in a 
manner that parallels LTCC modulation that enhances calcium cycling and systolic 
function without promoting pathological remodeling or progression to heart failure 
(Chapter 3).  Chronic, modulated ICa,L as a result of Rad deletion is also seen in sinoatrial 
nodal cardiomyocytes, thereby promoting elevated sinus heart rate (Chapter 4).  
Inactivation of the LTCC in the absence of Rad in a manner that mirrors LTCC modulation 
(Chapter 5).  LTCC regulation by Rad is governed by the C-terminus of Rad (Chapter 




calcium handling and contractile function under conditions of pressure-overload induced 
heart failure (Chapter 7).  Taken together, the results of this dissertation support the 
hypothesis that Rad serves as a major component of PKA-mediated LTCC modulation, and 





Figure 1.1 L-type Calcium Channel Complex.  
A) Structure of the voltage gated calcium channel: the pore-forming subunit 1, 
the extracellular 2 subunit connected to the transmembrane  subunit via a 
disulfide bridge, the intracellular  subunit and the transmembrane subunit 
 Modified from Ninomiya et. al 2020 [43]. B) A dendrogram of the three 
subfamilies for calcium channel genes showing the percent identity between the 
different cloned calcium channels. Modified from Hille, 1984 [27]. C) Tissue 









Figure 1.2 L-type Calcium Channel pore-forming subunit 1C.  
Schematic of 1C subunit topology showing  subunit binding to AID motif, 
calmodulin (CaM) associating with the C-terminus of  1C, and Rad interacting with 






CHAPTER 2. MATERIALS AND METHODS 
2.1 Animal Model 
All experimental procedures and protocols were approved by the Animal Care and 
Use Committee of the University of Kentucky and conformed to the National Institute of 
Health “Guide for the Care and Use of Laboratory Animals.” 
Transgenic animals were generated on a C57BL/6J background in the Transgenic 
Animal and Genome Editing Core at Cincinnati Children's Hospital Medical Center. The 
conditional RRAD allele was made via a sequential insertion strategy using CRISPR-Cas9 
technology, in which exons 2 and 3 were flanked by Cre recombinase-dependent loxP 
(flox: fl) recognition sequences (see Chapter 3, Figure 3.1A). The sgRNA's were 
engineered to contain either HindIII (5′) or EcoRI (3′) restriction sites, with offspring 
screened by genomic PCR analysis, and loxP insertion confirmed by Sanger sequencing. 
These mice (RADfl/fl) were then crossed (or not, as controls) with mice expressing a 
tamoxifen-inducible Cre recombinase (MerCreMer) under α-myosin heavy chain promoter 
[185] to produce RADfl/fl-MHC animals. RAD deficiency was induced by a single 
intraperitoneal injection in control (RADfl/fl) and experimental mice with tamoxifen 
dissolved in sunflower seed oil (40 mg/kg body weight). All mice received tamoxifen and 
were used ≥2 weeks after tamoxifen treatment unless otherwise stated. Radfl/fl-MHC after 
receiving tamoxifen are abbreviated ‘cRadKO,’ and control mice expressing endogenous 
Rad are abbreviated, CTRL. This single tamoxifen injection protocol minimizes 
cardiomyopathological effects observed with multiday administration of tamoxifen [186]. 




term follow up study in chapter 3.  The age of the oldest mice used for study in chapter 3 
were limited to 18 months, but the cellular studies were from mice <12 months of age. 
cRadKO was used for study in chapters 3-5, and 7. For telemetry studies in chapter 4, 
recordings were made before and after tamoxifen treatment in the same mice. For chapter 
5, 1- and 2-adrenergic receptor double knock-out mice were from The Jackson 
Laboratory, JAX stock #003810 [187]. These mice were bred onto our RADfl/fl-MHC animals 
to produce the triple knock out after administration of tamoxifen. For chapter 6, 
CRISPR/Cas9 gene engineering techniques were used to sequentially introduce a 3xFlag 
epitope tag to the N-terminus of the endogenous mouse Rrad gene (to generate 3xFlag-Rad 
mice), and then CRISPR/Cas9 was used to introduce a stop codon at A277 into the 
endogenous Flag-tagged Rrad gene to generate a second Flag-RadA277X mouse 
(generating a C-terminal truncation). See Chapter 6, Figure 6.1 for schematic. 
2.2 TAC 
Transverse aortic constriction was performed essentially as described previously 
[188]. Briefly, mice were sedated in an isoflurane sedation box (induction 3% and 
maintenance 1.5%) and anesthetized to a surgical plane with an i.p. dose of ketamine (50 
mg/kg) and xylazine (2.5 mg/kg). Anesthetized mice were intubated, and a midline cervical 
incision was made to expose the trachea and carotid arteries. A blunt 20-gauge needle was 
inserted into the trachea and connected to a volume-cycled rodent ventilator on 
supplemental oxygen at a rate of 1 L/min and respiratory rate of 140 bpm/min. Aortic 
constriction was performed by tying a 7–0 nylon suture ligature against a 27- gauge needle, 




gradients were determined by in vivo hemodynamics, and mice with gradients 30 mmHg 
were used. 
2.3 Immunoblotting 
Hearts freshly excised from RADfl/fl (CTRL) and RADΔ/Δ (cRadKO) were flash 
frozen, and tissue was pulverized using Freezer Mill (6775, SPEX SamplePrep) before 
sonication in cell lysis buffer containing (in mmol/liter), 50 Hepes, pH 7.5, 150 NaCl, 0.5% 
Triton X-100, 1 EDTA, 1 EGTA, 10 NaF, 2.5 NaVO4, complete Protease Inhibitor Mixture 
(Roche 11697498001-1 tablet per 50 ml), phosphatase inhibitor mixture 2 (Sigma, P5726, 
×100 solution), and phosphatase inhibitor mixture 3 (Sigma, P0044, ×100 solution) (500 
μl of each inhibitor mixture). Lysates were centrifuged at 14,000 rpm and protein 
concentrations of supernatants were measured. Lysates were prepared in 4× SDS-PAGE 
loading buffer with 40.0 μg of total protein per lane resolved on 8, 15, or 4–20% SDS-
PAGE gels and transferred to nitrocellulose/PVDF membranes. Immunoblotting was 
performed with: calsequestrin (1:3000, Abcam); RAD (1:2000, Everest Biotech); Cav1.2 
(1:1000, Alomone); CaMKIId (1:1000, Santa Cruz Biotechnology); pCaMKII (1:1000, 
Santa Cruz Biotechnology); SERCA2a (1:1000, Badrilla); phospholamban phosphoserine 
16 (1:1000, Badrilla); phosphor-threonine 17 (1:1000, Badrilla), and total PLN (1:1000, 
Invitrogen) antibodies, CTGF (1:1000, Santa Cruz Biotech) and GAPDH (1:1000, Cell 
Signaling Technology). Proteins were detected using SuperSignal enhanced 
chemiluminescence (Pierce), and immunoblots were developed and quantified using the 




staining the membranes with Coomassie staining after the detection of the desired proteins 
or using stain-free gels (Bio-Rad). 
2.4 Quantification of myofibril protein phosphorylation 
Myofibrils were prepared from frozen mouse ventricular tissue homogenized in 
relaxing solution containing protease and phosphatase inhibitors (PhosSTOP and cOmplete 
ULTRA Tablets, Roche Applied Science). Samples were skinned for 15 min using 1% 
Triton X-100, centrifuged at 10,000 × g for 5 min, and resuspended in fresh relax. Samples 
were reduced using 2-mercaptoethanol in Laemmli buffer and boiled for 5 min. 5 μg of the 
solubilized myofibrils were loaded and electrophoretically separated using 4–20% Tris 
glycine minigels at 160 V for 70 min. Gels were fixed and stained with Pro-Q diamond 
phosphoprotein stain (Invitrogen) per the manufacturer's protocol. The same gels were then 
stained with Coomassie Blue for total protein expression. Densitometry of bands in Pro-Q 
and Coomassie-stained gels was performed using ImageJ software (National Institutes of 
Health). The degree of phosphorylation of a given protein was determined by the ratio of 
the Pro-Q signal to the protein contented loaded. 
2.5 Ventricular myocyte isolation 
Isolated ventricular cardiomyocytes were prepared as previously described [19]. 
Prior to heart excision mice were anesthetized with ketamine + xylazine (90 + 10 mg/kg 
intraperitoneal). Hearts were excised from adult RADfl/fl (CTRL) and RADΔ/Δ (cRadKO) 
and immediately perfused on a Langendorff apparatus with a high-potassium Tyrode buffer 




were removed and ventricular myocytes were mechanically dispersed. Calcium 
concentrations were gradually restored to physiological levels in a stepwise fashion, and 
only healthy quiescent ventricular myocytes were used for electrophysiological analysis or 
calcium imaging within 12 h. 
2.6 Electrophysiological recordings 
ICa,L was recorded in the whole-cell configuration of the patch clamp technique as 
previously described [19]. All recordings were performed at room temperature (20 to 22 
°C). The pipette solution consisted of (in mmol/liter) 125 Cs-methanosulfonate, 15 TEA-
Cl, 1 MgCl2, 10 EGTA, and 5 Hepes, 5 MgATP, 5 phosphocreatine, pH 7.2. Bath solution 
contained (in mmol/liter) 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 5 Hepes, 5.55 glucose, 1 MgCl2, 
1.8 CaCl2, pH 7.4. Once a cell was successfully patched, zero sodium bath solution was 
introduced into the chamber (mmol/liter) 150 N-methyl-D-glucamine, 2.5 CaCl2, 1 MgCl2, 
10 glucose, 10 Hepes, 4-amino-pyridine, pH 7.2. Recordings of isoproterenol response 
were recorded in zero sodium bath solution containing 300 nM isoproterenol. Activation 
voltage dependence parameters were obtained by first transforming the peak 
current/voltage relationship to a conductance transform by fitting the ascending phase 
(typically Vtest +15 to +40 mV) to a linear regression to obtain a reversal potential. 
Using G = I/V the conductance as a function of voltage transform was then fitted to a 
Boltzmann distribution of the form G(V) = Gmax/(1 + exp(V1/2/k)), where Gmax is the 
maximal conductance and V1/2 is the activation midpoint. For steady-state availability 
curve, we pre-pulsed cells to Vpre ranging from −40 to +10 mV in 5-mV increments and 




distribution was fitted to the resulting curve. Recordings of barium response were recorded 
in zero sodium bath solution containing 2.5 mmol/L BaCl2. Recordings of Isoproterenol 
response were recorded in zero sodium bath solution containing 300 nM isoproterenol. 
Traces were normalized to peak ICa,L, and then mean amplitude was measured at 30 ms and 
150 ms after peak. Remaining current was then calculated by subtracting the mean 
amplitude from 1. AP recordings were performed in the physiological Tyrodes bath 
solution as used for the other recordings. For AP recordings, the pipette solution contained 
(in mmol/L) 115 K-glutamate, 45 KCl, 3 Mg-ATP, and 10 HEPES, pH 7.21 (KOH). All 
AP recordings were performed at room temperature (20° to 22°C). 
2.7 Calcium Transients 
Calcium transients were recorded from ventricular cardiomyocytes loaded with cell 
permeable fura2-AM (Invitrogen) at 1.0 Hz to determine transient amplitude, upstroke 
velocity, and rate of decay. Sarcomere dynamics were simultaneously recorded by 
acquiring an optical signal of visible striations of the cardiomyocyte. All measurements 
were made following >2 min of conditioning of 1-Hz field stimuli to induce steady-state. 
Transients were recorded at 1 Hz. All Ca2+ transient/sarcomere dynamic data were analyzed 
using IonOptix IonWizard 6.3. Background fluorescence (Fbackground) 
for F380 and F340 were determined from cell-free regions. Data are expressed as F340/380 and 
were corrected for Fbackground. 
Calcium transients were also recorded from ventricular cardiomyocytes loaded with 
cell permeable fluo4-AM (Invitrogen) at 1.0 Hz to determine the transient rate of decay. 




induce steady-state. Using confocal microscopy, a line scan was taken of an individual 
cardiomyocyte. Transient decays from line scans were then fitted with a single exponential 
to determine the rate of decay. 
2.8 Single Cell Database Analysis 
Fastq files from single-cell RNA-sequencing (scRNA-seq) analysis of isolated 
mouse sinus atrial node (SAN) tissue, as reported by Linscheid and colleagues [189], were 
retrieved from NCBI Gene Expression Omnibus (accession number GSE130710, sample 
H4). Cell Ranger 3.1 pipeline (10X Genomics, USA) was used for read alignment using 
the mouse mm10 release 93 reference genome modified to include pre-mRNA. Cell calls 
were made using default parameters for Cell Ranger. Unique molecular identifier counts 
for all partitions identified as cells were greater than 2150. The re-analyze function in Cell 
Ranger was used to eliminate cell clusters enriched in mitochondrial reads as described on 
the 10x website (https://kb.10xgenomics.com). Only one cluster was eliminated because 
of enrichment in mitochondrial genes (the topmost differentially expressed genes were 
mitochondrial genes indicating that these RNAseq reactions were from dead cells). The 
remaining 5,472 cells used for analysis. K means clustering was used to define clusters. In 
Loupe Cell Browser, cells containing RRAD were selected. For cell type determination, 
we used the genes that were found by Linscheid et al to be the most differentially expressed 
in each cell type [189]. To be defined as a specific cell type cluster, the cluster had to have 
the following genes as their most deferentially expressed genes: sinus node myocytes: 
Myh6, Ctnna3, Ryr2, Rbm20, Dmd, Ttn, and Tbx5; fibroblasts: Col1a1, Fbn1, Ddr2, 




F13a1, Cd163, C3ar1, P2yr6, Mrc1, Mgl2, Adgre1, and Dab2; vascular endothelial: Ptprb, 
Icam1, Vwf, Ldb2, Pecam1 and Cdh13; adipocytes: Ucp1, Cidea, Prdm16, Pparg, Lep, 
Ghr, Slc1a5, Pde3b, Sorbs1, Acsl1, and Adopr2; endocardial: Npr3, Cdh13, Engm Hmcn1 
and Gmds and epicardial cells: CTRL1, Rbfox1, Kcnd2, Grip1, Plxna4 and Syne2. 
2.9 Quantitative Proteomics Database Analysis 
The mass spectrometry proteomics data was downloaded from the ProteomeXchange 
Consortium via the PRIDE repository (https://www.ebi.ac.uk/pride/). Dataset for mouse 
SAN cells (PXD008736) include 6 samples with 12 fractions per sample performed in 
technical duplicate. Raw MS data were analyzed using MaxQuant v1.6.8.0 (Max-Planck 
Institute of Biochemistry, Department of Proteomics and Signal Transduction, Munich, 
Germany). Peptide search was performed using the UniProt reference proteome for Mus 
musculus (Proteome ID UP000000589). False-discovery rate (FDR) was set to 1% for 
peptide, protein, and side decoy identification with base FDR calculated on delta score. 
Unmodified, unique and razor peptides were used for protein quantification to address high 
amino acid sequence similarity between paralogous proteins. All other parameters were 
kept at default. For positive protein identification the minimum number of peptides was 2. 
Fixed and variable modifications included in the analysis were carbamidomethylation, 
methionine oxidation, and N-terminal acetylation with a maximum allowed number of 5 
modifications per peptide.  To ensure that sensitivity was adequate and that the cells 
isolated were SAN, we quantified the intensity of Catenin Alpha3 (CTNNA3) and 




eliminated any samples that did not exhibit a significant quantity for each of these proteins. 
The remaining samples were used to quantify Rad protein. 
2.10 RNA In Situ Hybridization 
The in situ hybridization experiment was done using RNAscope® [190] (Advanced 
Cell Diagnostics). Hearts were fixed with 10% neutral buffered formalin for 16-32 hours 
at room temperature (RT). Washed the tissue in 100% ethanol and embedded in paraffin. 
Prepared 5µM paraffin sections on a charge slide in RNAase free condition.  Sections were 
cut from the right atrial wall/appendage bounded by inferior and superior vena cava. 
RNAscope Multiplex Fluorescent Detection Reagent V2 kit (ACD, Cat. No. 323110) was 
used to probe Rrad and Hcn4 on the section as per the manufacturer’s protocol. A custom 
designed probe for Rrad was generated (Mm-Rrad-O1, 885451). The Rrad probe 
recognized sequence corresponding to transcript downstream of the flox site shown to be 
reduced in heart lysate by qRT-PCR [19, 191]. HCN4 probe was from the ACD catalog 
(Mm-Hcn4-C2, 421271-C2). 
2.11 Quantitative RT-PCR 
Mice were anesthetized with ketamine and xylazine and hearts were quickly 
excised, after which the apex of the left ventricle was removed and snap frozen in liquid 
nitrogen. Frozen tissue was then homogenized, and RNA was isolated using the 
RNAqueous kit (Life Technologies) and quantified using a Nanodrop (ThermoScientific). 
cDNA was generated from 500 ng of RNA, which was then amplified via RT-PCR using 




(Mm01255747_g1), rcan1 (Mm01213406_m1), cacna1c (Mm01188822_m1), cacna1d (
Mm01209927_g1), and ctgf (Mm01192933_g1). Threshold values (CT) for nppa, rrad, 
and rcan1 were normalized by subtraction from gapdh, and WT (CTRL) was then 
subtracted from cRadKO (ΔΔCT) and fold-changes were calculated as 2−ΔΔCT. 
2.12 Histology 
Mice were anesthetized with ketamine and xylazine and hearts were perfused with 
PBS followed by 10% formalin in PBS. Fixed hearts were halved along the short axis with 
papillary muscle visible, and both basal and apical regions were sectioned at 5-μm sections. 
Picosirius red staining (Direct red 80, Sirius red, Sigma 365548; icric acid, Sigma P6744; 
in acetic acid) for 1 h at room temperature was used to assess fibrosis (collagen). Sections 
were 100% ethanol treated and cleared with xylene. Bright field images were captured with 
polarized light and analyzed with FIJI (ImageJ2). 
2.13 Echocardiography 
Transthoracic echocardiography was performed using the Visual Sonics 770 imaging 
system equipped with a 30-MHz probe. Mice underwent transthoracic echocardiography, 
under light anesthesia (inhaled Isoflurane, 1–2%), with heart rate (350–500 beats per 
minute) and core temperature (37 °C) continuously monitored. The heart was visualized in 
2-dimensional form from modified parasternal long axis, short axis, and apical views. The 
left ventricular dimensions and calculated left ventricular EF were measured from the short 




sonographer was blinded to animal genotype, and data analysis was performed with animal 
genotype blinded. 
For the pharmacological stress echocardiogram, a single intraperitoneal injection of 
isoproterenol (ISO, 30 mg/kg, USP) was given immediately after baseline 
echocardiography measurements were recorded. Heart rate was monitored, within 5 min 
of increased heart rate the drug effect was confirmed, and echocardiography measures were 
repeated. 
2.14 Radiotelemetry 
For chapter 3, RADfl/fl-αMHC-CreERT2 mice were chronically instrumented in the 
left common carotid artery with a radiotelemetry probe (HD-X11, Data Sciences 
International; St. Paul, MN). Recordings commenced 2 weeks after surgical implantation 
of probes. Blood pressure was recorded continuously for 1 week prior to tamoxifen 
administration and then continuously for 2 weeks after tamoxifen. 
For chapter 4, mice were anesthetized with isoflurane, and telemetry transmitter units 
(PhysioTel ETA-F10; Data Sciences International) were implanted in the peritoneal cavity 
under aseptic conditions. The two ECG leads were secured near the apex of the heart and 
the right acromion. Mice were housed singly and allowed to recover for at least 2 weeks 
prior to the start of baseline recordings. ECG data was analyzed for RR interval and PR 
interval using Ponemah software (Data Sciences International). For intrinsic heart rate 
atropine (1mg/kg) + propranolol (1mg/kg) was administered ip during the sleep phase. For 




calculated SD of HR from normal to normal intervals for data collected from 3 runs of 1-3 
minute continuous periods without noise events before and after ISO; for the air jet we 
limited the analysis to cover the ~5 minutes of sporadic agitation of mice by air jets. Traces 
were manually examined to verify absence of noise events.  
2.15 Surface ECG 
Mice were anaesthetized using 2% isoflurane and supplemented with O2 at 1.5 
L/min.   Mice were placed in prone position on a Mouse Monitor S (Indus Instruments) 
and recorded according to the manufacturer’s recommended settings for 5 min under the 
default filter set. ECGs were recorded for leads I, II, III and aVL for each animal and 
analyzed. For intrinsic heart rate, atropine (1 mg/kg) + propranolol (1 mg/kg) were 
administered IP. 
2.16 Open Behavioral Assessment 
Each subject was placed in its own 2x2 box and tracked using the EthoVision 12 
software (Cincinnati, OH USA) for 15 min. Animals were assessed a month after surgery 
and again a month after tamoxifen treatment (two months post-surgery). Time duration 
(heat map), track visualization and distance traveled were collected.   
2.17 Statistical Analysis 
For statistical analyses performed on all cellular observations the mouse is the 




within-mouse averages of the cellular observations were used for analysis to perform the 
analysis on the level of the experimental units in the mice. The factors of mouse type and 
isoproterenol treatment (2 × 2 factorial design) were analyzed using 2-way ANOVA with 
multiple comparisons (specific test noted in figure legend). In the studies of responses 
across multiple time points, a repeated-measures ANOVA was performed. Post hoc t tests 
were performed to compare particular groups of interest. In the analyses involving the 
difference of means between CTRL and cRadKO mice under the assumption of normality 
of response variable, 2-sample t tests were used, and paired t tests were used before and 
after isoproterenol treatment comparisons. For ECG telemetry, Students paired t-test was 
used for baseline versus post-tamoxifen. In the analyses involving the difference of means 
between CTRL TAC and cRadKO mice, 2-sample t tests were used with Welch’s 
correction, and paired t tests were used before and after isoproterenol treatment 
comparisons. Survival curves were compared using a Gehan-Breslow-Wilcoxon test for 
difference. p < 0.05 was considered statistically significant. All statistical analyses were 




CHAPTER 3. MYOCARDIAL-RESTRICTED ABLATION OF THE GTPASE RAD RESULTS IN A 
PRO-ADAPTIVE HEART RESPONSE IN MICE 
3.1 Preface 
The work of chapter 3 has been published [24].  The entirety of the published paper 
is presented.  The nomenclature for cRadKO is labeled RADΔ/Δ and CTRL is labeled 
RADfl/fl in this chapter for consistency with what has been published.  The results and 
methods attributed to others are presented for clarity and flow are italicized. The figure 
numbering of the chapter has been edited from the published work for consistency within 
the dissertation.  
3.2 Introduction 
There is an unfulfilled need to identify inotropic agents for the heart [5]. However, 
long-term use of inotropic agents is associated with adverse outcomes in patients [9, 10] 
that may be related to Ca2+-homeostasis- or protein kinase A-induced maladaptive 
remodeling [192, 193]. The L-type Ca2+ channel complex (LTCC) provides trigger 
Ca2+ for Ca2+-induced Ca2+-release and serves as an upstream control point for modulating 
the inotropic response. The LTCC complex contains a pore-forming α-subunit (CaV1.2 in 
the ventricular myocardium) and auxiliary subunits including CaVβ2, α2δ, and calmodulin 
[194]. In addition to established contributions to channel trafficking and gating, CaVβ 
subunits mediate RGK (Rem, Rad, Rem2, and Gem/Kir) GTPase inhibition of LTCC 
function in muscle, neuronal, and endocrine cells [16-18, 195-197]. RAD (Ras associated 
with diabetes) GTPase, was originally identified as a gene up-regulated in the skeletal 




the RGK subfamily of Ras-related small GTPases [166]. In heterologous expression 
systems, RAD shares the common RGK protein property of binding CaVβ subunits and 
profoundly inhibiting CaV1/CaV2 channel trafficking and activity, with exogenous RAD 
overexpression potently inhibiting ICa,L in adult and embryonic ventricular myocytes [16-
20]. In vivo, RAD deficiency promotes positive inotropic effects [21, 23]. In contrast, 
genetic deletion of the Rem GTPase displays no evidence for inotropic effects secondary 
to only modest increases of ICa,L [19]. RAD is abundantly expressed in the heart, and our 
findings, as well as others showed that RAD protein levels fall in patients with end-stage 
nonischemic heart failure (heart failure with reduced ejection fraction, HFrEF) [23], and in 
a mouse model of cardiac hypertrophy [181], suggesting that RAD down-regulation may 
be an integral signaling component in myocardial adaptation. 
A growing literature indicates that RAD serves as an endogenous inhibitor of 
myocardial LTCC activity and attenuates β-AR signaling [21, 22, 183]. Whole body RAD 
deletion (gRAD−/−) results in progressive structural changes to the heart wall and increased 
myocyte size [22], increased up-regulation of the canonical fetal gene program associated 
with cardiac hypertrophy  [22], and cardiac fibrosis [198]. In keeping with these molecular 
changes, RAD-deficient mice are reported to be more susceptible to cardiac hypertrophy 
[181]. These results are in agreement with earlier studies of genetically modified mouse 
models designed to augment trigger Ca2+. Pore-forming CaV1.2 transgenic mice exhibit 
increased ICa,L and develop heart failure within about 8 months [12]. CaVβ2 overexpressing 
mice show a more rapid progression to pathological cardiac hypertrophy and death [149]. 





RAD protein is expressed in myocardial and nonheart tissues including, but not 
limited to, vascular smooth muscle [171] and in cells in the bone marrow [172]. Thus the 
complex cardiac phenotype observed in gRAD−/− mice may include noncardiac influences 
on cardiac remodeling that are superimposed over direct positive inotropic effect arising 
from increased trigger Ca2+-current in the myocardium. The purpose of this study is address 
the key question: are pro-adaptive, positive-inotropic effects of RAD-deletion obscured by 
the loss of RAD in noncardiac cell types? A key hypothesis maintains that RAD deletion, 
by targeting LTCC downstream of β-AR signaling provides a gain of systolic function. 
Therefore, we engineered an inducible, myocardial-restricted RAD knockout mouse 
(RADΔ/Δ). Our results show that RADΔ/Δ mice have enhanced heart function into 
senescence without evidence for structural remodeling. These major new findings 
challenge the dogmatic assumption that increased myocardial Ca2+ necessarily promotes 
pathology, and suggests that the heart pathology observed in gRAD−/− mice are the result 
of noncardiac influences of RAD loss. 
3.3 Results 
3.3.1 Development of conditional cardiac-restricted RAD-deficient transgenic mice 
Standard gene targeting of RRAD in the mouse results in a complex phenotype, 
including cardiac remodeling [22] and fibrosis [198], with increased cardiac output [21]. 
To examine the role of RAD signaling selectively in cardiomyocytes, we used conditional 
gene targeting with the Cre-loxP system. To achieve cardiomyocyte-specific deletion, 




recombination sites flanking exons 3 and 4 (RADfl/fl; Figure 3.1A). These exons encode a 
large portion of the RAD GTPase core that directs both guanine nucleotide binding and 
hydrolysis, and the C-terminal membrane targeting motif required for LTCC regulation 
[199] such that any transcribed mRNA that is translated following recombination would 
produce a truncated protein lacking biological activity. Successful introduction of loxP 
sites was confirmed by genomic PCR (Figure 3.1B). To permit cardiomyocyte-specific 
RAD deletion, RADfl/fl mice were crossed with a mouse line expressing a tamoxifen-
inducible Cre recombinase under control of the α-myosin heavy chain promoter (αMHC-
CreERT2) [185]. RAD is abundantly expressed in the heart and other tissues [17, 161, 
171, 172, 200], and administration of tamoxifen to RADfl/fl-MHC mice (Figure 3.1A) resulted 
in RAD deletion from the myocardium (RADΔ/Δ) but not the spleen (Figure 3.1C). 
Disruption of RAD expression in the heart was confirmed by qRT-PCR (Figure 3.1D). 
RADfl/fl without αMHC-CreERT2 (RADfl/fl) mice served as littermate controls, with RAD 
expression unaffected following tamoxifen challenge (Figure 3.1C,D). Unless stated, all 
RADΔ/Δ and RADfl/fl mice were subjected to analysis >2 weeks following tamoxifen 
exposure. 
3.3.2 Cardiac-restriced RAD-deficient mice (RAD) show improved function with no 
changes in heart dimensions 
Global constitutive RAD knockout mice (gRAD−/−) showed increased ICa,L [21] 
along with hypertrophic fetal gene program expression, structural remodeling [181], and 
fibrosis [198]. By contrast, ANF and RCAN1, markers of the fetal gene program, were not 




weight (Figure 3.2B) and RADΔ/Δ shows no significant difference in fibrosis compared with 
RADfl/fl (Figure 3.2C,D). This is in stark contrast to gRAD−/− hearts, in which RAD 
deficiency has been found to increase connective tissue growth factor (CTGF) expression, 
leading to greater extracellular matrix production and basal cardiac fibrosis [198]. 
Importantly, cardiomyocyte-restricted RAD deletion failed to increase CTGF expression 
(Figure 3.2E,F). Global RADKO mice experience hypertension [184], and this may be a 
significant driver of the cardiac remodeling observed in these mice, as gRAD−/− hearts 
have likely undergone adaptive alterations secondary to pressure overload. Importantly, 
RADΔ/Δ showed no change in aortic pressure (Figure 3.2G). Taken together, these data 
demonstrate that myocardial-restricted RAD deficiency improves cardiac output without 
instigating structural remodeling. 
To test the effect of myocardial-restricted RAD deficiency on heart function we 
longitudinally followed RADΔ/Δ mice from induced knockout in early adulthood for an 
additional 15 months (Figure 3.3A). Ejection fraction (EF) significantly increased 7 days 
after tamoxifen administration and remained increased continuously for 15 months 
(Figure 3.3B). There was no difference in heart chamber size (Figure 3.3C) or in heart 
wall thickness (Figure 3.3D,E). Cardiomyocyte-restricted RAD deletion effects on in 
vivo heart function were not different between males and females (Figure 3.3F-H). EF has 
a shallow dependence on heart rate (HR) that is preserved in RADΔ/Δ. Regression analysis 




3.3.3 RAD modification of voltage-gated calcium current, ICa,L 
A straightforward explanation for enhanced heart function would be increased 
ICa,L in RADΔ/Δ. Previous studies of whole body, constitutive RAD knockout showed that 
LTCC conductance increased, voltage dependence shifted negatively, and the predicted 
ICaL window increased [21]; however, constitutive global RAD knockout hearts displayed 
structural remodeling. Thus, it is possible that changes in gRAD−/− ICa,L were secondary to 
myocardial remodeling. To interrogate the contribution of RAD in structurally unaltered 
hearts, we measured ICa,L in cardiomyocytes from mature RADΔ/Δ hearts. Figure 3.4A 
shows representative families of ICa,L traces from RADfl/fl and RADΔ/Δ for evaluating 
current/voltage (I(V)) relationships, and Figure 3.4B shows representative current traces 
generated by the steady-state availability voltage protocol. These representative traces 
highlight the increased current density and accelerated kinetics of RADΔ/Δ. The I(V) curves 
for ICa,L show that RAD loss results in a greater current density compared with 
RADfl/fl myocytes (Figure 3.4C). RAD deficiency results in greater maximal conductance 
(Figure 3.4D,E; maximal conductance: RADΔ/Δ = 254 ± 19 pS/pF, n = 15; RADfl/fl = 144 
± 12 pS/pF, n = 18; p < 10−4). The normalized conductance voltage curves superimposed 
on the steady-state inactivation curves (Figure 3.4F) highlight the selective shift of steady-
state activation with RAD ablation; activation midpoint is shifted toward more negative 
membrane potential (Figure 3.4F,G; RADΔ/Δ = −18.3 ± 1.0 mV, n = 15; RADfl/fl = −8.1 ± 
1.9 mV, n = 18; p < 10−4). Steady-state availability shows no significant difference of 
midpoint between RADfl/fl and RADΔ/Δ (RADΔ/Δ = −24.2 ± 1.0 mV, n = 9; RADfl/fl = −22.1 
± 1.7 mV, n = 11; p = 0.11). There is no sexual dimorphism in the effect of RAD deletion 




test this, we performed qRT-PCR for CaV1.2 from RADfl/fl and RADΔ/Δ hearts and found 
CaV1.2 mRNA did not change (Figure 3.4H). CaV1.2 protein levels from RADΔ/Δ hearts 
was also not significantly different from that of RADfl/fl (Figure 3.4I). Taken together these 
data show that myocardial-restricted RAD deficiency is sufficient to increase ICa,L by 
modulating LTCC function. 
RADΔ/Δ ICa,L decay is biphasic with a prominent fast and slow decay phase compared 
with monophasic decaying RADfl/fl (Figure 3.4A; Supplemental Figure 3.11). At −5 mV 
the fast and slow decaying amplitudes of RADΔ/Δ ICa,L are roughly similar (Supplemental 
Figure 3.11); the slow-decay component is significantly slower than RADfl/fl decay. The 
fast ICa,L decay is >10-fold faster than the monotonic ICa,L time constant observed in 
RADfl/fl (Supplemental Figure 3.11). In summary, myocardial RAD-reduction results in 
larger, but faster decaying ICa,L. 
3.3.4 RAD enhances cellular calcium homeostasis 
ICa,L provides trigger Ca2+ for myocardial Ca2+-induced Ca2+ release. Whole-cell 
cytosolic Ca2+ dynamics are significantly larger in amplitude for RADΔ/Δ compared with 
RADfl/fl (Figure 3.5A,B), and the upstroke velocity of the cytosolic Ca2+-transient is 
accelerated in RADΔ/Δ (Figure 3.5C). To assess Ca2+ re-uptake we measured the time 
constant of the Ca2+ transient decay (τ). The value of the mean τ of RADΔ/Δ was faster than 
that for RADfl/fl but did not reach statistical significance using ratiometric imaging of fura2 
in cardiomyocytes (Figure 3.5D). We augmented ratiometric imaging with a separate 
series of experiments using fluo4 for high speed 2-dimensional cytosol-restricted 




nuclear Ca2+ signals. Two-dimensional cytosolic Ca2+ decay was statistically significantly 
faster in RADΔ/Δ than RADfl/fl (Figure 3.5E; RADΔ/Δ = 0.07 ± 0.003, n = 67, RADfl/fl = 
0.10 ± 0.005, n = 69; p < 10−4). To probe mechanisms of re-uptake we assessed SERCA2a 
protein levels (Figure 3.5F). RADΔ/Δ hearts expressed elevated SERCA2a protein levels 
(p < 0.05) but unchanged phospholamban (PLN) protein levels (see below). Taken together 
these data suggest that faster ICa,L trigger (Figure 3.4) and increased SERCA2a expression 
conspire to contribute to accelerate Ca2+ transient dynamics following RAD knockout. 
Sarcomere dynamics is an important determinant of myocardial function [201]. We 
therefore measured sarcomere length and dynamics (Figure 3.6A) simultaneously with 
calcium transients. Elevated calcium dynamics (Figure 3.5) accompanying RAD 
deficiency coincided with unchanged resting sarcomere length (Figure 3.6A,B), increased 
fractional shortening (Figure 3.6C; RADΔ/Δ = 16.1 ± 0.9, n = 24, RADfl/fl = 9.9 ± 1.0, n = 
15; p < 10−4), and the rate at which the cell shortened (Figure 3.6D; RADΔ/Δ = −4.8 ± 
0.4, n = 24; RADfl/fl = −2.8 ± 0.3, n = 15; p = 0.0002). Overall, these results suggest an 
increase in contractility in RADΔ/Δ compared with RADfl/fl, consistent with cellular 
dynamics driving improved heart function with RADΔ/Δ. 
Davis et al. [202] introduced a predictive model of cardiac growth based on 
integrated tension measured from mean twitch tensions or sarcomere shortening. A 
negative score of this tension-integral model predicts dilated cardiomyopathy; a positive 
score trends toward hypertrophic remodeling. Using this model, we calculated the index 
score for our RADΔ/Δ model to predict the direction and intensity of hypertrophy. The 
RADΔ/Δ tension index score is +0.03 relative to RADfl/fl (Figure 3.6E), predicting only a 




increasing trigger calcium does not necessarily promote significant cardiac hypertrophy 
and pathological remodeling. 
3.3.5 Basal ICa,L in  RAD cardiomyocytes reflects a modulated ICa,L 
The increase of ICa,L in response to β-adrenergic stimulation is atop a constellation 
of effectors that enhances cardiac output in the fight or flight response. We therefore next 
tested the effect of acute isoproterenol (ISO) treatment on ICa,L and calcium dynamics. 
RADfl/fl ventricular cardiomyocyte ICa,L conductance was significantly increased (Figure 
3.7A,Bi, Supplemental Figure 3.12); however, ISO had no detectable effect on 
RADΔ/Δ ICa,L (Figure 3.7A,Bii, Fig. S2) resulting in ISO-treated RADfl/fl conductance 
rising to a level that was indistinguishable from that of unstimulated 
RADΔ/Δ cardiomyocytes (Supplemental Figure 3.12). Comparison of the voltage-
dependence of activation of ICa,L reveals that the acute ISO effect in RADfl/fl, whereas 
shifted negative, remained more positive than that for RADΔ/Δ (Figure 
3.7D,E, Supplemental Figure 3.12). Acute ISO had no detectable effect on ICa,L kinetics 
(data not shown). Two summary conclusions are apparent: 1) RADΔ/Δ ICa,L is maximally 
modulated; and 2) RADfl/fl–modulated ICa,L remains at a more positive activation midpoint 
potential than that for RADΔ/Δ. We conclude that basal RADΔ/Δ phenocopies β-AR–
modulated RADfl/fl ICa,L. 
3.3.6 RAD basal heart function is elevated in vivo, yet retains a partial ISO response 
Given that RAD deficiency results in ICa,L resembling β-AR augmentation we next 




months after tamoxifen administration. Acute in vivo ISO resulted in a significant gain of 
EF in RADfl/fl and in RADΔ/Δ mice at 1-month post-tamoxifen treatment (Figure 3.8). The 
ISO effect was preserved at 1 year (16-month-old mice). We conclude that myocardial-
restricted RAD deletion provides stable inotropic support, without globally disrupting 
myocardial β-AR responsiveness. 
3.3.7 RAD retains -adrenergic receptor modulation of calcium and sarcomere 
dynamics 
To explore the source of ISO responsiveness in RAD knockout cardiomyocytes we 
next interrogated Ca2+ and sarcomere dynamical response to ISO. Acute ISO enhanced 
calcium dynamics in RADΔ/Δ and RADfl/fl ventricular cardiomyocytes (Figure 3.9A). For 
cytosolic Ca2+ handling, RADfl/fl ISO response demonstrated an increase in amplitude, a 
faster upstroke velocity, and a faster rate of calcium reuptake compared with basal 
conditions, as expected (Figure 3.9B-D, Supplemental Figure 3.13). RADΔ/Δ ISO 
response also demonstrated an increase in amplitude, faster upstroke velocity, and a faster 
rate of Ca2+-reuptake. Compared with RADfl/fl with ISO, RADΔ/Δ with ISO had a relatively 
larger amplitude (RADΔ/Δ = 2.6 ± 0.1, n = 49; RADfl/fl = 2.0 ± 0.2, n = 37; p = 0.008), faster 
upstroke velocity (RADΔ/Δ = 63 ± 3.0, n = 49; RADfl/fl = 47 ± 5.0, n = 37; p = 0.009), and 
faster rate of calcium reuptake (RADΔ/Δ = 0.11 ± 0.003, n = 49; RADfl/fl = 0.13 ± 0.006, n = 
38; p = 0.05; Supplemental Figure 3.13). To further test for active β-AR signaling in 
RADΔ/Δ we assessed PLN-serine 16 phosphorylation status. At baseline, PLN Ser-16P and 
Thr-17P relative to total PLN protein were not different between RADΔ/Δ and 




PLN–Ser-16P protein from RADΔ/Δ hearts (Figure 3.9F) providing a basis for accelerated 
Ca2+-reuptake. 
To test for preservation of acute β-AR signaling to contractile function we 
measured sarcomere dynamics in response to isoproterenol (Figure 3.10A). Fractional 
shortening (Figure 3.10B, Supplemental Figure 3.14) and sarcomere relaxation was 
accelerated in RADΔ/Δ (Figure 3.10C, Supplemental Figure 3.14). Acute ISO elevated 
the tension-integral index in RADfl/fl approaching the level observed for RADΔ/Δ (Figure 
3.10D,E). To further investigate contractile mechanisms underlying the response to ISO, 
we assessed the phosphorylation status of sarcomeric proteins that modulate contractility 
[203, 204]. Acute ISO significantly increased phosphorylation of cMyBPC and TnI 
(Figure 3.10F). These data support the conclusion that RADΔ/Δ does not exhibit de-
sensitized myocardial β-AR signaling. The reduction of RAD imposes a chronic modulated 
ICa,L while preserving β-AR modulation of critical targets, such as sarcoplasmic reticulum 
Ca2+-reuptake and contractile apparatus proteins. 
3.4 Discussion 
There is need for inotropic agents; however, targeting excitation-contraction 
coupling has been met with failure [205]. Consistent with this literature, early findings with 
constitutive global RAD−/− (gRAD−/−) suggested that elevated trigger Ca2+ led to increased 
cardiac hypertrophy [181]. The importance of the present study is the finding that 
cardiomyocyte-restricted RAD deletion results in a salutary cardiac phenotype, devoid of 
the wall remodeling observed in gRAD−/− mouse studies. Here, we successfully achieved 




biochemical analysis, we demonstrate that: 1) RAD is expressed in cardiomyocytes of the 
heart and myocardial RAD deficiency promotes chronic enhanced heart function without 
structural remodeling or fibrosis. 2) Cardiomyocyte-specific RAD deletion leads to 
enhanced basal ICa,L resembling β-AR modulated ICa,L. 3) Myocardial physiological 
function (Ca2+ handling and sarcomere dynamics) remain β-AR responsive. Moreover, 
RAD protein is reduced in nonischemic heart failure patients [23] suggesting that 
regulation of RAD contributes to a compensatory response. 
There are two dogmatic paradigms that our present results challenge: first, that 
increases of calcium dynamics necessarily promote pathogenic cardiac hypertrophy; and 
second, that absence of RAD exacerbates pathological cardiac remodeling [19, 198]. Each 
of these are discussed below. 
3.4.1 Increased calcium does not necessarily promote cardiac hypertrophy 
A major finding of this study is that myocardial RAD deletion, with increased ICa,L, 
did not demonstrate structural remodeling (Figure 3.3). Previous studies have reported a 
connection between calcium influx through the LTCC and adverse growth of the heart wall 
[52, 148, 149]. Increasing ICa,L through overexpression of the pore subunit α1C or the β2 
subunit of the LTCC led to cardiac hypertrophy, and eventual heart failure growth [12]. An 
ICa,L phenotypic difference with these over-expression models and RADΔ/Δ is in the 
kinetics of ICa,L. RADΔ/Δ demonstrates a biphasic decay of current with fast and slow 
components (Figure 3.4, Supplemental Figure 3.11). The time course of ICa,L is 
reminiscent of calcium-dependent fast inactivation contributed by the calcium load of the 




release from the SR might serve as a regulatory negative feedback mechanism to limit total 
LTCC Ca2+ flux, and in turn might not necessarily activate pathways to initiate 
pathological hypertrophy. Thus, even if dynamical total Ca2+ influx was increased in the 
intact myocardium, there may not be obligatory hypertrophic signaling by LTCC [152]. 
Over-expression of SERCA2a preserves myocardial function under conditions that 
otherwise would be expected to produce failure [207-210]. RADΔ/Δ hearts display 
increased SERCA2a expression without a detectable change in PLN phosphorylation 
(Figure 3.5,3.9), resulting in a change in the ratio of SERCA2a to PLN that is consistent 
with overall faster Ca2+ transient decay dynamics. This favorable alteration toward less 
regulated SERCA2a complexes in our model has also demonstrated cardiac protection in 
high-intensity exercise models [207] and PLN-null mice [145], as well as in phase 1 and 
phase 2 trials of patients suffering from advanced heart failure [209, 210]. To summarize, 
we observe contemporaneous mechanistic changes in RADΔ/Δ myocardium that plausibly 
sum to a stable gain of heart function including: increased, faster-decaying trigger Ca2+ and 
increased SERCA2a. 
Davis et al. [202] proposed a tension-integral index model that distinguishes 
between hypertrophic and dilated cardiac remodeling. A key insight of the tension-integral 
index study was that the tension-integral predicted myocardial structural changes, but there 
were poor correlations to changes in calcium handling indices [202]. The 
RADΔ/Δ approximates a WT tension-integral as a consequence of larger amplitude 
contractions offset by faster kinetics. Regardless, the RADΔ/Δ heart showed elevated EF. 
Thus, how RADΔ/Δ accommodates the increased demands of chronic increased cardiac 




In a similar vein to sarcomere dynamics, the faster kinetics of ICa,L in RADΔ/Δ could 
also potentially serve to attenuate arrhythmogenic potential. Mahajan et al. [50] proposed 
modifying ICa,L kinetics as a superior way to prevent arrhythmias, rather than through 
inhibiting ICa,L activation. This would allow early peak ICa,L to initiate normal SR calcium 
release, and diminish the effects of late ICa,L on repolarization. As encouraging as the 
present results are for suggesting myocardial RAD deletion as a therapeutic direction for 
cardioprotection, thorough analysis of arrhythmogenic potential will require further 
studies, including, but not limited to alternative model systems to the mouse. 
The RADΔ/Δ model also differs from other models of increased ICa,L because 
responsiveness to β-adrenergic receptor (β-AR) stimulation is retained. A hallmark 
feature of HFrEF is insensitivity of β-AR to chronic stimulation [145] that ultimately 
limits the contractile reserve of the heart. RADΔ/Δ hearts retain β-AR responsiveness at 
the level of the cell (Figure 3.9,3.10) and whole heart (Figure 3.8), and did not develop 
heart failure. ICa,L did not change after treatment with isoproterenol in our RADΔ/Δ model 
(Figure 3.7), similar to overexpression of the α1C model [197]. ICa,L was larger in 
RADΔ/Δ than in RADfl/fl stimulated with ISO. This suggests that RAD may play a critical 
role in the ability for the LTCC to be modulated by β-AR stimulation; when RAD is 
deleted, basal ICa,L is larger than currently seen following typical modulation. Further 
studies are warranted to define the molecular role for RAD in β-adrenergic Ca2+ current 
modulation. Finally, enhancing Ca2+ dynamics via targeting of β-AR signaling by G-
protein coupling receptor kinase [211] or Raf kinase inhibition [212] also provides 




Ca2+ dynamics in a manner that bypasses chronic β-AR activity is a potentially attractive 
target of therapeutic strategies for heart failure therapy. 
 
3.4.2 Myocardial-restricted RAD deletion differs from whole body RAD deletion 
Key differences exist between RADΔ/Δ and the whole body deletion of RAD 
leading to the existing erroneous conclusion that RAD-reduction is pro-hypertrophic 
[181]. In the global RAD knockout model (gRAD−/−), channel function and cellular 
calcium dynamics were similar to RADΔ/Δ, and in both models the myocardium retained 
responsiveness to β-AR stimulation [21]. However, myocardial RAD deficiency 
promotes enhanced heart function without structural remodeling or fibrosis. A major 
consideration is that gRAD−/− mice experience hypertension [184], whereas RADΔ/Δ do 
not. This may result from loss of RAD in vascular smooth muscle [171, 213]; increased 
ICa,L in vascular smooth muscle could lead to increased vascular resistance to progress 
toward hypertension. Regardless, gRAD−/− hearts have likely undergone adaptive 
signaling and therefore interpretation of studies of Ca2+ dynamics in gRAD−/− must 
consider the myriad of myocardial alterations secondary to pressure overload. 
 
In summary, our findings suggest that increasing myocardial calcium handling does not 
necessarily promote pathological remodeling, in fact, by imposing a chronic modulated 
ICa,L phenotype in the basal state we show that heart function increases stably into 
senescence. These findings are consistent with the notion that decreased RAD in heart 
failure patients [23, 181] contributes to a compensatory response. There is a major unmet 




might provide a potential new therapeutic target for positive inotropy without introducing 























Figure 3.1 Myocardial deletion of Rad. 
A) Graphic representation of the RRAD conditional targeting strategy.  Flanking 
exons 3 and 4 of RRAD with loxP sites generated the floxed allele (fl). Cre-mediated 
recombination of the loxP sites results in the cKO allele () The approximate 
locations of the PCR primers used for genotyping (a and b) are shown. B) 
Genotyping PCR of tail genomic DNA yielded the following genotypes: RRADwt 
(lane 1), RRADwt/fl (lane 2), and RRADfl/fl (lane 3). Amplicons were generated by 
primers a and b as shown in A). C) Western blot analysis for RAD in protein lysates 
from wildtype (WT), global RAD knockout (gRADKO), RADfl/fl and RAD (2 
weeks post-tamoxifen treatment) from total heart (top panel) and spleen (bottom 
panel). Note that RAD expression is retained in the spleen of RAD mice 
following tamoxifen treatment. D) qRT-PCR analysis in mRNA samples from 
RADfl/fl and RAD hearts. MW, 100 bp DNA ladder. E) Quantification by 
Western blotting of RAD levels in the heart 4 weeks post-tamoxifen treatment (n = 





Figure 3.2 Cardiomyocyte-restricted Rad deletion does not induce markers of 
myocardial pathology.  
A) qRT-PCR for ANF and RCAN1 mRNA expression levels. Radfl/fl (n=6) and Rad∆/∆ 
(n=5) as shown. B) Heart weight was not significantly different between Rad ∆/∆and 
Radfl/fl. C) Representative pictures of picroSirius Red staining with fibrosis quantification 
in D). Radfl/fl  (n=5) and Rad∆/∆ (n=7) as shown. E) Western blot analysis with 
quantification in F) demonstrates no difference in CTGF expression. Lanes run on the same 
gel, but noncontiguous lanes are marked by the black line. Radfl/fl (n=7) and Rad∆/∆ 
(n=9). **p=0.008. G) Aortic pressure recordings, 4 continuous days from baseline (prior 
to tamoxifen), and from same mice 2 weeks after tamoxifen administration (Rad∆/∆). Data 
are average of 3 mice. Data were fitted to a sine wave with fixed cycle length of 24h. Active 
(night-time) and resting (daytime) blood pressures were 129±2 mmHg (baseline), 132±5 





Figure 3.3 Figure 3.3. Myocardial Rad deletion results in a rapid, stable gain 
of cardiac function without pathological structural remodeling in vivo. 
A) Representative M-mode short-axis echocardiography of female mice 1- week through 
15-months following tamoxifen injection. Scale bars of depth: RADfl/fl baseline = 0.69 
mm; RADfl/fl 15 months = 0.67 mm; RAD/ baseline = 0.69 mm; RAD/ 15 months = 
0.76 mm; all images have a duration of 1 s. B) ejection fraction; C) left ventricular inner 
dimension; D) left ventricular anterior and E) posterior wall thickness. Dimensions (C-E) 
are shown in diastole. RADfl/fl (n=7) and RAD∆/∆ (n=17); by genetic modification, p = 
0.0002; F = 20; by time p = 0.04; F = 2; by gene x time, p = 0.04; F = 2). F-H) 
Echocardiography of male and female mice 3 months after tamoxifen treatment.  F) 
Ejection fraction.  Sidak’s multiple comparison test showed RAD/ increased in EF (p < 
10-3 males, p < 10-4 females; by genetic modification, p < 10-4; F = 49; by sex, p < 0.01; F 
= 8; no interaction). RADfl/fl 2-way ANOVA shows female gender contributed 8% to 
variance suggesting more sensitivity than males to RAD/ (p < 0.06). G) Anterior wall 
thickness and H) Posterior wall thickness was not difference by RAD/ or by male 
versus female. I) Linear regression of EF as a function of HR shows HR differences do 
not account for elevated EF in RAD/. The dashed lines show 95% confidence limits. 
The slope is not different between RAD∆/∆ and RADfl/fl; elevation of EF is significantly 






Figure 3.4 Myocardial Rad deletion results in increased calcium current 
(ICa,L). 
A) Representative family of ICa,L traces, Vtest ranging from -75 to +45 mV in 10-mV 
increments, with voltage protocol schematic shown above. B) Representative family of 
ICa,L traces, Vtest ranging from -50 to 0 mV in 10-mV increments for determing steady-
state availability, with voltage protocol schematic shown above.  Scale bars: 500 pA and 
200 ms. Scale bars common to panels A) and B).  C) Current voltage curve shows that 
ICa,L density is increased in cardiomyocytes from RAD
∆/∆ compared to RADfl/fl. D) 
Conductance transform of the current/voltage curve demonstrates higher maximal 
conductance in RAD∆/∆ compared with RADfl/fl with quantification shown in E). F) 
Conductance-voltage curve normalized to maximal conductance illustrates RAD∆/∆ 
cardiomyocytes have shifted the activation midpoint. Smooth curves are Boltzmann 
distribution fitted to data. Steady-state availability was not different. Note that voltage for 
the availability curve is the value for the 500-ms pre-puls potential step (see schematic in 
A). G) Activation midpoint is significantly negative-shifted in RAD∆/∆. Current data are 
from RADfl/fl (N = 7 mice, n = 18 cells), RAD∆/∆ (N = 7 mice, n = 17 cells). ****p<10- 4. 
H) Western blot analysis demonstrates no difference in CaV1.2 expression between 
RADfl/fl and RAD∆/∆. Lanes run on the same gel, but noncontiguous lanes are marked by 
the black line; total protein stained with Coomassie Blue and quantification are shown on 






Figure 3.5 Rad∆/∆ enhances cellular calcium handling. 
A) Representative calcium transients from isolated ventricular cardiomyocytes loaded 
with fura2-AM, RADfl/fl (top) and RAD∆/∆ (bottom) paced at 1 Hz. B) Amplitude of the 
transients from RAD∆/∆ are higher than in RADfl/fl. C) The velocity at which calcium 
enters the cytosol (upstroke of the transient) is faster in RAD∆/∆ than in RADfl/fl. D, E) 
Calcium transient decay is faster in RAD∆/∆ than in RADfl/fl. Measurements in E) used 
fluo4 AM and high speed 2- dimensional imaging. Measurements in A-D) used fura2 
AM, RADfl/fl (N = 10 mice, n = 38), RAD∆/∆ (N = 8 mice, n = 49). For E) RADfl/fl (N = 10 
mice, n = 69), RAD∆/∆ (N = 8 mice, n = 67). F) Western blot analysis demonstrates 
increased expression of SERCA2a, quantification is shown on the right (p = 0.035). 
Lanes run on the same gel, but noncontiguous lane marked by the black line. Below, total 



















Figure 3.6 RAD∆/∆ enhances sarcomere shortening and increases the tension- 
integral.  
A) Representative sarcomere traces of RADfl/fl and RAD∆/∆ paced at 1 Hz. B) Diastolic 
sarcomere length was not different between RADfl/fl and RAD∆/∆. C) Sarcomere fractional 
shortening was higher in RAD∆/∆ than in RADfl/fl. D) The velocity of shortening was 
faster in Rad∆/∆ than in Radfl/fl. E) Integral of sarcomere length is larger for RAD∆/∆ than in 























Figure 3.7 ISO does not alter RAD∆/∆ ICa,L. 
A) Representative ICa,L traces at Vtest of -5 mV before (black line) and after treatment with 
ISO (colored line; blue for RADfl/fl and red for Rad∆/∆). Scale bars: 500 pA and 200 ms.  
B) Current voltage curves superimposing basal and acute 1M ISO treatment for RADfl/fl 
(B,i) and RAD∆/∆ (B,ii). C) Fractional change of maximal conductance between baseline 
and ISO response of RADfl/fl (mean = 32.68%) and RAD∆/∆ (mean = 0.84%). D) 
Conductance-voltage curve normalized to maximal conductance for ISO treated cells 
demonstrates RAD∆/∆ cardiomyocytes have negative shifted activation midpoint relative 
to RADfl/fl in ISO. Smooth curves are Boltzmann distribution fitted to data. Steady-state 
availability was not different. E) Difference between activation midpoints between 
baseline and ISO response of RADfl/fl (mean = - 4.47) and RAD∆/∆ (mean = -0.19). 















Figure 3.8 β-AR-mediated responsiveness retained following Rad deletion in 
vivo 
Mice scanned at baseline (filled symbol) and after injection of isoproterenol (open 
symbol with connecting line). Ejection fraction increased with addition of isoproterenol 
in both RADfl/fl and RAD∆/∆. This response was retained 1 month and 12 months after 
induction of knock out. Data displayed from RADfl/fl (N = 7) and RAD∆/∆ (N = 17) using 






















Figure 3.9 Cardiomyocyte cytosolic Ca2+ handling responds to β-AR-
mediated activation in RAD∆/∆. 
A) Representative calcium transients from RADfl/fl and RAD∆/∆ cardiomyocytes paced at 1 
Hz in 1M ISO. B) Fractional change (ISO/baseline) of Ca2+ transient amplitude. C) 
Upstroke velocity, and D) Rate of decay. RADfl/fl (N = 10 mice, n = 38 cells), RAD∆/∆ (N 
= 8 mice, n = 49 cells) are shown. E) Western blot analysis of total and phosphorylated 
PLN, RAD, and calsequestrin (15% SDS-PAGE). Lower panel, quantification shows no 
significant effect of myocardial Rad deletion. RADfl/fl (N = 6 mice) and RAD∆/∆ (N = 9 
mice) are shown. F) Acute ISO increased PLN Ser16P in RAD∆/∆ (4-20% SDS-PAGE). 








Figure 3.10 Sarcomere dynamics and proteins respond to β-AR-mediated 
activation in RAD∆/∆. 
A) Representative sarcomere traces of RADfl/fl and RAD∆/∆ paced at 1 Hz after treatment 
with 1M ISO. B) Fractional change (ISO/baseline) in fractional shortening, and C) 
relaxation velocity. ISO significantly increases shortening and relaxation velocity in 
RAD∆/∆. D) Integral of sarcomere length is larger in RAD∆/∆ than in RADfl/fl. E) ISO 
treatment increased tension-integral index in RADfl/fl but not in RAD∆/∆. RADfl/fl (N = 3 
mice, n = 8 cells) and RAD∆/∆ (N = 5 mice, n = 16 cells) are shown. F) Coomassie stain 
and ProQ phosphostain analysis demonstrating increased phosphorylation of proteins 
from RAD∆/∆ hearts after treatment with ISO of cMyBPC and TnI, quantification to the 


















Supplemental Figure 3.11 Myocardial Rad deletion results in increased 
calcium current (ICa,L). 
A) Representative ICa,L traces for Vtest at -5 mV, with voltage protocol shown above. B) 
and C) Amplitufe and rate of decay were measured using a fitted exponential function on 
current traces. RADfl/fl was measured using a single exponential function. RAD∆/∆ 
required the sum of two exponential functions. B) Total amplitude was larger in RAD∆/∆ 
than in RADfl/fl at -5 mV. C) Rate of decay (t) was faster RAD∆/∆ than in RADfl/fl, both in 
the fast and slow phases at -5 mV. Data displayed from RADfl/fl (7 mice, 18 cells) and 















Supplemental Figure 3.12 RAD∆/∆ ICa,L response after -adrenergic receptor 
stimulation. 
A) No difference in maximal conductance in RAD∆/∆ compared to RADfl/fl (p = 0.161). B) 
Activation midpoint is also significantly negative-shifted in RAD∆/∆. Rate of decay of 
current was measured using a fitted exponential function on current traces. RADfl/fl was 
measured using a fitted exponential function. RAD∆/∆ had two different phases, and was 
fitted best using two exponential functions. C) Fractional change in tau, in RADfl/fl at -5 
mV (mean = 4%) and RAD∆/∆ (mean: slow = 2%; fast = 7%). Data displayed from 



















Supplemental Figure 3.13 RAD∆/∆ cellular response after β-adrenergic 
receptor stimulation. 
A) Amplitude of the transients from RAD∆/∆ are higher than in RADfl/fl. B) The upstroke 
velocity is faster in RAD∆/∆ than in RADfl/fl. C) and D) Rate of decay is faster in RAD∆/∆ 
than in RADfl/fl. Measurements in A-C) used 5 mM Fura2 AM and measurements in D) 
used 5 mM Fluo4 AM (p = 0.53). Data displayed from RADfl/fl (10 mice, n = 38) and 





















Supplemental Figure 3.14 No effect on sarcomere dynamics after treatment 
with ISO. 
A) Diastolic sarcomere length was not different after ISO between RADfl/fl and RAD∆/∆. 
B) Percentage of fractional shortening was not different after ISO between RADfl/fl and 
RAD∆/∆. C) Relaxation velocity was no different after ISO between RADfl/fl and RAD∆/∆.  
D) Shortening velocity was not different after ISO between RADfl/fl and RAD∆/∆. Data 

















CHAPTER 4. RAD-GTPASE CONTRIBUTES TO HEART RATE VIA L-TYPE CALCIUM 
CHANNEL REGULATION 
4.1 Preface 
The work of chapter 4 has been published [214] .  The entirety of the published paper 
is presented.  The results and methods attributed to others are presented for clarity and flow 
are italicized. The figure numbering of the chapter has been edited from the published work 
for consistency within the dissertation.  
4.2 Introduction 
Spontaneous electrical activity of the sinoatrial node (SAN) initiates cardiac rhythm 
and is a critical determinant of heart rate (HR). Cardiomyocytes of the SAN (SANcm) are 
highly specialized cells that generate automatic activity and form the cellular basis for 
cardiac pacemaking. SANcm exhibit a spontaneous diastolic depolarization. The early 
phase of diastolic depolarization is dominated by inward cationic funny current (If [215] 
carried by HCN4 [216]). The latter phase of diastolic depolarization is driven by voltage-
gated L-type calcium channels (LTCC, with the main pore forming subunit, CaV1.2 or 
CaV1.3) [217] . To a large extent, If and the LTCC complex determine the ‘membrane 
clock’ that interacts with the calcium clock in the SAN [218, 219]. The inter-relation of the 
membrane clock and calcium clock is underscored by studies of the genetic model of loss 
of CaV1.3 impairing sarcoplasmic reticulum Ca2+-release [220, 221], and by computational 
studies linking feedback loops among sarcoplasmic Ca2+-release, NCX, and ICa,L [222, 




suggests that targeted regulation of the LTCC is a potentially powerful approach to control 
HR. Although cellular and molecular mechanisms that contribute to pacemaker activity are 
well established [224], bradyarrhythmia treatment options are limited mainly to electronic 
devices that are insensitive to autonomic nervous system regulation. Experimentally, 
nifedipine (an LTCC antagonist) has a negative chronotropic effect on the leading 
pacemaker site of the SAN [225]; similarly, genetic knockout of CaV1.3 induces 
bradycardia [226]. A fundamental premise of this study is that modulation of LTCC 
activity conferred by Rad provides a central nodal mechanism for sympathetic nervous 
system (SNS) control of SAN rhythm.  
The LTCC is a heteromultimeric protein complex [194]. The pore-forming subunit 
of the LTCC in SANcm is carried by CaV1.3 [226-228] and CaV1.2 [217] channels. Key 
auxiliary subunits of the LTCC complex include CaVβ2, α2δ, and CaM [194]. Recent work 
[117] highlights the importance of RGK proteins [166] as regulators of ICa,L via association 
with the β subunits [17, 21, 24, 184]. Rad is a constituent of the LTCC complex in the 
myocardium [17, 92]. Sympathetic nervous system drive acts via β-AR signaling cascades, 
resulting in the activation of PKA which in turn modulates LTCC activity [229]. β-AR 
modulation is maintained in transgenic mouse models expressing mutant CaV1.2 and CaVβ 
that cannot be phosphorylated by PKA [91, 117], suggesting that a non-channel  PKA 
target is central to channel modulation. Using proximity biotinylation to analyze β-
adrenergic-dependent changes within the LTCC complex, Rad was recently shown to be 
depleted from the LTCC complex following acute β-AR stimulation. Rad depletion from 
the LTCC relieves the constitutive inhibition imposed by Rad association [17, 21, 24, 183].  




showed that LTCC activity is increased In Rad-null mice (Rad-/-) with properties mirroring 
β-AR modulation of ICa,L [21]. ECG telemetry showed that Rad-/- mice have a complex 
phenotype that includes differential vascular and inflammatory properties [184].  However, 
this model has multi-organ involvement [172, 184] and possible development-related 
effects that potentially confound analysis of heart rhythm modification originating from 
channel modulation in cardiomyocytes. To circumvent these effects, we recently developed 
an inducible myocardium-restricted Rad knockout (cRadKO) mouse [24]. Cardiomyocyte 
selective Rad deletion was shown to phenocopy β-AR modulated LTCC properties, 
increasing basal ventricular contractile function [24]. Using this same conditional KO 
model, we now test the hypothesis that myocardial Rad-knockout will modulate sinus heart 
rate. Here we show that cRadKO mice exhibit an elevated intrinsic heart rate, and elevated 
sleep phase heart rate. Mechanistically, Rad regulation of HR appears to be driven by 
modulated ICa,L following Rad loss in SANcm. This work reveals Rad – LTCC interactions 
as a novel target for future therapeutics for symptomatic bradycardia.  
4.3 Results 
4.3.1 SANcm express Rad 
In the cRadKO mouse model cre-recombinase is driven by a myosin heavy chain 6 
promoter limiting expression to all cardiomyocytes (reference [185], and personal 
communication Jeff Molkentin). Following tamoxifen-mediated cre-recombination Rad 
protein levels are not detected from the whole hearts of cRadKO mice [24], suggesting 




(snRNAseq) analysis of the mouse SAN showed that RRAD transcript is enriched ~10-
fold in SAN cardiomyocytes (SANcm) compared to non-cardiomyocytes from the SAN 
region [189]. However, the SAN contains a heterogeneous mixture of cardiomyocytes 
[230]. To assess Rad expression among SANcm, we re-examined a proteomics and 
snRNAseq dataset using tissue obtained from a segment of the right atrial wall, containing 
SAN and surrounding tissue [189]. t-distributed stochastic neighbor embedding (t-SNE) 
shows 203 (of 5,472) cells analyzed can be classified as SANcm (cardiomyocytes) based 
on the expression of Myh6, Ctnna3, RyR2, Rbm20, Dmd, Ttn, and Tbx5 [189, 231]. In 
addition to SANcm, clusters were classified as fibroblasts, epicardial, endocardial, 
macrophage, adipocyte, and an unidentified cluster [189]. Rad RNA was heterogeneously 
expressed in the SANcm cluster and enriched in a sub-population of SANcm. (Figure 
4.1A). Within the SANcm cluster 38% of cells expressed RRAD transcript (77 of 203 cells). 
Re-analysis of scRNAseq data from van Eif and colleagues [231] also showed RRAD 
transcript in SANcm (data not shown). Analysis of the available proteomic database also 
support SAN expression of Rad protein. For context we also re-analyzed data for 
expression of HCN4, RyR2, and CaV1.2 (Figure 4.1B).  To examine Rad expression in 
SANcm in CTRL mice we performed RNA in situ hybridization. HCN4+ cells prominently 
express Rad (Figure 4.2, upper panels). By contrast, cRadKO hearts show dramatically 
reduced Rad transcript (Figure 4.2, middle panels). Consistent with our previously 
published study [24] , tamoxifen induction of the floxed-Rad gene results in loss of Rad 
from cardiomyocytes across the heart. Taken together, these new data suggest that Rad is 




4.3.2 L-type calcium current (ICa,L) in SANcm 
Cells dispersed from the SAN region of cRadKO were morphologically 
indistinguishable from those of control mice (Figure 4.3A). Cells selected for recording 
beat spontaneously in physiological salt solution, were spindle shaped (Figure 4.3A). Cell 
capacitance was not different in cells from cRadKO mice (42+4pA/pF, n=17 and 
42+4pA/pF, n=21 for CTRL and cRadKO, respectively; Figure 4.3B). SANcm from 
cRadKO mice showed larger current density (Figure 4.3C) with the peak of the peak ICa,L 
occurring at +5mV for CTRL and 0mV for cRadKO (Figure 4.3D).  A Boltzmann fit of 
the I(V) curves yielded maximal LTCC conductance showing a significant increase with 
Rad loss (4.8+0.8pS/pF, n=17, and 10+1.3pS/pF, n=21, p=0.0015 for CTRL and cRadKO, 
respectively, Figure 4.3E). The midpoint of current activation (V½) was -7.5+1.4mV for 
CTRL and -10.1+1.4 for cRadKO (Figure 4.3F). Steady state inactivation was not different 
between CTRL and cRadKO ICa,L (data not shown).  There was no significant difference 
in ICa,L properties (current density, maximal conductance, or voltage dependence between 
females and males, Supplemental Figure 4.8).  These data are consistent with alterations 
observed in ICa,L from ventricular cardiomyocytes following Rad ablation [24], suggesting 
a major contribution of Rad to basal ICa,L in SANcm.   
A growing literature suggests that Rad, and other members of the RGK GTPase 
subfamily, play critical roles in calcium-channel modulation, serving as constitutive LTCC 
inhibitors, whose actions are regulated by protein phosphorylation [17, 92, 166]. In 
agreement with this model, we previously showed that Rad deletion results in ventricular 




activation by isoproterenol (ISO) [24]. We next tested the effect of acute ISO on ICa,L in 
SANcm from CTRL and cRadKO hearts. ICa,L from CTRL SANcm was significantly 
increased (Figure 4.4Ai). Maximal conductance increased (+2.8+0.9pS/pF; Figure 4.4Bi) 
and the midpoint of activation shifted negative (-2.1+0.8mV; Figure 4.4Ci). By contrast, 
ICa,L in SANcm from cRadKO hearts show no significant increase of conductance (-
0.9+1.2pS/pF; Figure 4.4Bii) and no effect on activation midpoint (-0.2+0.6mV; Figure 
4.4Cii). These results are consistent with our earlier findings from cardiac ventricular 
cardiomyocytes [21, 24], and support the working hypothesis that Rad functions as a key 
mediator of -AR modulation of ICa,L.  
4.3.3 RAD reduction increases intrinsic heart rate 
Rad deletion instills a PKA modulated ICa,L under otherwise unstimulated 
conditions in a cell autonomous fashion (Figure 4.3) [21, 23, 24]. ICa,L contributes to the 
latter phase of the pacemaker depolarization in SANcm [224, 232-234] ; thus, modulated-
like ICa,L arising from Rad silencing predicts an elevated intrinsic SAN heart rate.  To 
examine the effect of Rad loss on HR in vivo, Radfl/fl.MHC mice were implanted with 
radiotelemetry units. Measurements were made at baseline and 3 weeks after tamoxifen 
administration to compare the impact of Rad loss on the same mice. Combined -AR-block 
(propranolol) and cholinergic antagonist (atropine) revealed intrinsic HR from 
ambulatory mice. Induced knockout of cardiomyocyte Rad resulted in a significant elevated 
intrinsic HR (Figure 4.5A). In females, intrinsic HR increased 153+19bpm between 
baseline and >3 weeks after tamoxifen (483+22bpm and 637+18bpm, for baseline and 




intrinsic HR after tamoxifen (mean difference 63+12bpm; 502+8bpm and 565+11bpm, for 
baseline and post-tamoxifen, respectively, Figure 4.5C). 
4.3.4 Rad-deletion effects on HR are greatest when Sympathetic Drive is Relatively 
Low 
The autonomic nervous system (ANS) modulation of heart function is apparent as 
the diurnal variation of HR. Sympathetic nervous system (SNS) drive is mediated in 
cardiomyocytes via activation of -ARs.  Figure 4.6A shows representative ECG traces 
during the sleep (day) and active phases (night) along with a 48h continuous recording of 
the moving average of HR at baseline and after Rad loss (Figure 4.6B). Sleep phase HR 
was significantly elevated with cRadKO (535+15bpm and 593+13bpm, baseline and 
cRadKO, respectively; Figure 4.6C) but the active phase HR was not different (652+8 and 
671+10, baseline and post-tamoxifen, respectively; Figure 4.6D). Similar results were 
obtained for male mice (sleep phase, 511+11bpm and 598+11bpm; active phase, 647+9 
and 671+13bpm, baseline and post-tamoxifen, respectively; Figures 4.6E,F). Diurnal 
variation remained, but the difference between active and sleeping phase HR diminished 
after Rad silencing. Taken together these results are consistent with elevated ICa,L in 
cRadKO SANcm driving more rapid sinus rhythm unmasked by reduced SNS drive during 
the sleep phase.  
We observed no evidence of pathological effects on the heart into senescence with 
the knockout of Rad [22, 24]. Heart rate variability (HRV) reflects ANS input to the heart, 
and a decrease of HRV is associated with pathologies including progression to heart failure 




contribute to heart failure progression [236] motivated us to measure HRV. Cardiac Rad 
deletion has no effect on HRV in either the active or sleep phases (mean differences 
before/after tamoxifen 2.2+4ms and 1.5+6ms, for sleep and active phase, respectively; 
Figure 4.7A,B). In our recently published work we noted that despite tonic modulated ICa,L, 
the heart in cRadKO mice retains responsiveness to acute β-AR stimulation [24] consistent 
with the function of a healthy heart. To test for retention of autonomic nervous control of 
HR in cRadKO we measured the acute responses to a rapid air jet puff and exogenous ISO. 
The rapid air jet activates the endogenous ANS ‘fight or flight’ response, whereas 
exogenous ISO acutely over-rides ANS control of HR. The air jet acutely increased HR 
+33+23bpm (593+13 to 623+24bpm; p=0.18), and HRV (39+6ms and 68+14ms, before 
and after air-jet, respectively; Figure 4.7C) whereas exogenous ISO increased HR 
+59+10bpm (674+11 to 733+8bpm, p<0.01), and reduced HRV (46+3ms and 18+2ms, 
for post-tam and ISO, respectively; Figure 4.7D). Also, Poincare plots during the sleep 
and active phases also showed similar patterns in CTRL and cRadKO (Figures 4.7E,F).  
4.4 Discussion 
We showed previously that Rad-deficiency confers a β-AR –modulated phenotype 
on basal ICa,L without structural or functional remodeling of the heart [23]. The main 
findings of this study are that in SANcm, the deletion of Rad results in elevated ICa,L with 
properties approximating SNS modulated ICa,L. Second, the absence of Rad elevates 
intrinsic HR.  Third, HR in ambulatory mice is unchanged during the active phase, but is 
significantly elevated during the sleep/resting phase. Early studies showed that modulated 




SANcm [237]. Thus, these results support a key contribution of Rad – LTCC regulation of 
sinus rhythm in the heart (Figure 4.9).   
SANcm have relatively low membrane capacitance and high input resistances; 
consequently, in theory, any relatively small inward cation flux, such as Ca2+ current, can 
accelerate pacemaker depolarizations [234, 238]. The contribution of ICa,L to sinus rhythm 
was experimentally validated by demonstration of the slower HR of CaV1.3 knockout mice 
[226]. There has been some controversy in the field striving to attribute dominant 
mechanisms to pace-making. For example, some studies suggested that the sarcoplasmic 
reticulum Ca2+ clock shapes the spontaneous rate, but may not be a dominating factor [239]. 
Here we now show that ICa,L modulation by Rad GTPase regulates the intrinsic SAN firing 
rate. Our findings do not challenge the primacy of the membrane versus Ca2+ clock;  rather, 
the interdependence of the membrane and Ca2+ clock [224] underscores the critical impact 
of altered ICa,L on SANcm autonomous firing. Perhaps most importantly, our work shows 
that Rad-LTCC regulation is a key molecular signaling node for SNS regulation of sinus 
rhythm. 
4.4.1 Rad is a key contributor to SANcm ICa,L modulation 
SANcm express ICa,L carried by pore forming CaV1.2 and CaV1.3 proteins. CaV1.3 
contributes to pacemaker activity [226] and regulates the calcium clock in nodal cells 
[221]. CaV1.2 resides mainly in non-junctional plasma membrane where it is thought to 
mainly contribute to the membrane clock [240]. Our approaches do not allow us to dissect 
whether Rad has biased influence on CaV1.2 or CaV1.3. Liu et al showed that CaV1.2 and 




lines of evidence to support the contention that Rad functions in cardiomyocytes to regulate 
ICa,L modulation. First, our early studies of global, constitutive Rad-KO mice showed Rad 
deletion phenocopies acute stimulation of the heart [23], and in this model ICa,L was 
modulated at baseline [21]. Second, in the inducible, cardiac-restricted RadKO (cRadKO, 
as in the present study), ventricular ICa,L was modulated at baseline [24]. Third, proximity 
proteomics evaluation in transgenic mice showed that following acute ISO stimulation, 
Rad association was reduced with LTCC proteins CaVβ2 and CaV1.2 [92]. Taken together 
with the present findings, we conclude that Rad interacts with LTCC; thus, dynamical 
regulation by PKA of the LTCC heteromultimeric complex is an important contributor to 
SNS elevation of HR. In native myocardium the signal for Rad-LTCC rearrangements is 
likely in response to the β-AR –PKA signaling axis. The Rad knockout model provides an 
extreme, whereby the absence of Rad would represent a maximally depleted CaV1.2 
microenvironment, relieving any Rad-dependent inhibition with respect to LTCC function.   
There is an imperfect correspondence between intrinsic HR and ICa,L by biological 
sex in cRadKO (Supplementary Figure 4.8, Figure 4.3, 4.6). Intrinsic HR response in 
cRadKO is greater in females than males, but there is not a significant difference in ICa,L 
by sex. This finding raises new questions, principally, ‘What male-specific factors 
contribute to lower intrinsic HR in the absence of Rad?’  This doesn’t necessarily mean 
that Rad influences other ion channels or Ca-clock components in a sex-specific manner; 
rather, this line of reasoning suggests that there are sex-specific intrinsic HR regulatory 
mechanisms, exclusive of Rad-LTCC signaling. For example, our early work showing Rad 
– ICa,L regulation established absence of effects on T-type calcium channel current [17]. 




channel interaction partners with Rad are CaVβ subunits [166] and the C-terminus of the 
L-type channel [241]. There are a large number of signaling systems that sum to setting 
intrinsic HR [242] any one of which possibly can be altered in a sex specific fashion. The 
important conclusion is that regardless of sex, a common effect of Rad-deletion is increase 
ICa,L along with intrinsic HR.  
 
4.4.2 Relationship among SANcm heterogeneity, Rad expression, and SAN function 
In rabbits, peripheral pieces of SAN tissue from regions bordering the crista 
terminalis have faster firing rates than the central pacemaker site, and pieces bordering the 
left atrium were quiescent [243]. The leading pacemaker site is not, however, a fixed 
location. During autonomic nervous system signaling different firing rates are driven by 
different cells in the SAN[244] and depending on external stimuli subsidiary areas can be 
activated [245]. Cell-cell coupling creates complex behavior [246]. For this reason, it is 
important to interpret cellular studies in context of tissue-level, or as in the present case in 
vivo studies of SAN function. Our finding that 38% of SANcm express enriched Rad 
transcript suggests an additional, new mechanism of heterogeneity that should be tested in 
future studies. It follows that the SANcm sub-types that do not express Rad may not 
possess adaptability to speed heart rate via a modulated ICa,L mechanism, or that other RGK 
GTPases may play yet to be investigated regulatory roles.  Conversely, Rad-expressing 
SANcm theoretically have the ability to increase rate and shape the ultimate overall SAN 
rate because the fastest firing SANcm should determine rate, which is consistent with the 




mapping might help resolve whether Rad-ICa,L contributes to anatomical pacemaker shifts 
during sympathetic nervous system activation.  
Modifiers of sinus rhythm may extend beyond regulation of HR per se, to secondary 
impacts on heart failure evidenced as promising effects of ivabradine in heart failure 
patients [247]. Moreover, β-AR blockers have been employed as a first line of HF treatment 
[248]. In the present study we show Rad reduction increases HR, and we previously 
showed Rad reduction increases cardiac inotropy without pathological consequences [21-
24]. Thus, the suggestion that Rad knockout provides beneficial effects in the setting of HF 
is paradoxical to HR slowing effects of ivabradine and β-AR blockers; however, Rad 
reduction would directly treat loss of cardiac inotropy in failing heart, and thus we maintain 
is worthy of further study.  
4.4.3 Diurnal impact and ANS drive with Rad reduction 
Rad deletion elevates intrinsic HR consistent with the SANcm origin of the increased 
sinus rhythm. ANS net input is the sum of SNS drive and parasympathetic input, and the 
level of ANS drive is regulated by the baroreflex. With elevated HR, hence elevated cardiac 
output in cRadKO, it follows there should be compensatory reduced SNS drive. More 
direct measures of sympathetic nerve activity and circulating catecholamines are necessary 
to examine this issue, yet are highly invasive and can be difficult to interpret secondary to 
agitation of animals. For example, blood cannot be drawn from conscious mice without 
provoking a fight or flight response. Anesthesia can be used, but dramatically depresses 
measurements of circulating catecholamines (for example, compare [249] to [250]). To 




cRadKO heart, rather we suggest that modulated ICa,L in cRadKO dominant pacemaker cell 
may usurp the reflexive requirement for added SNS to balance net autonomic drive. In this 
way, Rad reduction strategies might aid aging related [251, 252] symptomatic bradycardia 
which has been attributed to depressed SANcm excitability, possibly secondary to declines 
of CaV1.2 protein [225].  
4.5 Limitations 
Heterogeneity of function at the cellular level is not fully explored here. We did not 
measure spontaneous AP nor spontaneous firing frequencies. Many of the dispersed SAN 
cells displayed irregular automatic beating or quiescence. A range of spontaneous activity 
from fast, regular activity to irregular to quiescence has been noted in dispersed SANcm 
[253]. Heterogeneity among SANcm is also demonstrated in single nucleus[189] and tbx3+ 
cell-sorted transcriptomics studies [231]. It is also possible that differential dispersed cell 
activity might arise from differential cellular damage artifact during enzymatic dispersal. 
We also did not consider Rad-deletion effects on non-LTCC targets. If is a major 
contributor to sinus heart rate [215, 218, 219], and while there is no evidence for Rad 
interactions in the cardiomyocyte beyond protein interactions of with LTCC-component 
proteins, we cannot completely rule out other interactions with Rad. Studies here are 
limited to the mouse. In future studies it will be important to test the impact of Rad 
reduction on human or other large mammalian SANcm retained in ex vivo tissue 





In summary, we have demonstrated that ICa,L contributes to sinus rate by a 
mechanism including Rad-regulated control of LTCC [24, 92]. We previously showed that 
Rad- ablation promotes a beneficial elevation in Ca2+ dynamics, stimulating heart 
ventricular function [23], albeit without any apparent pathological consequence [24]. 
Taken together, Rad reduction within all cardiomyocyte types is a powerful potential 
therapeutic approach for increasing cardiac output as it simultaneously increases HR and 
stroke volume. Future novel therapeutics for symptomatic bradycardia targeting Rad – 


















Figure 4.1 RRAD is expressed in SANcm. 
A) Two-dimensional t-SNE (Stochastic Neighbor Embedding) plot outlines the 
major populations of the sinus node. Analysis of database from Linscheid et al. 
2019. Each point represents a single nucleus. Cell populations are colored 
according to intensity of RRad expression, with an expanded view of the SANcm. 
B) Quantification of data mined from Linscheid et al. 2019, of the expression of 
Rad protein in relation to other proteins known to be expressed specifically in 









Figure 4.2 RAD is expressed in SANcm. 
Representative images of single-molecule fluorescence in situ hybridization against Rad 
(green) and HCN4 (red) in CTRL (top images) and cRadKO (middle images) in SANcm. 
Lower panel, probe for bacterium DapB gene serves as a background control (bottom 
images). Heart tissue was collected >2 weeks after tamoxifen treatment.  Tissue samples 
were stained with DAPI (blue).  Images of channels merged displayed on the right.  















Figure 4.3 Rad reduction increases SANcm ICa,L.  
A) Representative photomicrographs of SANcm selected for patching studies 
from CTRL (Ai) and cRadKO (Aii) hearts. B) Cell capacitance is not significantly 
different (p = 0.77). C) Family of ICa,L for CTRL (blue) and cRadKO (red). Scale 
bars: 5 pA/pF, 100 ms. D) Current-voltage relationship for peak ICa,L from CTRL 
and cRadKO SANcm. E) Maximal conductance is significantly increased (**p < 
0.01) and F) activation midpoint trends toward a negative shift with Rad deletion 










Figure 4.4 β-AR stimulation has no significant effect on cRadKO SANcm 
ICa,L. 
A) Current-voltage relationships for CTRL (Ai) and cRadKO (Aii) for basal 
(closed symbols) and after 100 nM ISO (open symbols). B) Maximal conductance 
before and ISO for CTRL (Bi, **p =0.01) and cRadKO (Bii, p = 0.45). C) 
Activation midpoint before and ISO for CTRL (Ci, *p =0.05) and cRadKO (Cii, p 
















Figure 4.5 Intrinsic heart rate increases after Rad deletion. 
A) Representative ECG signals during the sleep phase demonstrate an increase in 
intrinsic heart rate after tamoxifen treatment. B,C) Heart rate increases after 
tamoxifen treatment in B) females (***p < 10-3, N=7 mice) and in C) males (**p 












Figure 4.6 Rad deletion increases heart rate in the sleep phase. 
A) Representative ECG signals demonstrate an increase in heart rate during sleep 
after tamoxifen treatment, but no change while active. B) Continuous recording of 
heart rate over 48 hours, before (Baseline) and after tamoxifen treatment (Post-
TAM). C) Heart rate in the sleep phase increases after tamoxifen treatment in 
females (***p < 10-3, N = 7 mice). D) No significant difference in heart rate 
during the active phase after tamoxifen treatment in females (p = 0.13). E) Heart 
rate during the sleep phase increases after tamoxifen treatment in males (**p = 
0.0003, N = 7 mice). F) Heart rate in the active phase increases after tamoxifen 






Figure 4.7 Rad deletion demonstrates preserved Heart Rate Variability 
(HRV). 
A) HRV is not significantly different after tamoxifen treatment in the sleep phase 
(p = 0.59), or B) in the active phase (p = 0.80). C) HRV increases in Post-TAM 
after exposed to an airjet (*p = 0.03). D) HRV increases Post-TAM after an 
injection of isoproterenol (***p < 10-3, N = 7 mice). E), F) Poincare plots in 
which the RR interval is plotted against the subsequent RR interval (RR + 1) in a 












Supplemental Figure 4.8 No significant difference between males and females 
of ICa,L in CTRL and cRadKO. 
A) Current-voltage relationship for peak ICa,L from CTRL males (blue circles) and 
females (black circles). B) Current-voltage relationship for peak ICa,L from 
cRadKO males (red squares) and females (black squares). C) Maximal 
conductance for CTRL (males and females, p = 0.10) and cRadKO (males and 
females, p = 0.10). D) Activation for CTRL (males and females, p = 0.62) and 
cRadKO (males and females, p = 0.34). CTRL: Males: N = 6 mice, n = 12 cells; 
Females: N = 2 mice, n = 5 cells. cRadKO: Males: N = 8 mice, n = 19 cells; 











Figure 4.9 Rad Deletion Increases Sinus Heart Rate.  
Rad deletion in sinoatrial cardioyocytes increases ICa,L and increases heart rate consistent 
with -adrenergic receptor modulated ICa,L regulation. Heart rate during the sleep cycle is 
selectively elevated by Rad deletion. Rad-LTCC association may be a useful target for 














CHAPTER 5. ENHANCED INACTIVATION BALANCES INCREASED PEAK L-TYPE CALCIUM 
CURRENT IN THE ABSENCE OF RAD 
5.1 Preface 
The work of chapter 5 has been submitted for review .  The entirety of the paper is 
presented.  The results and methods attributed to others are presented for clarity and flow 
are italicized. The figure numbering of the chapter has been edited from the submitted work 
for consistency within the dissertation.  
5.2 Introduction 
The L-type calcium channel (LTCC) is a heteromultimeric protein complex that 
governs the entry of calcium necessary to initiate a contraction, and the LTCC contributes 
to the cardiac action potential (AP) plateau phase [64].  Cardiomyocyte LTCC activity is 
tightly regulated to prevent calcium overload [254] and after-depolarizations of the AP 
[124, 125]. Decay kinetics of ICa,L is a key point of control. Inactivation of the LTCC occurs 
by two distinct mechanisms: calcium dependent inactivation (CDI) and voltage dependent 
inactivation (VDI) [64, 65].  The early peak of L-type calcium current (ICa,L) triggers 
calcium induced calcium release (CICR) from the sarcoplasmic reticulum (SR) that is 
essential for excitation contraction coupling; calcium released from the SR, or entering 
through the channel itself, binds to calmodulin (CaM) prebound to the EF hand of the 
carboxyl-terminus of the main pore-forming subunit of the LTCC [255]. Ca2+-CaM 
complexed within the LTCC causes a conformational change to induce CDI [68-71]. In 
addition, ICa,L decay occurs by voltage dependent inactivation contemporaneously with the 




non-exponential decay with relatively early, fast and late, slow components [50, 61-63].  It 
is generally accepted that CDI contributes to the early, fast component and the late, slow 
component is dominated by VDI [60, 66]. Other studies claim that VDI contributes to both 
components but is dampened when calcium influx increases [60, 74-76]. 
The regulation of LTCC decay becomes particularly critical when the channel is 
modulated upon -adrenergic receptor (-AR) stimulation. During the fight-or-flight 
response, ICa,L amplitude increases, voltage dependence of activation shifts to more 
negative potentials, and inactivation rates accelerate [60, 66, 256, 257].  Regulation of the 
LTCC by -adrenergic receptor (-AR) stimulation has been thoroughly investigated, yet 
complete understanding remains elusive, especially in regards to how inactivation is 
accelerated.  Many studies claim that CDI is the major contributor to ICa,L decay under 
modulated conditions because elevated calcium influx leads to more calcium interaction 
with CaM [60, 66]; however, increased ICa,L due to overexpression of 1C, the pore-
forming subunit of the LTCC, or of CaV2a did not alter decay kinetics compared to the 
controls [12, 149].  Others argue that inactivation is accelerated due to interactions of the 
N-terminus and C-terminus with each other or other proteins [258-260]. Because -
adrenergic receptor (-AR) stimulation initiates multiple molecular mechanisms, it is 
difficult to assess the main contributors to LTCC regulation [31]. 
In recent studies, Rad has emerged as a major contributor to LTCC modulation [23, 
24, 92].  Rad is a member of the RGK subfamily of Ras-related small GTPases [166], and 
shares the common RGK protein property of profoundly inhibiting CaV1/ CaV2 channel 
activity. Overexpression of Rad in heterologous expression systems potently inhibits ICa,L 




positive inotropy and is a critical determinant of current amplitude [24] and modulation 
[23, 92]. Our recent work showed that the absence of Rad from the channel complex results 
in increased LTCC activity that mirrors -AR modulated ICa,L and accelerates ICa,L decay 
[21-24]. These findings were definitively supported utilizing proximity biotinylation to 
show that under conditions of -AR stimulation, protein kinase A-mediated Rad 
phosphorylation alleviated constitutive inhibition caused by Rad association with the 
LTCC [92].  
If Rad loss from the LTCC complex is essential for -AR modulation of ICa,L, then 
the absence of Rad in myocardium could serve as a novel tool to investigate LTCC 
regulation under modulated conditions without interfering contributions of other signaling 
pathways normally activated under -AR stimulation. Using a cardiomyocyte-restricted 
Rad deletion mouse model, we re-visit the hypothesis that modulation of the LTCC by -
AR stimulation is governed by the presence of Rad in the CaV1.2 macromolecular complex. 
Mechanistically, the absence of Rad yields increased inactivation to offset the increase in 
peak ICa,L. Here, we show that CDI and VDI are both accelerated in the absence of Rad.  
The combination of greater peak and accelerated kinetics conspires to prevent significant 
changes to action potential duration or QT interval, despite large peak ICa,L. The 
preservation of Rad knockout-instilled ICa,L modulation in the absence of -AR expression; 
thus showing that Rad imparts channel complex modulation independent of -AR 
signaling.  This work suggests Rad-LTCC interactions may be a novel target for future 





5.3.1 cRadKO mirrors modulated LTCC 
ICa,L decay consists of an early, fast component and a late, slow component [50, 61-
63, 65].  CDI is the dominant mechanism of inactivation of the fast component and under 
conditions of β-adrenergic stimulation [61, 68, 71, 74]; this idea, coupled with the emergent 
model that phosphorylated Rad is re-oriented from the LTCC during -adrenergic 
stimulation to drive ICa,L modulation [21, 23, 24, 92], predicts that Rad-deletion (in the 
basal state) should yield ICa,L properties that are not different from wild-type (CTRL) 
following -adrenergic modulation.  We therefore compared the kinetics of ICa,L in 
cardiomyocytes from CTRL after the addition of isoproterenol with basal ICa,L in 
cardiomyocytes from cRadKO (Figure 5.1). For brevity, we will henceforth refer to CTRL 
ICa,L and cRadKO ICa,L as a stand-in for ICa,L from CTRL or cRadKO ventricular 
cardiomyocytes.  EGTA was used to allow a readout of the influence on global Ca2+.  ICa,L 
traces from cRadKO and ISO-stimulated CTRL normalized to peak current demonstrates 
that basal cRadKO ICa,L decay is not different from modulated CTRL (Figure 5.1A). 
Remaining early current (r30) was not different between modulated CTRL ICa,L  and 
cRadKO ICa,L (Figure 5.1B; Supplemental Figure 5.10A for 2-way ANOVA tabular 
results); similarly, there was no difference in the late component (r150) [50, 63, 261, 262], 
at individual voltage steps (Figure 5.1C, Supplemental Figure 5.10B for 2-way ANOVA 
tabular results). cRadKO displayed larger current density at r30 (Figure 5.1E) and r150 
(Figure 5.1F) compared to CTRL.  Taken together, these results demonstrate that the 




5.3.2 Increased Ca2+ and Rad both contribute to CDI 
If CDI is the dominant mechanism when the LTCC is modulated, then the source 
of calcium contributing to CDI could emanate from the sarcoplasmic reticulum, or from 
local calcium entering through the channel itself [263]. To evaluate global versus local 
Ca2+, we investigated ICa,L decay kinetics in the presence of either EGTA or BAPTA.  These 
calcium buffers have similar steady-state binding affinities for calcium, but differ in 
binding rate constants [264].  EGTA buffers slower than BAPTA and allows investigation 
of the influence of global calcium on CDI; by contrast, the use of BAPTA limits CDI to 
local sources, mainly Ca2+ fluxing in the nanodomain of the channel [264, 265].  
Figure 5.2 summarizes the analysis of r30 between cRadKO ICa,L and CTRL ICa,L 
under conditions reporting global Ca2+ (EGTA used as calcium buffer).  Traces from 
cRadKO and CTRL ICa,L demonstrate that cRadKO ICa,L fast decay is greater than that for 
CTRL (Figure 5.2A).  Across multiple voltage steps, there is less r30 in cRadKO ICa,L than 
in CTRL ICa,L (Figure 5.2B, Supplemental Figure 5.10C for 2-way ANOVA tabular 
results). Current density was larger in cRadKO compared to CTRL (Figure 5.2C). To 
assess whether remaining current depended on elevated current density, we plotted r30 as a 
function of current density (Figure 5.2D).  CTRL trends towards a negative slope meaning 
that as current density increases, there is less remaining current, as expected for early, fast 
inactivation by CDI [60].  In contrast, cRadKO has a positive slope; as current density 
increases, there is more remaining current. This finding suggests a Ca2+-independent 




We next assessed r30 in the presence of BAPTA to limit the pool of calcium local 
to the channel complex [264, 265] (Figure 5.3). Representative traces reveal an apparent 
smaller difference in decay between cRadKO and CTRL (Figure 5.3A). r30 across 
individual test potentials demonstrates no significant difference between cRadKO and 
CTRL ICa,L (Figure 5.3B, Supplemental Figure 5.10D for 2-way ANOVA tabular 
results). In the presence of BAPTA, cRadKO maintains a larger current density compared 
to CTRL (Figure 5.3C).  Local buffering by BAPTA eliminates the negative correlation 
of r30 with current density for CTRL ICa,L; however, the positive correlation of cRadKO 
r30 and current density remains in the presence of BAPTA (Figure 5.3D, compare with 
Figure 5.2D). Taken together these results suggest that the early, fast decay of ICa,L in 
cRadKO is driven in part by SR released calcium, and in part by a Ca2+-independent 
mechanism.  
5.3.3 Rad does not alter the late component of LTCC decay  
Late ICa,L contributes to repolarization and SR calcium loading [50]; impaired 
inactivation of the late phase can result in AP duration prolongation and EADs [50, 61-63, 
262]. We therefore analyzed ICa,L r150 in cRadKO and CTRL in the presence of EGTA.  
Representative traces demonstrate no difference between cRadKO and CTRL ICa,L (Figure 
5.2A, superimposed star). There was no difference in r150 between the models at multiple 
test potentials (Figure 5.4A, Supplemental Figure 5.10E for 2-way ANOVA tabular 
results) but the interaction between voltage and CTRL versus cRadKO was significantly 
different, as shown by the crosses in Figure 5.4A.  cRadKO, in comparison to CTRL, has 




and CTRL when r150 is displayed as a function of current density (Figure 5.4C). In the 
presence of BAPTA, there was no difference in r150 (see Figure 5.3A, superimposed star; 
Figure 5.4D, Supplemental Figure 5.10F for 2-way ANOVA tabular results). Current 
density was not different for cRadKO compared to CTRL ICa,L (Figure 5.4E). r150 plotted 
against current density demonstrated a positive correlation in both cRadKO and CTRL 
(Figure 5.4F). These data show that Rad deletion does not promote alterations to late ICa,L 
kinetics. 
The late, slow component of ICa,L decay is thought to be dominated by voltage 
dependent inactivation (VDI) [60, 66, 74].  We therefore measured VDI in cRadKO by 
using barium as the charge carrier (Figure 5.5).  Representative traces demonstrate faster 
decay in cRadKO compared to CTRL both at r30 and r150 (Figure 5.5A).  There was less 
r30 in cRadKO (Figure 5.5B,D; Supplemental Figure 5.11A for 2-way ANOVA tabular 
results for B).  At r150, remaining current in cRadKO was not significantly less compared 
to CTRL (Figure 5.5C,E; Supplemental Figure 5.11B for 2-way ANOVA tabular results 
for C).  A positive correlation is seen in cRadKO when either r30 or r150 are plotted as a 
function of current density (Figure 5.5F,G). This data, in concert with the regression plots 
from Figures 5.2 and 5.3, show that the absence of Rad enhances VDI. This suggests the 
presence of Rad contributes to dampening VDI.  
5.3.4 Faster kinetics in cRadKO prevent alterations in cardiac electrophysiology 
ICa,L plays a critical role in regulating cardiac action potential duration; slight 
alterations to current density or inactivation of the LTCC can lead to electrical 




prolonged QT intervals [50, 61-63, 131, 132, 262]; Sympathetic stimulation via the -AR 
signaling axis modulates trigger calcium, and shortens action potential duration [266]. 
Studies have shown that female mice exhibit prolonged action potential repolarization 
and longer QT intervals [267], making females more sensitive to reveal if Rad deletion 
has an effect on action potential duration and QT interval. We therefore measured action 
potentials from isolated ventricular cardiomyocytes, and used surface electrocardiogram 
(ECG) recordings to assess QT interval in female mice.  Action potentials (AP) measured 
at 1 Hz from CTRL ventricular cardiomyocytes showed a pronounced inflection point 
positive to 0 mV (Figure 5.6A, arrow), rapid repolarization, and a slower repolarization 
phase negative to -50 mV (Figure 5.6A). cRadKO APs (Figure 5.6A, red line) 
demonstrated similar morphology to CTRL at baseline (Figure 6A, blue line) and after 
addition of isoproterenol [268] (Figure 5.6B; cRadKO: black line, CTRL: green line). 
Baseline AP amplitudes were not significantly different between models (Figure 5.6C; 
cRadKO: 127.41.0 mV, CTRL: 123.03.3 mV;).  Comparing baseline action potential 
duration at 50% repolarization (APD50) and at 80% repolarization (APD80) demonstrates 
no significant difference between cRadKO and CTRL (Figure 5.6D: cRadKO: 6.50.98 
ms, CTRL: 6.20.58 ms). At 80% repolarization (APD80), cRadKO demonstrates faster 
repolarization than CTRL (Figure 5.6E, cRadKO: 17.11.5 ms, CTRL: 21.21.1 ms). 
CTRL action potential amplitude was not significantly different from cRadKO after ISO 
(Figure 5.6F). cRadKO APD50 was slightly shorter compared to baseline, but not 
significantly different from CTRL (Figure 5.6G; APD50 after ISO: cRadKO: 6.41.2 ms, 




significantly different from cRadKO (Figure 5.6H; APD80 after ISO: cRadKO: 18.01.8 
ms, CTRL: 23.42.0 ms).   
We next assessed in vivo electrical function. The increase in heart rate in response 
to sympathetic stimulation is the result of integrative mechanisms in both branches of the 
autonomic nervous system (ANS) [266], which could obscure a potential effect on QT 
interval due to a selective increase in ICa,L in the absence of Rad.  We therefore measured 
the ECG under ANS block by treating the mice with atropine and propranolol [269].  
Baseline ECG measurements demonstrated no significant difference in QT or QTc 
(Supplement Figure 5.12). After administration of atropine and propranolol, 
representative surface ECG traces showed no apparent differences between CTRL and 
cRadKO (Figure 5.6I).  Raw QT interval (Figure 5.6J; cRadKO: 406 ms, CTRL: 507 
ms; p=0.35) and corrected QT interval (QTc) demonstrated no significant difference 
(Figure 5.6K; cRadKO: 335 ms, CTRL: 405 ms; p=0.41). This data, combined with 
the action potential measurements, support the idea that the faster kinetics balance the 
increase in peak ICa,L, thereby preventing significant alterations in cardiac 
electrophysiology.    
5.3.5 cRadKO yields modulated kinetics of LTCC downstream of -AR signaling 
1-AR activation mediates positive chronotropic and inotropic responses of 
cardiomyocytes, and 2-AR is thought to contribute to these processes more locally 
within cardiomyocytes [270].  To determine whether these receptors were contributing to 




double knockout mouse [271] (dKO) to create an induced RAD/,1,2-AR triple knock 
out mouse (tKO) after administration of tamoxifen. Analysis of cardiac function through 
echocardiography demonstrated that ejection fraction was significantly different between 
CTRL and dKO after acute isoproterenol, demonstrating that 1,2-AR response was 
disrupted (Supplement Figure 5.12A; CTRL: 931%, dKO: 603%; p<0.0001; data for 
CTRL+ISO echocardiography taken from our previously published dataset [24]; 
Supplement Figure 5.13A). Disruption of Rad expression in the heart in tKO was 
confirmed by qRT-PCR (Supplement Figure 5.13B). After the deletion of Rad, ejection 
fraction significantly increased in the tKO compared to dKO (Figure 5.7A,B; tKO: 
722%, dKO: 514%; p<0.0001). Left ventricular inner dimensions decreased in the tKO 
(Figure 5.7C; tKO: 3.60.1 mm, dKO: 4.20.1 mm; p=0.003) without significant 
changes in the anterior or posterior walls (Figure 5.7D,E; For F: tKO: 0.880.1 mm, 
dKO: 0.800.1 mm; p=0.43; For G: tKO: 0.860.05 mm, dKO: 0.820.1 mm; p=0.52).  
Surface ECG showed no significant difference in raw QT interval (Figure 5.7F,G; tKO 
394 ms, dKO 306 ms; p=0.19), corrected QT interval (QTc) (Figure 5.7H; tKO 314 
ms, dKO 234 ms; p=0.14) or RR interval (Figure 5.7I; tKO 314 ms, dKO 234 ms; 
p=0.14) between dKO and tKO female mice. This data supports that the absence of Rad 
enhances cardiac function independent of 1,2-AR signaling.  
At the level of channel current, peak ICa,L was significantly increased in tKO 
compared to dKO (Figure 5.8A,B). Rad deletion also resulted in a greater maximal 
conductance (Figure 5.8C,D; Gmax: tKO: 50833 pS/pF, dKO: 23032 pS/pF; 




dKO: -6.121.7 mV; p=0.04).  Analysis of kinetics demonstrated a trend of less 
remaining current in the tKO at r30 (Figure 5.8F,G,I,) and no difference at r150 (Figure 
5.8F,H,J). The interaction of voltage and dKO versus tKO was significantly different 
both at r30 and r150 (crosses in Figure 5.8G,H). Taken together, these results support the 
hypothesis that the deletion of Rad increases peak ICa,L that mirrors modulated LTCCs 
without stimulation of 1,2-AR signaling. 
5.4 Discussion 
The main findings of this study are that in the absence of Rad, increased peak L-
type calcium current (ICa,L) is balanced by accelerated calcium dependent inactivation 
(CDI) and voltage dependent inactivation (VDI) (Figure 5.9).  Accelerated LTCC 
kinetics prevent significant action potential and QT interval prolongation. In fact, APD80 
is shorter in cRadKO (Figure 5.6). The loss of Rad from the L-type calcium channel 
(LTCC) complex results in modulated ICa,L independent of -adrenergic receptor (-AR) 
signaling.  To our knowledge, the cardiomyocyte-restricted Rad deletion model is the 
only known model to increase ICa,L without disrupting calcium homeostasis, and without 
promoting pathological signaling [12, 149]. Therefore, myocardial Rad-LTCC interaction 
is a potential therapeutic target for positive inotropy while preserving -AR signaling 




5.4.1 Rad contributes to regulation of LTCC inactivation 
A major implication of this study is the presence of Rad slows inactivation of the 
LTCC.  The deletion of Rad accelerated only the early, fast component of ICa,L decay 
without significantly altering the late, proarrhythmogenic component [50, 61-63, 262] 
(Figure 5.1-5.5).  CaV1.2 channels have been shown to form clusters through physical 
interactions of their C-terminal tails [57-59, 272]. Calcium binding to calmodulin (CaM) 
on the LTCC promotes the physical interactions between channels, allowing channels to 
have synchronous activity [58]. This process is thought to occur in response to -AR 
stimulation in order to enhance calcium influx through calcium dependent facilitation 
(CDF), but also to accelerate inactivation through CDI to prevent the development of 
arrhythmogenic events [59]; hyperactivation of a few channels could dictate the activity 
of the entire cluster [57, 58].  Rad, as well as the other members of the RGK protein 
family, bind to CaM in a calcium dependent manner via a conserved binding site on their 
C-termini [166].  It has been well established that CDI occurs when calcium binds to 
CaM and causes a conformational change to induce LTCC inactivation [68-71]. With 
CaM playing a major role in CDI and channel clustering, and Rad binding to CaM, it is 
therefore possible that Rad contributes to channel clustering and calcium dependent 
inactivation.  In the absence of Rad, more channels may cluster together, thereby 
promoting an increase in peak ICa,L [24] and an acceleration of the fast component of ICa,L 
decay (Figure 5.1-5.3). Future studies investigating clustering in the absence of Rad 





5.4.2 Rad is a key contributor to LTCC Modulation 
The activation of protein kinase A (PKA) downstream of -AR stimulation results 
in an increase in ICa,L, an increase in channel open probability, and an increase in the 
number of functional channels [109, 256], also known as ‘modulation’ of the LTCC.  
Phosphorylation of CaV1.2 was long thought to be the underlying mechanism of 
modulation [31], but recent studies have proposed that the mechanism of modulation 
relies more on protein-protein interactions within the LTCC or on LTCC clustering [24, 
31, 57-59, 92, 109, 272]. It was also recently shown that Rad is essential for cAMP-PKA 
regulation of CaV1.2 [92]. Our studies have demonstrated that Rad-LTCC interaction is a 
key molecular signaling axis for LTCC modulation both in the ventricle and in sinoatrial 
node cardiomyocytes [24, 214] (see Chapter 4), and that the absence of Rad from the 
complex yields modulation of the LTCC. Our current findings expand on this through 
kinetic analysis, demonstrating that CTRL ICa,L stimulated with isoproterenol decayed in 
a manner that was indistinguishable from cRadKO ICa,L (Figure 5.1). When treated with 
isoproterenol, channels may form “super-clusters” along the t-tubules to amplify Ca2+ 
influx [59] and modify kinetics.  The absence of Rad could promote these “super-
clusters” to form under basal conditions, which could in turn promote more calcium 
induced calcium release from the sarcoplasmic reticulum to feedback onto the clusters to 
then accelerate CDI. The “super-clusters” that form in response to sympathetic 
stimulation via the -AR axis signaling modulates trigger calcium, which could shorten 
action potential duration [266]. At the tissue level, sympathetic drive reduces transmural 




equal, the resulting ventricular action potential duration would prolong, appearing on the 
ECG as a longer QT interval [274]. In cRadKO cardiomyocytes, increased LTCC peak 
current is offset by faster kinetics; thus, raising the possibility that the net effect of Rad 
loss on cardiac electrophysiology for action potential duration and QT prolongation is 
nullified [21] (Figure 5.6,5.9).  
An alternate idea stems from Findlay who proposed that modulation of LTCC 
from -AR stimulation resulted in a switch from VDI to CDI.  Under basal conditions, it 
was thought that CDI contributed to decay at more negative potentials, while VDI 
dominated as the membrane became more depolarized.  Findlay and others showed that 
VDI has a biphasic decay, and that rapid VDI contributes to the fast component of ICa,L, 
not just CDI [60, 74-76, 275].   However, in the presence of isoprenaline, CDI dominated 
at all voltages, and VDI was suppressed. Findlay’s prediction was that CDI would then 
have little contribution to the action potential under basal conditions, but could promote 
severe slowing of ICa,L decay and therefore elongation of the action potential after -AR 
stimulation [60]. Our results demonstrate that the absence of Rad accelerates VDI both in 
the fast and slow components of ICa,L decay (Figure 5.5). This does not result in 
elongation of the action potential nor does it significantly prolong the QT interval 
(Figure 5.6). It is therefore possible that Rad contributes to LTCC regulation by allowing 
this switch between VDI and CDI.  Under basal conditions, the presence of Rad regulates 
VDI; when -ARs are activated, Rad phosphorylation causes dissociation from the LTCC 
[92] and CDI then becomes the dominant inactivation mechanism as channels cluster 
together and elevate intracellular calcium. The synchronous activity of these clusters then 




alter action potentials. Further studies into how phosphorylation of Rad alters its location 
within the complex or its interactions with other proteins could help elucidate how Rad 
contributes to LTCC inactivation, especially under conditions of -AR stimulation. 
5.4.3 Rad regulation of LTCC is independent of -adrenergic receptor signaling 
Our work has demonstrated that Rad is a critical component in LTCC modulation 
by -AR stimulation [21, 23, 24].  Indeed, cardiomyocyte-restricted Rad-deletion 
demonstrates the extreme by which the loss of Rad yields maximally modulated ICa,L that 
translates from channel function up to enhanced, in vivo cardiac function. Data collected 
from the 12-AR x Rad-triple knockout demonstrate that the maximal modulation of 
ICa,L is due to the absence of Rad from the LTCC, exclusive of activation of -ARs 
(Figure 5.7-5.9). Others who have utilized 1-AR knock out, 2-AR knock out, or 12-
AR double knock models have reported minimal impacts on basal cardiac function, 
suggesting that there are potentially other controls for critical physiological functions, 
such as cardiac rate and contractility, to compensate for the loss of these receptors [187, 
270, 276-279]. In 12-AR double knockout neonatal myocytes, 3-AR was shown to 
stimulate contraction after treatment with isoproterenol, though desensitization occurred 
more rapidly compared to 1-AR or 2-ARs [279].  It is therefore possible there is a 
minor contribution from other sources to how the heart responds to increased sympathetic 
drive.  However, our data clearly demonstrates a significant increase in function both at 
the level of whole heart and at the level of the channel when Rad is deleted in the 12-
AR double knock out without significant prolongation of the QT interval. We have 




damaging effects that are normally associated with the chronic use of positive inotropes 
[21, 24].  Therefore, we suggest that Rad reduction could serve as a treatment for heart 
failure that enhances systolic function while preserving -AR signaling pathways, and 
without increasing proarrhythmic late ICa,L  [50, 61-63].   
5.5 Limitations 
It is possible that differential dispersed cell activity might arise from cellular 
damage artifact during enzymatic dispersal.  However, our findings in this study are 
similar to other reports of Rad deletion on cardiac function [17, 21, 24, 92]. These studies 
are limited to the mouse.  Mice have a larger sarcoplasmic reticulum calcium content and 
greater SERCA activity compared to larger species [257, 268].  Repolarizing current is 
mostly carried by Ito and IKur in the mouse, while larger species express IKr and IKs [268].  
Despite these differences, the cardiac fight-or-flight response is conserved across 
multiple species, and this study gives further insight into how LTCC activity is 
modulated.    
5.6 Conclusions 
In summary, we have demonstrated that modulation of the LTCC is governed by 
the presence of Rad in the CaV1.2 macromolecular complex.  The absence of Rad yields 
an increase in peak ICa,L that is offset by an increase in both VDI and CDI so that action 
potential and QT interval are not significantly prolonged.  -AR mediated modulation of 
the LTCC is governed by Rad.  Taken together, Rad reduction within cardiomyocytes is a 




need for -blockers, thereby improving quality and quantity of life for those that suffer 





















Figure 5.1 Rad deletion ICa,L phenocopies modulated ICa,L. 
A) Exemplar Ca2+ currents with 10 mM EGTA for CTRL with ISO (green) and 
cRadKO (no ISO, red), traces normalized to peak current at 0 mV Scale bar: 100 
ms. Black dots indicate r30, Black stars indicate r150. Remaining current across 
voltage steps 30 ms after peak B) and 150 ms after peak C) . ICa,L current density 
30 ms D) and 150 ms E) after peak. Data in (B,C) analyzed by two-way ANOVA 
plus Šídák’s multiple comparisons test (For B: voltage x CTRL v cRadKO: †††p 
= 0.0009; For C: voltage x CTRL v cRadKO: ††p = 0.007). N = 4 mice, n = 7 














Figure 5.2 Rad deletion accelerates fast component of ICa,L decay.  
A) Exemplar Ca2+ currents with 10 mM EGTA for CTRL (blue) and cRadKO 
(red), traces normalized to peak current at 0 mV Scale bar: 100 ms. Black dots 
indicate r30. B) Remaining current 30 ms after peak across voltage steps. C) ICa,L 
current density 30 ms after peak. D) Regression plot of the absolute values of 
current density versus r30 (CTRL: slope = -0.01, deviation from zero: p = 0.28, r2 
= 0.5; cRadKO: slope = 0.03, deviation from zero: p = 0.002, r2 = 0.4; dotted lines 
represent 95% confidence intervals). Data in (B) analyzed by two-way ANOVA 
plus Šídák’s multiple comparisons test (For between CTRL and cRadKO: *p < 
0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001, alternating asterisks for 
presentation clarity; For voltage x CTRL v cRadKO: ††††p < 0.0001). Data in 
(D) analyzed by simple linear regression. N = 10 mice, n = 25 cells for CTRL; N 










Figure 5.3 Rad regulation of ICa,L kinetics requires SR Ca2+ release. 
A) Exemplar Ca2+ currents with 10 mM BAPTA for CTRL (blue) and cRadKO 
(red), traces normalized to peak current at 0 mV Scale bar: 100 ms. Black dots 
indicate r30. B) Remaining current 30 ms after peak across voltage steps. C) ICa,L 
current density 30 ms after peak. D) Regression plot of the absolute values of 
current density versus r30 (CTRL: slope = -0.003, deviation from zero: p = 0.91, 
r2 = 0.002; cRadKO: slope = 0.03, deviation from zero: p = 0.03, r2 = 0.6; dotted 
lines represent 95% confidence intervals). Data in (B) analyzed by two-way 
ANOVA plus Šídák’s multiple comparisons test (For voltage x CTRL v cRadKO: 
†p = 0.03). Data in (D) analyzed by simple linear regression.  N = 4 mice, n = 8 











Figure 5.4 Rad does not alter slow component of ICa,L decay.  
A-C) Current measured with EGTA; D-F) Current measured with BAPTA; A) 
Remaining current 150 ms after peak across voltage steps.  B) ICa,L current density 
150 ms after peak. C) Regression plot of the absolute values of current density 
versus r150 (CTRL: slope = 0.04, deviation from zero: p = 0.03, r2 = 0.2; cRadKO: 
slope = 0.03, deviation from zero: p = 0.09, r2 = 0.2; dotted lines represent 95% 
confidence intervals).  N = 10 mice, n = 25 cells for CTRL; N = 10 mice, n = 23 
cells for cRadKO. D) Remaining current 150 ms after peak across voltage steps. 
E) ICa,L current density 150 ms after peak. F) Regression plot of the absolute 
values of current density versus r150 (CTRL: slope = 0.02, deviation from zero: p 
= 0.54, r2 = 0.1; cRadKO: slope = 0.04, deviation from zero: p = 0.003, r2 = 0.9; 
dotted lines represent 95% confidence intervals). N = 4 mice, n = 8 cells for 
CTRL; N = 4 mice, n = 7 cells for cRadKO. Data in (A,D) analyzed by two-way 
ANOVA plus Šídák’s multiple comparisons test. (For A: For voltage x CTRL v 
cRadKO: †††p = 0.0009; For D: For between CTRL and cRadKO: *p = 0.03; For 







Figure 5.5 Rad deletion enhances VDI. 
A) Exemplar Ba2+ currents with 10 mM EGTA for CTRL (blue) and cRadKO 
(red), traces normalized to peak current at 0 mV Scale bar: 100 ms. Black dots 
indicate r30, Black stars indicate r150. B) Remaining current 30 ms after peak 
across voltage steps. C) Remaining current 150 ms after peak across voltage 
steps. D) IBa,L current density 30 ms after peak. E) IBa,L current density 150 ms 
after peak. F) Regression plot of the absolute values of current density versus r30  
(CTRL: slope = -0.006, deviation from zero: p = 0.33, r2 = 0.2; cRadKO: slope = 
0.02, deviation from zero: p = 0.10, r2 = 0.4; dotted lines represent 95% 
confidence intervals). G) Regression plot of the absolute values of current density 
versus r150 (CTRL:slope = 0.04, deviation from zero: p = 0.73, r2 = 0.03; cRadKO: 
slope = 0.03, deviation from zero: p = 0.16, r2 = 0.3; dotted lines represent 95% 
confidence intervals). N = 3 mice, n = 7 cells for CTRL; N = 4 mice, n = 8 cells 
for cRadKO. Data in (A,D) analyzed by two-way ANOVA plus Šídák’s multiple 
comparisons test (For A: For voltage x CTRL v cRadKO: †††p = 0.0002; For D: 






Figure 5.6 Rad deletion does not prolong action potential duration or QT 
interval. 
Exemplar action potentials at A) baseline from CTRL (blue) and cRadKO (red), 
and after ISO B) from CTRL (green) and cRadKO (black); Scale bar: 20 mV, 50 
ms; arrow indicating inflection point. C) Action potential ampltiude at baseline (p 
= 0.18) D) Action potential duration at 50% repolarization at baseline (p = 0.81). 
E) Action potential duration at 80% repolarization at baseline (*p = 0.04).  N = 2 
mice, n = 9 cells for CTRL; N = 2 mice, n = 7 cells for cRadKO. F) Action 
potential ampltiude after ISO (CTRL: p = 0.10, cRadKO: p = 0.20). G) Action 
potential duration at 50% repolarization after ISO (CTRL: p=0.45; cRadKO: p = 
0.38). H) Action potential duration at 80% repolarization after ISO (CTRL: *p = 
0.05; cRadKO: p=0.18).  N = 2 mice, n = 9 cells for CTRL with ISO; N = 2 mice, 
n = 6 cells for cRadKO. I) Representative raw QT interval of intrinsic heart rate 
from surface ECG of CTRL and cRadKO, Scale bar: 0.5 mV, 50 ms. J) Raw QT 
interval (ms) is not significantly different (p = 0.35). K) Corrected QT interval 
(ms) is not significantly different (p = 0.41).  CTRL: N = 6 mice; cRadKO: N = 7 
mice. P values calculated using Student unpaired t-test comparing CTRL to 
cRadKO (C-E,F-H, J-K) and Student paired t-test comparing baseline to ISO (F-






Figure 5.7 Rad deletion increases heart function exclusive of β1β2-
Adrenergic Receptors. 
A) Representative M-mode short axis echocardiography from dKO and tKO mice. 
Scale bars: 1 sec; 2 mm. B) Ejection fraction  (****p<0.0001).  C) Left 
ventricular inner dimensions  (**p=0.003).  D) Left ventricular anterior and E) 
Left ventricular posterior wall thickness (LVAW: p=0.43; LVPW: p=0.52). 
Dimensions (C-E) in diastole.  dKO: N = 11 mice; tKO: N = 15 mice. F) 
Representative raw QT interval  from surface ECG of dKO and tKO, Scale bar: 
0.5 mV, 50 ms. G) Raw QT interval (ms) is not significantly different (p = 0.19). 
H) Corrected QT interval (ms) is not significantly different (p = 0.14).  I) RR 
interval (ms) is not significantly different (p = 0.27). dKO: N = 6 mice; tKO: N = 









Figure 5.8 Rad deletion yields modulated ICa,L in the absence of β1β2-
Adrenergic Receptors. 
A) Exemplar family of Ca2+ currents of dKO (dark blue) and tKO (dark red), 
Scale bar: 1 nA, 100 ms. B) Peak ICa,L current density is larger in tKO compared 
to dKO.  C) Conductance transform of current voltage curve demonstrates higher 
maximal conductance in tKO compared to dKO with quantification shown in D) 
(****p < 0.0001). E) Activation midpoint is significantly negative-shifted in tKO 
(*p = 0.04). F) Exemplar Ca2+ currents with EGTA for dKO (dark blue) and tKO 
(dark red), traces normalized to peak current at 0 mV Scale bar: 100 ms. Black 
dots indicate r30, Black stars indicate r150.  Remaining current across voltage steps 
30 ms after peak G) and 150 ms after peak H). ICa,L current density 30 ms I) and 
150 ms J) after peak. dKO: N = 3 mice, n = 7 cells; tKO: N = 3 mice, n = 9 cells. 
P values calculated using Student unpaired t-test for (D,E). Data in (G,H) 
analyzed by two-way ANOVA plus Šídák’s multiple comparisons test (For G: For 
voltage x CTRL v cRadKO: ††††p < 0.0001; For H: For voltage x CTRL v 







Figure 5.9 Rad modulates ICa,L independent of β1β2-Adrenergic Signaling to 
Confer Systolic Advantage. 
The absence of Rad results in modulated ICa,L that enhances cardiac contraction 
(Early Phase) without promoting electrical dysfunction because of accelerated 






Supplemental Figure 5.10 Two-way ANOVA 95% confidence intervals and 
tabular results. 
A) 95% confidence intervals and tabular results for Figure 5.1B. B) 95% 
confidence intervals and tabular results for Figure 5.1C. C) 95% confidence 
intervals and tabular results for Figure 5.2B. D) 95% confidence intervals and 
tabular results for Figure 5.3B. E) 95% confidence intervals and tabular results for 









Supplemental Figure 5.11 Two-way ANOVA 95% confidence intervals and 
tabular results. 
A) 95% confidence intervals and tabular results for Figure 5.5B. B) 95% 
confidence intervals and tabular results for Figure 5.5C. C) 95% confidence 
intervals and tabular results for Figure 5.8G. D) 95% confidence intervals and 

















Supplemental Figure 5.12 Surface ECG Measurements. 
A) Representative raw QT interval of baseline heart rate from surface ECG of 
CTRL and cRadKO, Scale bar: 0.5 mV, 50 ms. B) Raw QT interval (ms) is not 
significantly different (p = 0.16). C) Corrected QT interval (ms) is not 
significantly different (p = 0.14). D) Baseline RR interval (ms) is not significantly 
different (p = 0.97). E) Intrinsic RR interval (ms) is not significantly different (p 
= 0.48) CTRL: N = 6 mice; cRadKO: N = 7 mice. P values calculated using 


















Supplemental Figure 5.13 Whole Heart measurements of dKO and tKO. 
A) Ejection fraction of CTRL (N = 23) and dKO (N = 6) after acute isoproterenol 
(30 mg/kg). Data for CTRL+ISO taken from published dataset in [24]. 














CHAPTER 6. ALTERATIONS TO RAD STRUCTURE MODULATE LTCC GATING 
6.1 Preface 
The results and methods attributed to others are presented for clarity and flow are 
italicized.  
6.2 Introduction 
The L-type calcium channel (LTCC) is a critical signal transducer within 
cardiomyocytes that translates the electrical signal from an action potential into calcium 
release needed for a contraction [25]. Because of this essential role, the LTCC is tightly 
regulated to prevent calcium overload and electrical dysfunction [6, 124, 125]. Regulation 
of the LTCC is governed by auxiliary subunits within the complex, protein associations, 
and transiently interacting signaling molecules [25, 92, 280-282]. CaVβ, a key auxiliary 
subunit within the channel complex, contributes to channel trafficking and gating, and 
serves as a mediator of protein associations with the LTCC, including RGK proteins [16, 
17, 195-197]. Studies in heterologous expression systems demonstrate all RGK proteins 
inhibit LTCC current (ICa,L) [16, 17, 161, 283-285]; data from these studies suggest that 
RGK proteins contribute to LTCC regulation through  stabilization of voltage sensing, 
reduced channel open probability, and cell surface stabilization [199, 241, 286, 287]. 
Rad was the founding member of the RGK subfamily, first identified as a gene 
upregulated in skeletal muscle [161]. Similar to other RGK proteins, Rad binds to CaVβ 
and acts as an endogenous inhibitor of the LTCC [16-20]. Overexpression of Rad blocks 




activation to hyperpolarized potentials, and enhances inactivation [16, 17, 19, 20, 166, 195] 
(see chapter 3,5).  Rad also plays a central role in modulation of the LTCC by β-adrenergic 
stimulation [92, 118] (see chapter 3,5). These studies strongly implicate Rad as a key 
regulator of LTCC activity; however, the mechanism by which Rad governs channel 
function remains unknown [288]. 
Rad-mediated regulation of ICa,L requires the presence of Rad’s C-terminal tail, but 
does not necessarily require an interaction with CaVβ [196, 199]. Indeed, the absence of 
the C-terminus of Rad eliminates LTCC inhibition; replacement of the tail with an artificial 
membrane anchor restores ICa,L blockade [199].  Because the C-terminus of Rad includes 
binding regions for key regulators of LTCC, such as 14-3-3, PKA, and calmodulin, it is 
possible that the C-terminus is the mediator of Rad regulation of the LTCC [55, 92, 175, 
177, 241, 281, 289]. In order to assess the structural mechanisms by which Rad governs 
ICa,L in vivo, two mouse models were developed: Rad-Flag and Rad-Flag A277X.  Both 
models contain three copies of the Flag epitope tag attached to the N-terminus of Rad, with 
Rad-Flag A277X bearing a C-terminal truncation of the Flag-tagged Rad gene. In the 
absence of the C-terminus, cardiac function was enhanced and wall thickness increased.  
This was due to elevated ICa,L; in fact, ICa,L in Rad-Flag A277X mirrored modulated ICa,L 
and Rad deletion because current density was increased, voltage dependent activation 
shifted in a hyperpolarizing direction, and inactivation was accelerated [24, 103] (see 
chapter 3,5). This work confirms the requirement of the C-terminus of Rad for inhibition 





Studies in heterologous expression systems report Rad mediated regulation of the 
LTCC requires the C-terminus of Rad [17, 92, 199, 280, 282]; however, this has not been 
tested in vivo. Therefore, we developed two mouse models: a wild-type 3xFlag-Rad (Figure 
6.1, red; abbreviated Rad-Flag) and 3xFlag-RadA277X (Figure 6.1, blue; abbreviated as 
Rad-Flag A277X) that bears a C-terminal truncation within the endogenous Flag-tagged 
Rad gene.  The 3x indicates the three copies of Flag epitope introduced in frame to the 
amino terminus of endogenous wild-type Rrad gene. This allows investigation of potential 
interactions and binding partners of Rad that are currently unknown while preserving the 
native protein stoichiometry; this also provides a background to compare how these 
interactions change when the C-terminus of Rad is truncated. Therefore, Rad-Flag is used 
as a control for Rad-Flag A277X. For comparison, the means of published WT and 
cRadKO are also included in graphs as black dotted lines.  
6.3.1 Rad-Flag A277X increases cardiac function and wall thickness 
Transgenic mouse models that alter components of the L-type calcium channel 
complex can promote pathological hypertrophy and death [12, 149, 290]. It was therefore 
important to assess cardiac structure and function through echocardiography to determine 
if there were any adverse effects from knocking in 3X Flag-Rad (referred to as Rad-Flag) 
or truncating the C-terminus of Rad (Rad-Flag A277X). Surprisingly, we found that Rad-
Flag hearts demonstrated a phenotype similar to dilated cardiomyopathy compared to 
published data for WT (Figure 6.2). Ejection fraction (EF) was significantly decreased in 




ventricular inner dimensions were significantly smaller in Rad-Flag A277X compared to 
Rad-Flag (Figure 6.2B).  Rad-Flag A277X exhibited significantly thicker walls in both the 
anterior wall and posterior wall compared to Rad-Flag (Figure 6.2 C,D, respectively).  
This data suggests the absence of the C-terminus of Rad enhances cardiac function while 
also promoting cardiac hypertrophy. 
6.3.2 Rad-Flag A277X enhances LTCC gating 
A potential explanation for an increase in cardiac performance and wall thickness 
in Rad-Flag A277X could be due to increased L-type calcium current (ICa,L) density [12, 
149].  I therefore measured ICa,L from isolated ventricular cardiomyocytes from Rad-Flag 
and Rad-Flag A277X mice (Figure 6.3). Figure 6.3A shows representative families of ICa,L 
traces from Rad-Flag (teal) and Rad-Flag A277X (pink) for evaluating current/voltage 
(I(V)) relationships.  The I(V) curve for Rad-Flag A277X shows increased current density 
compared Rad-Flag (Figure 6.3B). Capacitance is significantly larger in Rad-Flag A277X 
than in Rad-Flag (Figure 6.3C). Rad-Flag A277X also demonstrated a larger maximal 
conductance compared to Rad-Flag (Figure 6.3D).  The normalized conductance voltage 
curves superimposed on the steady-state inactivation curves (Figure 6.3E) highlight the 
negative shift in activation and inactivation in Rad-Flag A277X; activation midpoint was 
significantly shifted toward more negative membrane potential (Figure 6.3F). Analysis of 
the decay kinetics revealed Rad-Flag A277X enhances inactivation (Figure 6.4). Traces 
from Rad-Flag and Rad-Flag A277X ICa,L demonstrated that Rad-Flag A277X ICa,L decay 
is faster than that for Rad-Flag (Figure 6.4A).  Across multiple voltage steps, there was 




in Rad-Flag ICa,L (Figure 6.4B, Figure 6.4F for 2-way ANOVA tabular results). Current 
density of r30 was larger in Rad-Flag A277X compared to Rad-Flag (Figure 6.4C). 
Analysis of the late component of decay (r150) revealed less remaining current in Rad-Flag 
A277X (Figure 6.4D, Figure 6.4G for 2-way ANOVA tabular results) with larger current 
density at r150 (Figure 6.4E). These data support that Rad regulates channel gating through 
interactions with its C-terminus; in the absence of the C-terminus, LTCC activity is 
enhanced. 
6.4 Discussion 
The major finding of this study is that the C-terminus of Rad is required for Rad-
mediated regulation of the LTCC.  By deleting the C-terminus of Rad, ICa,L significantly 
increases and activates at more negative potentials; inactivation is also accelerated. These 
effects mirror LTCC modulation and when Rad is not present in the channel complex [24, 
103]. These alterations in LTCC function further support that Rad plays a critical role in 
physiological modulation of the LTCC.   
The mechanism by which Rad governs LTCC activity remains unclear [288]. As a 
regulator of ICa,L, Rad must govern I in a manner that alters one or multiple variables of the 
equation: I = NT X pf X po x I where I represents macroscopic calcium current of the cell, 
NT is the total number of channels, pf is the probability that a given channel is available to 
open, po is the probability the channel will open, and i is the unitary current through an 
open pore [282, 291, 292]. Voltage-dependence of activation of CaV1.2 is thought to be 
controlled by the interactions of multiple components within the channel complex, 




AID (α-interacting domain), the I-II linker between domain I and II of the α1 subunit, and 
CaVβ [55, 118, 293]. A recent study also implicated that Rad inhibits LTCC function 
through an interaction with CaVβ that alters the IS6-AID connection and is alleviated after 
PKA phosphorylation [55]. A hallmark feature of PKA-mediated LTCC modulation is a 
hyperpolarizing shift in activation [103]. Rad serves as a critical target of phosphorylation 
by PKA, and the absence of Rad from the complex results in modulated-like ICa,L [92, 103] 
(see chapter 3,5). Studies in heterologous expression systems demonstrate the C-terminus 
of RGK proteins is critical to inhibition of the LTCC [17, 92, 280], and Rad-Flag A277X 
supports this in vivo. When the C-terminus of Rad is deleted, ICa,L mirrors LTCC 
modulation: increase in ICa,L current density, hyperpolarizing shift in activation, and 
accelerated inactivation [103]. Results from these studies support that the C-terminus of 
Rad is essential for Rad-mediated regulation of the LTCC. 
The C-terminus of Rad includes a region that can bind to negatively charged 
phospholipids in the plasma membrane, such as PI(3,4,5)P3 and PI (4,5)P2 [92, 177]; when 
the plasma membrane is depleted of PI (4,5)P2, Rad was unable to target to the plasma 
membrane [177]. It is therefore possible that Rad-Flag A277X mirrors Rad deletion 
because Rad is not present in the complex. The C-terminus of Rad also includes key sites 
of PKA phosphorylation that induce modulation of the LTCC [92]. It is therefore possible 
that Rad regulates the LTCC through interactions with the C-terminus of Rad, S4 and S6 
segments of α1C, and CaVβ.  Upon phosphorylation of one or multiple sites within the C-
terminus of Rad, Rad is somehow removed from the LTCC that may allow CaV to 




Rad inhibition of LTCC can occur either through mechanisms dependent on binding 
to CaVβ or mechanisms independent of binding to CaVβ [281]; these independent 
mechanisms could be through calmodulin regulation since the C-terminus of Rad also 
contains a binding region for calmodulin [175, 281, 289]. CaM plays a critical role in LTCC 
inactivation and channel clustering and binds to Rad in a calcium-dependent manner [58, 
59, 68-71, 166]. Clustered channels promote cooperative gating of neighboring channels 
and larger calcium influx, especially under conditions of β-adrenergic receptor stimulation 
[58, 59]. In the absence of the C-terminus of Rad, there is larger calcium influx (Figure 
6.3) and enhanced inactivation, specifically the early component of inactivation that is 
dominated by CDI (Figure 6.4); the large increase in ICa,L mirrors modulated ICa,L that is 
not drastically different from a lack of Rad in the channel complex [24, 50, 61-63] (Figure 
6.3; see chapter 3,5). A clear mechanism by which Rad regulates LTCC activity and 
modulation remains unknown; however, it is evident from these studies that Pf and Po of 
the LTCC are mediated, in part, by multiple interactions between the C-terminus of Rad 
and other components of the LTCC. 
A limitation to this study is the unexpected alterations in cardiac function and 
structure exhibited by the Rad-Flag mouse.  Compared to multiple parameters published 
for healthy WT, Rad-Flag had decreased function and chamber dilation, indicating that 
inserting a Flag-tag on Rad somehow induced dilated cardiomyopathy [290] (Figure 6.2). 
In the presence of 3XFlag, Rad gains a net -12 charge.  Because of the location of Rad 
within the complex, binding with CaVβ [92, 195, 280, 281], it is possible that the new net 
negative charge in Rad-Flag interacts with the positive charged S4 segments of the LTCC 




midpoint is shifted more positive (Figure 6.3) and cardiac function is compromised 
(Figure 6.2). The changes in cardiac structure and function make it difficult to truly 
compare Rad-Flag to Rad-Flag A277X.  However, even in this complex phenotype, it is 
evident that Rad is in close proximity to the LTCC and the absence of the C-terminus of 
Rad induces similar effects of Rad-deletion: large increase in calcium current density, a 
hyperpolarized shift in activation, and accelerated inactivation (Figure 6.2,6.3). Future 
studies utilizing a different knock-in strategy, such as a biotin ligase-based system like 
BioID, may be better suited to analyze the protein-protein interactions that are crucial for 
Rad-LTCC since recent published work demonstrates this model system does not affect 
cardiac function or structure [295]. 
In summary, these studies confirm that Rad-mediated regulation of the LTCC 
requires the C-terminus of Rad. Deletion of the C-terminus of Rad induced a modulated 
state of the LTCC, similar to a LTCC complex devoid of Rad, further supporting Rad as a 
critical component to LTCC modulation. Though the mechanism of Rad inhibition of the 













Figure 6.1 Schematic of Rad-Flag and Rad-Flag A277X transgenic mice. 
CRISPR/Cas9 gene engineering techniques were used to sequentially introduce 
3xFlag epitope tag to the N-terminus of the endogenous mouse Rrad gene (to 
generate Rad-Flag mice). CRISPR/Cas9 was then used to introduce a stop codon 
at A277 into the endogenous Flag-tagged Rrad gene to generate a second mouse, 

















Figure 6.2 Rad-Flag A277X enhances cardiac function and increases wall 
thickness. 
A)  Representative M-mode short axis echocardiography from Rad-Flag and Rad-
Flag A277X mice. Scale bars: 1 sec; 2 mm. B) Ejection fraction (****p < 
0.0001). C) Left ventricular inner dimensions (****p < 0.0001). D) Left 
ventricular anterior and E) Left ventricular posterior wall thickness (LVAW: 
****p < 0.0001; LVPW: ****p < 0.0001). Dimensions (C-E) in diastole. Dotted 
lines represent mean summary of published WT and published cRadKO (Ahern 
et. al 2019, [24]). Data displayed from female mice: Rad-Flag: N = 11 mice; Rad-









Figure 6.3 Rad-Flag A277X enhanced LTCC function 
A) Representative family of ICa,L currents from Vtest ranging from -75 mV to +45 
mV in 10 mV increments, with voltage protocol schematic shown above. Scale 
bars: 10 pA/pF, 100 ms. B) Current-voltage relationship for peak ICa,L from Rad-
Flag and Rad-Flag A277X ventricular cardiomyocytes. C) Cell capacitance is 
significantly larger in Rad-Flag A277X compared to Rad-Flag (*p = 0.01). D) 
Maximal conductance is significantly increased in Rad-Flag A277X compared to 
Rad-Flag (***p = 0.0003). E) Conductance-voltage curves normalized to 
maximal conductance in Rad-Flag and Rad-Flag A277X. Smooth curves are 
Boltzmann distribution fitted to data. F) Activation midpoint is significantly 
negative-shifted in Rad-Flag A277X compared to Rad-Flag (****p < 0.0001). 
Data for C,D,F analyzed by unpaired Student’s t-test. Data displayed from female 










Figure 6.4 Rad-Flag A277X enhanced inactivation. 
A) Exemplar Ca2+ currents with EGTA for Rad-Flag (teal) and Rad-Flag A277X 
(pink), traces normalized to peak current at 0 mV Scale bar: 100 ms. Black dots 
indicate r30, Black stars indicate r150.  B) Remaining current across voltage steps 
30 ms after peak (*p < 0.05; **p < 0.009; ***p < 0.0002; ****p < 0.0001; p 
values alternated between above and below for clarity). C) ICa,L current density 30 
ms after peak. D) Remaining current across voltage steps 150 ms after peak (*p < 
0.02; ***p < 0.0052; p values alternated between above and below for clarity).   
E) ICa,L current density 150 ms after peak. Data for B,C analyzed by two-way 
ANOVA plus Šídák’s multiple comparisons test with F) 95% confidence intervals 
and tabular results for Figure 6.3B and G) 95% confidence intervals and tabular 
results for Figure 6.3D. Data displayed from female mice: Rad-Flag: N = 3 mice, 







CHAPTER 7. MYOCARDIAL RAD DELETION PRESERVES CARDIAC FUNCTION IN 
PRESSURE-OVERLOAD INDUCED HEART FAILURE 
7.1 Preface 
The results and methods attributed to others are presented for clarity and flow are 
italicized.  
7.2 Introduction 
Heart failure (HF) is an emerging epidemic. About 50% of HF patients die within 
five years of their diagnosis [296]. Heart failure occurs when a substantial amount of 
functional myocardial cells is lost (or altered) in response to injury, leading to left 
ventricular systolic dysfunction [297]. In an effort to maintain adequate function, the heart 
initiates several compensatory mechanisms to improve contractility; however, these 
processes contribute to the progression of failure [297]. Leading therapeutics include 
positive inotropic agents, but these drugs induce pathological signaling when used 
chronically [5]. Therefore, an ideal goal would be to identify a novel target that could safely 
improve inotropy and cardiac function without promoting pathological signaling and 
remodeling.  
The L-type calcium channel (LTCC) is a heteromultimeric protein complex that 
provides trigger calcium necessary to induce a contraction, and is an upstream regulator of 
modulating inotropy within cardiomyocytes. The LTCC complex is comprised of a pore-
forming α-subunit (CaV1.2 in the myocardium), CaVβ2, α2δ, and calmodulin [194]. LTCC 
function is tightly regulated to prevent calcium overload and stimulation of multiple 




regulator of LTCC activity is Rad (Ras associated with diabetes), a member of the RGK 
subfamily (Rem, Rad, Rem2, and Gem/Kir) of Ras-related small GTPases; Rad serves as 
an endogenous inhibitor of LTCC activity and is abundantly expressed in the heart [16-18, 
195-198]. Rad deficiency yields an increase in ICa,L that promotes enhanced cardiac 
function [21, 23, 24]; expression levels of Rad significantly decrease in patients suffering 
from heart failure with reduced ejection fraction [23] as well as in a mouse model of cardiac 
hypertrophy [181].  This suggests that Rad down-regulation may be a critical component 
in the signaling for ventricular remodeling. 
Studies utilizing whole-body Rad knockout (gRAD-/-) mice reported progressive 
structural remodeling, increased myocyte size, increased up-regulation of the fetal gene 
program associated with cardiac hypertrophy, and cardiac fibrosis [21, 198].  These results 
are in line with other mouse models that have dramatically increased ICa,L as seen in the 
absence of Rad [12, 149]. However, our recent studies have shown that myocardial Rad 
deficiency increases ICa,L to enhance cardiac function into senescence without evidence for 
structural remodeling or progression to heart failure [24]. This may be because Rad 
expression has been maintained in non-cardiac tissue, such as vascular smooth muscle 
[171] and in cells in the bone marrow [172], that could influence cardiac remodeling in 
response to increased positive inotropy.   A key hypothesis is that decreased Rad 
contributes to a compensatory response under conditions of a failing heart [23, 181]. Given 
that myocardial Rad deletion improves systolic heart function without pathological 
remodeling, we hypothesized that myocardial Rad deletion will mitigate myocardial 
remodeling in advanced stages of heart failure. Utilizing our inducible, myocardial-




response to pressure-overload induced heart failure by transverse aortic constriction 
(TAC).  We assessed cardiac function and structure when Rad was depleted before TAC, 
when the induction of Rad deletion was initiated at time of surgery, and when Rad deletion 
was induced one-month post-TAC surgery.  We found in all three paradigms that cRadKO 
had better survival and improved cardiac function compared to our CTRL.  This was 
commensurate with enhanced trigger calcium and preserved excitation contraction 
coupling. These major new findings suggest Rad as a novel potential target to safely 
enhance positive inotropy to rescue cardiac function under failing conditions. 
7.3 Results 
7.3.1 cRadKO protects in vivo heart function from pressure-overload induced heart 
failure 
cRadKO was induced 4 weeks prior to TAC and mice were followed for 3 months 
after surgery (Figure 7.1A).  Survival was significantly improved in cRadKO mice 
subjected to TAC compared to CTRL mice (Figure 7.1B).   In vivo cardiac function was 
assessed by echocardiography before surgery and at time points shown in the timeline 
(Figure 7.1A).  At 3-months post-surgery, cRadKO with TAC maintained an elevated 
ejection fraction compared to CTRL (Figure 7.1C; Figure 7.2A for 2-way ANOVA tabular 
results). There was no difference in heart chamber size in cRadKO with TAC compared to 
sham (Figure 7.1D; Figure 7.2B for 2-way ANOVA tabular results) or in heart wall 
thickness (Figure 7.1E-F; Figure 7.2C,D respectively for 2-way ANOVA tabular results); 




significantly elevated heart weight/body weight in CTRL but not in cRadKO, consistent 
with the echocardiography in vivo measures (Figure 7.1G; Figure 7.2E for 2-way ANOVA 
tabular results). TAC significantly increased fibrosis in CTRL and in cRadKO compared 
to CTRL Sham, but there was no difference in the degree of fibrosis with respect to 
knockout. (Figure 7.3B,C; Figure 7.4A for 1-way ANOVA tabular results). qRT-PCR of 
ANF displayed no significant difference in any of the groups (Figure 7.3D; Figure 7.4B 
for 1-way ANOVA tabular results). Taken together these data suggest that Rad reduction 
confers a gain of systolic function that promotes survival and prevents structural 
remodeling.  
7.3.2 cRadKO enhances in vivo heart function after pressure-overload 
Current management of advanced heart failure is limited in improving quality of life, 
and ultimately does not prevent the progression of heart failure to advanced stages; 
however, HF patients demonstrate functional benefit to inotropic agents [298]. Using ECG 
telemetry we previously observed tamoxifen increase of heart rate within 3 to 7 days. In 
the present experiment we administered tamoxifen at the time of surgery; consequently, 
myocardial Rad reduction is expected to occur by ~7days after surgery (see timeline, 
Figure 7.5A).  No mortality was observed in cRadKO after TAC, while 25% mortality was 
seen in our CTRL mice (Figure 7.5B). Echocardiographic assessment of these mice at 
baseline (see timeline) demonstrated no significant difference between groups in function 
or structure, as expected (Figure 7.5C-F; Figure 7.6A-D for 2-way ANOVA tabular 
results).  However, one month after surgery, cRadKO maintained normal function while 




left ventricular inner dimensions while CTRL mice had enlarged inner dimensions (Figure 
7.5D).  cRadKO demonstrated thicker anterior and posterior walls compared to CTRL 
mice (Figure 7.5E,F).  Three months after surgery, we measured heart weight/body weight 
from the surviving animals and found no significant difference between groups (Figure 
7.5G). This data supports that in the early stages of heart failure, Rad reduction preserves 
systolic function.  
7.3.3 cRadKO maintains elevated calcium cycling after pressure-overload 
The increase in left anterior wall and posterior wall thickness seen in cRadKO could 
be due to defective excitation-contraction coupling within cardiomyocytes [181, 299-303].  
Therefore, we isolated cardiomyocytes from our CTRL and cRadKO TAC mice that were 
given tamoxifen at time of surgery and measured ICa,L (Figure 7.7; see timeline, Figure 
7.7A) and calcium handling (Figure 7.9; see timeline, Figure 7.9A).  Representative ICa,L 
traces in Figure 7.7B,G highlight increased current density and accelerated kinetics, 
respectively. The current/voltage (I(V)) curves for ICaL show that cRadKO had a greater 
current density compared to CTRL (Figure 7.7C). Maximal conductance was greater for 
cRadKO (Figure 7.7D; maximal conductance: cRadKO = 450 ± 41 pS/pF, n=12; CTRL = 
195 ± 25 pS/pF, n=8; ****p<0.0001) and the activation midpoint was shifted towards more 
negative membrane potential (Figure 7.7E,F; cRadKO = -10.3 ± 1.1 mV, n=12; CTRL = 
-3.2 ± 2.1 mV, n=8; *p=.01). Analysis of kinetics demonstrated less remaining current in 
cRadKO TAC compared to CTRL TAC in the early component (r30) (Figure 7.7G,H; 
Figure 7.8A for 2-way ANOVA tabular results) and no difference in the late component 




Whole-cell cytosolic calcium dynamics were also significantly larger in amplitude 
in cRadKO compared to CTRL (Figure 7.9B,C; cRadKO = 2.2 ± 0.2 F340/380, n=11; CTRL 
= 1.5 ± 0.2 F340/380, n=21; *p=.03).  Upstroke velocity of the calcium transient was also 
accelerated in cRadKO compared to CTRL (Figure 7.9D; cRadKO = 55.2 ± 5.1 
(F340/380)/ms, n=11; CTRL = 39.1 ± 4.8 (F340/380)/ms, n=21; *p=.03). To assess cytosolic 
clearance of Ca2+, we measured the time constant (τ) of the calcium transient decay, and 
found that it was faster in cRadKO compared to CTRL (Figure 7.9E; cRadKO = 0.16 ± 
0.01 s, n=11; CTRL = 0.12 ± 0.01 s, n=21; *p=.02).   
Under normal physiological heart rates, the contractility of failing myocytes is 
significantly less than normal [303, 304]; increasing the pacing rate of isolated myocytes 
decreases contractility while normal myocytes demonstrate an increase in contractility 
[303].  We therefore measured sarcomere dynamics from failing myocytes isolated from 
cRadKO and CTRL simultaneously with calcium transients (Figure 7.10).  Elevated 
calcium dynamics accompanying Rad deletion coincided with unchanged resting 
sarcomere length (Figure 7.10B,C), unchanged fractional shortening (Figure 7.10D), and 
no change to the rate at which the cell shortened (Figure 7.10E). Using the model 
published by Davis et. al [202], we calculated the integrated tension and found the index 
score for cRadKO is +0.06 and CTRL is +0.05 (Figure 7.10F), indicating a modest trend 
toward concentric hypertrophy in response to pressure overload in both models.  This is 
further supported by the increase in wall thickness we observed in both CTRL and cRadKO 
(Figure 7.1,7.5). Taken together, this data suggests that excitation-contraction coupling is 




7.3.4 Response to -adrenergic receptor stimulation remains blunted in cRadKO after 
pressure-overload  
A hallmark feature of heart failure is the down-regulation of β-adrenergic receptors, 
resulting in a blunted response in contractility [303, 305]. We therefore measured ICa,L and 
calcium transients after the addition of isoproterenol to assess whether there was a β-
adrenergic receptor response (Figure 7.11,7.12).  Given that ICa,L from cRadKO resembles 
β-adrenergic modulated ICa,L, we did not expect any response.  As expected, we did not see 
any change in current density (Figure 7.11Bii), maximal conductance (Figure 7.11C,D) 
or activation midpoint (Figure 7.11E,F) in response to isoproterenol in cRadKO with 
TAC.  Compared to CTRL, cRadKO had larger maximal conductance and trended towards 
a more negative activation midpoint (Figure 7.11C,E). For cytosolic calcium handling, 
there was no difference between cRadKO and CTRL in calcium transient amplitude, 
upstroke velocity or the rate of decay (Figure 7.12B-E).  There was also no response to 
isoproterenol in either CTRL or cRadKO in amplitude or upstroke velocity (Figure 
7.12F,G). The rate of decay accelerated in CTRL in response to isoproterenol, with no 
change in cRadKO (Figure 7.12H).  Taken together, this data demonstrates that ICa,L is 
maximally modulated in the absence of Rad, and responsiveness to β-adrenergic 
stimulation remains blunted in both CTRL TAC and cRadKO TAC.  
7.3.5 cRadKO promotes recovery of function in advanced stages of pressure-overload 
Increased positive inotropy due to Rad deletion preserved cardiac structure and 




and in the early stages of onset (Figure 7.5-7.12). We therefore induced Rad deletion in 
mice one month after TAC surgery to assess more advanced heart failure (Figure 7.13A, 
timeline).  Survival was assessed beginning at the time of surgery (Figure 7.13B). One 
month after Rad knockout (two months post-surgery) resulted in 71% survival in cRadKO 
TAC and 26% survival in CTRL TAC.  Echocardiographic assessment showed enhanced 
ejection fraction after Rad deletion that was not significantly different from CTRL Sham 
(Figure 7.13C; Figure 7.14A for 2-way ANOVA tabular results).  There was no 
significant difference in heart chamber size after Rad deletion compared to CTRL Sham, 
while CTRL TAC showed significant chamber dilatation (Figure 7.13D; Figure 7.14B for 
2-way ANOVA tabular results). Left ventricular anterior wall thickness significantly 
increased after Rad deletion compared to CTRL Sham, while no difference was detected 
in left ventricular posterior wall (Figure 7.13E,F; Figure 7.14C,D for 2-way ANOVA 
tabular results). Taken together, these data suggest that the reduction of Rad in the presence 
of pressure-overload induced heart failure promotes increased cardiac function through a 
compensatory response. 
7.3.6 cRadKO prevents progression of cardiac dysfunction in advanced stages of 
pressure-overload  
Left ventricular ejection fraction can appear normal under conditions of left 
ventricular systolic function [306]. To further assess left ventricular systolic function, we 
also used speckle-tracking echocardiography to evaluate global longitudinal strain and 
circumferential strain in CTRL TAC and cRadKO TAC compared to CTRL Sham (Figure 




demonstrated significantly lower longitudinal strain compared to Sham; however, after 
Rad deletion cRadKO TAC returned to the level of CTRL Sham and cRadKO Sham, while 
CTRL TAC remained lower (Figure 7.15B; Figure 7.16A for 1-way ANOVA tabular 
results). Analysis of circumferential strain resulted in a similar improvement in cRadKO 
TAC compared to CTRL Sham, while CTRL TAC remained low (Figure 7.15C; Figure 
7.16B for 1-way ANOVA tabular results). These data further support that the reduction of 
Rad improves left ventricular systolic function in the presence of pressure-overload 
induced heart failure.  
Hearts that undergo hypertrophy without left ventricular dysfunction demonstrate an 
increase in heart weight/body weight and in wall thickness without changes to lung 
weight/body weight or left ventricular chamber size [307]. We therefore measured heart 
weight/body weight and lung weight/body weight in CTRL TAC and cRadKO TAC 
compared to respective Sham groups (Figure 7.15D-F).  CTRL TAC heart weight/body 
weight was significantly increased compared to CTRL Sham, as expected, while cRadKO 
TAC heart weight/body weight was not significantly increased compared to CTRL Sham 
(Figure 7.15D; Figure 7.16C for 1-way ANOVA tabular results).  Lung weight/body 
weight was significantly increased in CTRL TAC, with no significant difference in cRadKO 
TAC, compared to CTRL Sham (Figure 7.15E; Figure 7.16D for 1-way ANOVA tabular 
results).  Both of these measurements correlate with contractile function and heart failure 
[307].  Plotting this correlation for CTRL TAC, cRadKO TAC, and our Sham groups 
support this and reveal that cRadKO TAC develops hypertrophy without progressing 




both Sham groups, demonstrating that Rad reduction promotes recovery from pressure-
overload induced heart failure.   
7.3.7 cRadKO improves quality of life in advanced stages of pressure-overload 
Locomotor activity is significantly reduced in mice that suffer from congestive heart 
failure [308]. To determine if elevated cardiac function due to Rad loss improved behavior 
and quality of life, we subjected our mice to an open field test to assess locomotive behavior 
(Figure 7.17).  Mice were assessed a month after surgery, and again one month after 
tamoxifen treatment (2 months post-surgery; see timeline in Figure 7.17A).  cRadKO TAC 
mice spent more time walking around the cage, while CTRL TAC mice mostly resided in 
the corner in which they were placed (lower right corner; see heat map and track 
visualization, Figure 7.17B,C respectively).  When compared to TAC mice before 
tamoxifen, cRadKO TAC mice covered similar distance within the cage while CTRL TAC 
mice covered significantly less distance (Figure 7.17D; Figure 7.17E for 1-way ANOVA 
tabular results). Taken together, our data supports the hypothesis that the deletion of Rad 
provides a positive inotropic boost that promotes survival and improves quality of life in 
advanced stages of heart failure.   
7.4 Discussion 
The main finding of this study is Rad depletion from the myocardium improves 
survival and preserves cardiac function against pressure-overload induced heart failure. 
This is demonstrated by reduced mortality, reduced lung congestion, elevated cardiac 




calcium and preserved excitation contraction coupling. In combination with previous 
studies that report reduced Rad protein in nonischemic heart failure patients [23, 181], our 
study demonstrates that regulation of Rad contributes to the compensatory response and by 
depleting Rad, cardiac function is preserved in heart failure. This suggests Rad should be 
considered as a potential therapeutic target to safely enhance positive inotropy without 
promoting further damage to the heart.    
7.4.1 Myocardial-restricted Rad deletion preserves cardiac function in pressure-
overload induced heart failure 
Classical inotropes (such as dobutamine, dopamine, and PDE-inhibitors) have 
failed due to adverse outcomes when used long-term due to maladaptive cardiac 
remodeling in response to increased adrenergic activity [5, 192]. In theory, treatments that 
could enhance inotropy without stimulating adrenergic activity would be ideal in order to 
increase contractility without long-term consequences of adrenergic activation [5].  Indeed, 
it has been shown that antagonists of β1-adrenergic receptors can reverse remodeling, 
improve left ventricular function and prolong survival [192]. Our current study, combined 
with our previous work with myocardial-restricted depletion of Rad, supports Rad as a 
unique target for a new generation of positive inotropes to achieve this ideal therapy. We 
have previously shown that depleting the myocardium of Rad serves as a positive inotrope 
without stimulating pathological remodeling into senescence; this was possible because 
calcium cycling was enhanced downstream of β-adrenergic signaling [24].  In conditions 
of pressure-overload, the reduction of Rad continues to enhance positive inotropy through 




This translates to protection from pressure-overload induced heart failure (Figure 7.1,7.3) 
as well as the ability to rescue cardiac function and structure in advanced stages of pressure-
overload induced heart failure (Figure 7.5,7.13,7.15,7.17).  By increasing contractility 
independent of adrenergic activation, cRadKO preserves the compensatory phase so that 
function and structure remain in a healthy range (Figure 7.15) reminiscent of endurance 
training [309] rather than the canonical heart failure phenotypes. Our work is further 
supported by evidence of down-regulation of Rad protein seen in patients with nonischemic 
heart failure [23, 181]. As encouraging as the present results are for suggesting Rad as a 
therapeutic direction for cardioprotection, future studies should investigate the effects of 
Rad deletion in heart failure in larger animal species. 
A major consideration in using positive inotropes as a treatment for heart failure is 
the energetic demands that these drugs incur.  In normal cardiomyocytes, calcium activates 
both ATP-consumption and ATP-regeneration in order to maintain the redox state of 
NADH and FADH2 [5].  However, under conditions of failure, calcium uptake into the 
mitochondria is disrupted and leads to oxidative stress [5, 310, 311].  This promotes 
arrhythmias, systolic dysfunction, and pathological remodeling [5, 311].  A theory to avoid 
this mismatch is to increase sarcoplasmic reticulum calcium content and release, supported 
by animal models and patients with improved left ventricular ejection fraction having 
significant upregulation of SERCA [312, 313]. We have previously shown that myocardial 
Rad deletion promotes upregulation of SERCA without a reciprocal upregulation of PLN 
in the presence of elevated systolic function and no pathological remodeling [24]. Data 
shown in chapter 2 and 3 also show no detectable arrhythmias or electrical dysfunction in 




accelerated kinetics that resemble ICa,L kinetics measured from healthy cRadKO myocytes 
(Figure 7.7). It is therefore possible that the deletion of Rad is preserving the balance of 
ATP-consumption and ATP-regeneration, allowing cardiac function to be protected in the 
presence of pressure-overload induced heart failure. Future studies should explore the role 
in which Rad contributes to energy production within the myocardium, and the mechanism 
by which the absence of Rad potentially improves mitochondrial function. This would give 
more insight into how positive inotropes could balance excitation contraction coupling and 
the energetic demands of the heart to provide better, more sustainable treatment [5]. 
7.4.2 Myocardial-restricted Rad deletion differs from whole-body knockout of Rad 
In the TAC model the heart experiences an abrupt and chronic increase of afterload. 
Despite a large number of studies utilizing the TAC model for pressure overload 
hypertrophy the initial signaling effects that signal compensatory changes in the 
myocardium are poorly understood [192]. When Rad is deleted before surgery, cRadKO 
showed an increase of fibrosis (Figure 7.3), suggesting that while myocardial Rad deletion 
spares functional and myocardial architectural remodeling, the heart remains responsive to 
effectors activated in response to TAC surgery. In whole-body Rad knockout mice, CTGF 
is elevated and fibrosis spontaneously develops as early as ten weeks of age [198]; in 
contrast, myocardial Rad deletion did not demonstrate any spontaneous fibrosis or 
increased expression of CTGF [24], except under the stress of pressure-overload in our 
current study.  Rad has also been associated with non-LTCC functions [21, 145, 211], thus, 
we cannot rule out contributions to transcriptional regulation or cell signaling outside the 




function following TAC also raises an interesting question – namely, the suggestion here 
is that cRadKO illuminates a possible distinction between fibrotic signaling and protection 
against loss of function as an association rather than a necessary cause-effect relationship, 
at least in certain cases. In summary, in sharp contrast to global Rad knockout studies, we 
now show that myocardial Rad deletion is beneficial for heart function in health in response 
to imposed chronic pressure overload. 
In conclusion, our findings suggest that increasing positive inotropy through 
myocardial-restricted Rad deletion protects the cardiac function from pressure-overload 
induced heart failure by maintaining a compensated-like heart. Deleting Rad also rescues 
cardiac function in advanced stages of pressure-overload induced heart failure.  There is a 
major unmet need for treatments targeting inotropy [5]; these results support Rad as a 








Figure 7.1 Loss of cardiomyocyte Rad before pressure overload prevents 
progression of cardiac dysfunction. 
A) Experimental timeline. Red arrows indicate time of tamoxifen injection and 
TAC surgery.  Black arrows above timeline indicate echocardiography time 
points following surgery. B) Kaplan-Meier survival plot of CTRL with TAC, 
cRadKO with TAC, and Sham. Between group differences in survival were tested 
by Gehan-Breslow-Wolcoxon test (*p = 0.03). C-F) Echocardiographic 
assessment of ejection fraction (C, *p = 0.05), left ventricular inner dimensions in 
diastole (D), and left ventricular wall thickness of anterior wall (E, ††p = 0.007, 
##p = 0.009); posterior wall in diastole (F, †p = 0.01). Data in C-F analyzed by 2-
way repeated measures ANOVA with Dunnett’s multiple comparisons test. Data 
displayed from male mice; CTRL (Sham: N = 3; TAC: N = 3) and cRadKO 
(Sham: N = 6; TAC: N = 9). G) Heart-to-body weight ratio at 3 months post-TAC 
(**p = 0.002). Data from mice that did not survive not included. Data in G 
analyzed by 1-way ANOVA with Dunnett’s multiple comparisons test.  Data 
displayed from male mice; CTRL (Sham: N = 5; TAC: N = 3) and cRadKO 
(Sham: N = 5; TAC: N = 4). For all panels: *CTRL Sham v CTRL TAC; †CTRL 






Figure 7.2 ANOVA 95% confidence intervals and tabular results. 
A) 95% confidence intervals and tabular results for two-way ANOVA for Figure 
7.1C. B) 95% confidence intervals and tabular results for two-way ANOVA for 
Figure 7.1D. C) 95% confidence intervals and tabular results for two-way 
ANOVA for Figure 7.1E. D) 95% confidence intervals and tabular results for 
two-way ANOVA for Figure 7.1F. E) 95% confidence intervals and tabular 









Figure 7.3 Loss of cardiomyocyte Rad before pressure overload does not 
protect all pathological signaling. 
A) Experimental timeline. B) Representative pictures of picrosirius Red staining 
with fibrosis quantification in C) (*p = 0.02; ††p = 0.001); Scale bar: 100 µm. 
Data displayed from male mice; CTRL (Sham: N = 6; TAC: N = 3) and cRadKO 
(Sham: N = 4; TAC: N = 5). D) qRT-PCR for ANF mRNA expression levels. 
Data analyzed by one-way ANOVA plus Dunnett’s multiple comparisons test. 
Data displayed from male mice; CTRL (Sham: N = 8; TAC: N = 8) and cRadKO 
(Sham: N = 5; TAC: N = 7). For all panels: *CTRL Sham v CTRL TAC; †CTRL 








Figure 7.4 One-way ANOVA 95% confidence intervals and tabular results. 
A) 95% confidence intervals and tabular results for two-way ANOVA for Figure 
7.3C. B) 95% confidence intervals and tabular results for two-way ANOVA for 















Figure 7.5 Loss of cardiomyocyte Rad before pressure overload promotes 
survival and enhances cardiac function. 
A) Experimental timeline. Red arrows indicate time of tamoxifen injection and 
TAC surgery.  Black arrows above timeline indicate echocardiography time 
points following surgery. B) Kaplan-Meier survival plot of CTRL with TAC and 
cRadKO with TAC. Between group differences in survival were tested by Gehan-
Breslow-Wolcoxon test (p = 0.05). C-F) Echocardiographic assessment of 
ejection fraction (C, *p = 0.04), left ventricular inner dimensions in diastole (D), 
and left ventricular wall thickness of anterior wall (E); posterior wall in diastole 
(F). Data in C-F analyzed by 2-way repeated measures ANOVA with Šídák’s 
multiple comparisons test. Data displayed from female mice; CTRL (N = 4) and 
cRadKO (N = 8). G) Heart-to-body weight ratio at 3 months post-TAC and post 
Rad deletion. Data from mice that did not survive not included. Data in G 
analyzed by Student’s unpaired t-test with Welch’s correction. Data displayed 






Figure 7.6 ANOVA 95% confidence intervals and tabular results. 
A) 95% confidence intervals and tabular results for two-way ANOVA for Figure 
7.5C. B) 95% confidence intervals and tabular results for two-way ANOVA for 
Figure 7.5D. C) 95% confidence intervals and tabular results for two-way 
ANOVA for Figure 7.5E. D) 95% confidence intervals and tabular results for 












Figure 7.7 Loss of cardiomyocyte Rad increases ICa,L after pressure-
overload. 
A) Experimental timeline showing study design. B) Exemplar family of Ca2+ 
currents of CTRL TAC (blue) and cRadKO TAC (red) from Vtest ranging from  
-75 to +50 mV in 10 mV increments (voltage protocol shown above); Scale bar: 5 
pA/pF, 100 ms. C) Current-voltage relationship for peak ICa,L current density from 
CTRL TAC and cRadKO TAC ventricular myocytes.  D) Maximal conductance is 
significantly increased in cRadKO TAC compared to CTRL TAC (****p < 
0.0001; dotted lines represent maximal conductance for published unoperated WT 
and cRadKO, included for reference). E) Conductance-voltage curves normalized 
to maximal conductance in CTRL TAC and cRadKO TAC.  Smooth curves are 
Boltzmann distribution fitted to data. F) Activation midpoint is significantly 
negative-shifted in cRadKO TAC (*p = 0.01). G) Exemplar Ca2+ currents with 
EGTA for CTRL TAC (blue) and cRadKO TAC (red), traces normalized to peak 
current at 0 mV Scale bar: 100 ms. Black dots indicate r30, Black stars indicate 
r150.  Remaining current across voltage steps 30 ms after peak H) and 150 ms after 
peak I). P values calculated using Student unpaired t-test for (D,F). Data in (H,I) 
analyzed by two-way ANOVA plus Šídák’s multiple comparisons test (**p < 
0.009; *p < 0.03). Data displayed from female mice; CTRL (N = 4 mice, n = 8 






Figure 7.8 ANOVA 95% confidence intervals and tabular results. 
A) 95% confidence intervals and tabular results for two-way ANOVA for Figure 
7.7H. B) 95% confidence intervals and tabular results for two-way ANOVA for 

















Figure 7.9 Loss of cardiomyocyte Rad enhances cellular calcium handling 
after pressure-overload. 
A) Experimental timeline showing study design. B) Representative calcium 
transients from isolated ventricular cardiomyocytes loaded with fura2-AM, CTRL 
TAC (top, blue) and cRadKO TAC (bottom, red) paced at 1 Hz. Scale bar: 1 
second. C) Amplitude of the calcium transients from cRadKO TAC are larger 
compared to CTRL TAC (*p = 0.03). D) The velocity at which calcium enters the 
cytosol (upstroke of the transient) is significantly faster in cRadKO TAC 
compared to CTRL TAC (*p = 0.03). E) Rate at which calcium leaves the cytosol 
(downstroke of the transient) is significantly faster in cRadKO TAC compared to 
CTRL TAC (*p = 0.02). P values calculated using Student unpaired t-test for (C-
E). Data displayed from female mice; CTRL (N = 5 mice, n = 21 cells) and 










Figure 7.10 Loss of cardiomyocyte Rad does not alter sarcomere dynamics 
after pressure-overload. 
A) Experimental timeline showing study design. B) Exemplar sarocomere length 
traces from isolated ventricular cardiomyocytes loaded with fura2-AM, CTRL 
TAC (top, blue) and cRadKO TAC (bottom, red) paced at 1 Hz. Scale bar: 1 
second. C) Diastolic sarcomere length (dotted lines represent means of diastolic 
length for published unoperated WT and cRadKO, included for reference). D) 
Sarcomere fractional shortening (dotted lines represent means of diastolic length 
for published unoperated WT and cRadKO, included for reference). E) Sarcomere 
shortening velocity (dotted lines represent means of diastolic length for published 
unoperated WT and cRadKO, included for reference). F) Integral of sarcomere 
length (dotted lines represent means of diastolic length for published unoperated 
WT and cRadKO, included for reference). P values calculated using Student 
unpaired t-test for (C-F). Data displayed from female mice; CTRL (N = 5 mice, n 







Figure 7.11 -AR stimulation does not alter ICa,L in Rad deletion after 
pressure-overload. 
A) Experimental timeline showing study design. Bi,ii) Current-voltage 
relationship for peak ICa,L current density from CTRL TAC (left, blue) and 
cRadKO TAC (right, red) from isolated ventricular myocytes after treatment with 
300 nM isoproterenol (ISO).  C) Maximal conductance is significantly increased 
in cRadKO TAC compared to CTRL TAC (***p = 0.0007; dotted lines represent 
maximal conductance for published unoperated WT + ISO and cRadKO + ISO, 
included for reference). D) Fractional change of maximal conductance between 
baseline and ISO response of CTRL TAC (mean = 47%) and cRadKO (mean = 
7%). Neither group demonstrated a significant response, as measured by deviation 
from zero.  E) Activation midpoint is not significantly negative-shifted in 
cRadKO TAC compared to CTRL TAC after treatment with ISO (dotted lines 
represent maximal conductance for published unoperated WT + ISO and cRadKO 
+ ISO, included for reference). F) Difference in activation midpoint between 
baseline and ISO response of CTRL TAC (mean = -3.1 mV) and cRadKO (mean 
= 0.51 mV). CTRL TAC demonstrated a significant response, as measured by 
deviation from zero (*p = 0.03). P values calculated using Student unpaired t-test 
for (C,E) and one sample t-test for (D,F). Data displayed from female mice; 





Figure 7.12 -AR stimulation response in cellular calcium handling is 
blunted after pressure-overload. 
A) Experimental timeline showing study design. B) Representative calcium 
transients from isolated ventricular cardiomyocytes loaded with fura2-AM, CTRL 
TAC (top, blue) and cRadKO TAC (bottom, red) after treatment with 1 µM 
isoproterenol (ISO), paced at 1 Hz. Scale bar: 1 second. C) Amplitude of the 
calcium transients from cRadKO TAC and CTRL TAC after treatment with ISO. 
D) The velocity at which calcium enters the cytosol (upstroke of the transient) in 
cRadKO TAC and CTRL TAC after treatment with ISO. E) Rate at which 
calcium leaves the cytosol (downstroke of the transient) in cRadKO TAC and 
CTRL TAC after treatment with ISO. F) Fractional change of amplitude between 
baseline and ISO response of CTRL TAC (mean = 78%) and cRadKO (mean = 
7%). Neither group demonstrated a significant response, as measured by deviation 
from zero. G) Fractional change of upstroke velocity between baseline and ISO 
response of CTRL TAC (mean = 7%) and cRadKO (mean = 3%). Neither group 
demonstrated a significant response, as measured by deviation from zero. H) 
Fractional change of rate of decay between baseline and ISO response of CTRL 
TAC (mean = -19%) and cRadKO (mean = -6%). CTRL demonstrated a 
significant response, as measured by deviation from zero (*p = 0.04). P values 
calculated using Student unpaired t-test for (C-E) and one sample t-test for (F-H). 
Data displayed from female mice; CTRL (N = 4 mice, n = 10 cells) and cRadKO 





Figure 7.13 Loss of cardiomyocyte Rad after pressure overload prevents 
progression of cardiac dysfunction. 
A) Experimental timeline. Red arrows indicate time of TAC surgery and time of 
tamoxifen injection 1-month post-surgery.  Black arrows above timeline indicate 
echocardiography time points following surgery. B) Kaplan-Meier survival plot of 
CTRL with TAC, cRadKO with TAC, and Sham. Between group differences in 
survival were tested by Gehan-Breslow-Wolcoxon test (****p < 0.0001). C-F) 
Echocardiographic assessment of ejection fraction (C, ****p < 0.0001; †††p = 
0.0003; ##p = 0.002), left ventricular inner dimensions in diastole (D, **p = 
0.003), and left ventricular wall thickness of anterior wall (E, ††p = 0.009); 
posterior wall in diastole (F, *p = 0.02). Data in C-F analyzed by 2-way repeated 
measures ANOVA with Dunnett’s multiple comparisons test. Data displayed from 
male mice; CTRL (Sham: N = 6; TAC: N = 10) and cRadKO (Sham: N = 7; TAC: 
N = 10). Data from mice that did not survive not included. For all panels: *CTRL 








Figure 7.14 ANOVA 95% confidence intervals and tabular results. 
A) 95% confidence intervals and tabular results for two-way ANOVA for Figure 
7.13C. B) 95% confidence intervals and tabular results for two-way ANOVA for 
Figure 7.13D. C) 95% confidence intervals and tabular results for two-way 
ANOVA for Figure 7.13E. D) 95% confidence intervals and tabular results for 













Figure 7.15 Loss of cardiomyocyte Rad after pressure overload prevents 
progression of cardiac dysfunction. 
A) Experimental timeline. B) Pooled data for longitudinal strain. Rad deletion 
increased global longitudinal strain (****p < 0.0001; ††p = 0.0003; **p = 0.03). 
C) Pooled data for circumferential strain. Rad deletion enhanced circumferential 
strain (*p = 0.01; †p = 0.02; ****p < 0.0001). D) Heart weight to body weight 
ratio measured two-months post-surgery, one-month post Rad deletion (***p = 
0.0002). E) Lung weight to body weight ratio measured two-months post-surgery, 
one-month post Rad deletion (**p = 0.002). F) Linear regression of lung weight 
body weight ratio as a function of heart weight body weight ratio. Orange region 
indicates hearts with left ventricular hypertrophy and in failure; green region 
represents hearts with left ventricular hypertrophy but not in failure. Data in (B,C) 
analyzed by two-way repeated measures ANOVA with Dunnett’s multiple 
comparisons test. Data in (D,E) analyzed by one-way ANOVA with Dunnett’s 
multiple comparisons test. Data displayed from male mice; CTRL (Sham: N = 6; 
TAC: N = 10) and cRadKO (Sham: N = 7; TAC: N = 11). Data from mice that did 
not survive not included. For all panels: *CTRL Sham v CTRL TAC; †CTRL 










Figure 7.16 ANOVA 95% confidence intervals and tabular results. 
A,B) 95% confidence intervals and tabular results for two-way ANOVA for 
Figure 7.15B,C respectively. C,D) 95% confidence intervals and tabular results 
















Figure 7.17 Loss of cardiomyocyte Rad after pressure overload improves 
locomotive activity. 
A) Experimental timeline. Black arrows indicate when behavior was measured (1 
month after surgery, before tamoxifen injection, labeled as TAC Before TAC;2 
months after surgery, 1 month after tamoxifen injection labeled as CTRL TAC or 
cRadKO TAC). B) Heat maps of activity in the open field, color is defined as the 
average time spent in seconds in a given location. Blue represents the least 
duration to Red, representing the highest duration. cRadKO TAC spent more time 
moving around within the open field compared to CTRL TAC. C) Representative 
15 min. of tracks in the open field of CTRL TAC (left) and from cRadKO TAC 
(right). cRadKO TAC demonstrated more movement compared to CTRL TAC. 
D) Quantification of the distance covered within the open field. CTRL TAC mice 
covered significantly less distance compared to their one month time point (TAC 
Before TAM) while cRadKO covered similar distance (*p = 0.03). Data analyzed 
by one-way ANOVA plus Dunnett’s multiple comparisons test, with 95% 
confidence intervals and tabular results in E). Data displayed from male mice; 
TAC Before TAM (N  = 15), CTRL TAC (N = 8), and cRadKO TAC (N = 7). For 




CHAPTER 8. DISCUSSION 
A novel treatment for heart failure with reduced ejection fraction would be to improve 
contractility in a manner that preserves the fight-or-flight response within the heart.  The 
main objective of this dissertation was to test the hypothesis that disrupting Rad inhibition 
of the L-Type calcium channel (LTCC) can stably enhance cardiac function by increasing 
LTCC calcium current (ICa,L) downstream of -adrenergic receptor (-AR) stimulation; 
this improves cardiac performance without inducing pathological remodeling and 
progression to heart failure. It is well established that the absence of Rad results in 
increased ICa,L [17, 19-24, 288, 314]; however, the mechanism by which Rad inhibits the 
LTCC remains unclear [288]. The work of this dissertation contributes to the understanding 
of Rad-mediated LTCC inhibition by: 1) revealing the role of Rad in LTCC modulation, 
and 2) unmasking a potential new target to selectively enhance ICa,L without promoting 
pathology.  Each of these are discussed below.  
8.1 Rad is a critical regulatory site for LTCC modulation 
A major mechanism for modulating calcium cycling is sympathetic stimulation [6, 
25, 28, 31, 92, 94, 95, 103]. cRadKO leads to enhanced basal ICa,L resembling β-AR 
modulated ICa,L (Chapter 3, Chapter 4, Chapter 5). The hallmark features of PKA-
mediated LTCC modulation are: significant increase in ICa,L, hyperpolarized shift in 
voltage dependent activation, and increased rate of inactivation; all result in a gain of LTCC 
function [103]. In the absence of Rad, ICa,L increases ~three fold compared to control 
(CTRL), voltage dependent activation is shifted to more negative potentials, and the rate 
of inactivation is accelerated in ventricular and sinoatrial cardiomyocytes (Chapter 3, 
Figure 4; Chapter 4, Figure 3; Chapter 5, Figure 1-5 ).  The effect of Rad deletion on 
ICa,L is not dependent on signaling from β-ARs, demonstrating no detectable response to 
isoproterenol (Chapter 3, Figure 4; Chapter 4, Figure 3) and increasing ICa,L in the 
absence of β-ARs (Chapter 5, Figure 7-9).  These results led to the conclusion that Rad 
may be absent from the LTCC in order for modulation to occur.  Proximity proteomics 




following acute isoproterenol treatment, Rad association with the CaV1.2 and CaVβ was 
reduced [92]. Taken together, the results of this dissertation and that of recent publications 
establish Rad as the critical phosphorylation site by PKA to induce LTCC modulation [21-
24, 92].   
8.2 Rad governs ICa,L by multiple mechanisms 
Amplification of ICa,L can be described by the classic equation: I = NT x Pf x Po x i, 
where I represents macroscopic calcium current of the cell, NT is the total number of 
channels, Pf is the probability that a given channel is available, Po is the probability that the 
channel will be open, and i is the unitary current through an open pore [282, 291, 292]. Rad 
regulation of ICa,L can occur by manipulating one or multiple variables of this equation to 
produce an increase in macroscopic current. 
It is well established PKA phosphorylation increases ICa,L by elevating Pf and Po 
[315]. Indeed, single channel recordings of CaV1.2 depleted of Rad displayed almost no 
blank sweeps, and most sweeps exhibited either intermediate or high levels of opening 
[92]. The mechanism of voltage-dependent of activation of CaV1.2 remains unclear but has 
been proposed to include a number of critical elements: S4 and S6 segments of domain I 
of the α1 subunit (IS4, IS6 respectively), the AID (α-interacting domain), the I-II linker 
between domain I and II of the α1 subunit, and CaVβ [55, 118, 293]. CaVβ binding to CaV1.2 
enhanced Po and caused a hyperpolarizing shift in activation; this required a rigid linker 
between IS6 and the AID [92, 316]. It has been speculated that Rad interaction with CaVβ 
may structurally alter the IS6-AID linker as a way to lower Po-gating, and thereby inhibit 
the LTCC [118].  The C-terminal tail of Rad is the domain that binds to CaVβ and is critical 
to Rad-mediated LTCC regulation [17]. Sites for PKA and CaMKII phosphorylation, 
binding for 14-3-3, binding for CaM, and association with plasma membrane all reside 
within the C-terminus of Rad [175, 177, 281]. These studies suggest that Rad-mediated 
inhibition of the LTCC, and therefore LTCC modulation, is regulated through its C-
terminal tail.  Indeed, the truncation of the C-terminus of Rad results in ICa,L that is 
indistinguishable from cRadKO (Chapter 6, Figures 6.2-6.4), supporting the hypothesis 




Rad phosphorylation, Rad is sequestered from the complex by 14-3-3 binding to sites both 
on the N- and C-terminal extensions, alleviating the association with CaVβ so that the IS6-
AID linker can be stabilized to support high Po gating [118, 166, 281].  
Another emerging hypothesis of the mechanism enhancing Pf and Po, and thereby 
LTCC modulation, is channel clustering.  Calcium bound to CaM allows channels to form 
physical connections between the C-terminal tails of neighboring channels to induce 
clustering (~8 channels within an average cluster) [57-59]. The activity of the cluster would 
be driven by the channel(s) with the highest activity within the cluster [57]. These channels 
also inactivate more rapidly through calcium-dependent inactivation in order to prevent 
arrhythmogenesis; this causes coupling between channels to fade [58].  However, coupling 
persists longer than the current that evoked it, thereby acting as a type of ‘molecular 
memory’ that might serve to augment calcium influx in times of repetitive membrane 
depolarization, such as seen in calcium-dependent facilitation or an increase in action 
potential frequency [58].  Upon β-AR stimulation, channels can form ‘super-clusters’ 
(~32% increase in cluster size) that allow them to gate cooperatively [59]. These ‘super-
clusters’ were localized to transverse tubules, same microdomain as the source of cAMP 
used for signaling downstream of β-AR stimulation [59, 101, 102]. Rad binds to CaM in a 
calcium dependent manner through a region located on the C-terminus of Rad [166]. With 
CaM playing a central role in calcium-dependent facilitation, calcium dependent 
inactivation, and clustering, it is possible that Rad inhibits LTCC PF and Po through binding 
to CaM and blocking cluster formation. Upon phosphorylation by PKC, Rad binding to 
CaM is reduced [317]. Therefore, the absence of Rad from the complex would result in a 
constant state of channel clustering that would display enhanced calcium influx and 
accelerated inactivation, as seen both in cRadKO and when the C-terminus of  Rad is absent 
(Rad-Flag A277X) (Chapter 3, Figure 3.4; Chapter 4, Figure 4.3; Chapter 5, Figure 
5.1-5.5; Chapter 6, Figure 6.2-6.4). The reduction of Rad binding could also cause a 
conformational change within the LTCC so that CaV could stabilize the IS6-AID linker. 
Future studies investigating channel clustering in the absence of Rad might shed light onto 




A potential explanation for enhanced ICa,L seen in the absence of Rad is an increase 
in the total number of channels expressed in the plasma membrane. An initial hypothesis 
for RGK regulation of CaV1.2 channels was by regulating surface expression and limiting 
channel trafficking to the membrane [16, 176, 314, 318]. Indeed, in PC12 cells, Rad 
blocked surface expression of LTCCs by binding to CaVβ3 and sequestering the subunit to 
the nucleus so that α-subunits could not be trafficked to the membrane [176]. In a 
transgenic mouse model that expressed a dominant negative mutant of Rad (S105N), α1C 
protein expression was significantly increased [182]. Based on these studies, the prediction 
would be that Rad governs channel activity by simply limiting channel formation and 
proper surface trafficking; therefore, in the absence of Rad, channel expression would 
increase. Interestingly, qRT-PCR for CaV1.2 mRNA was not significantly different 
between CTRL and cRadKO nor was CaV1.2 total protein expression different; however, 
this does not reveal whether protein was trafficked to the membrane (Chapter 3, Figure 
3.4). Investigation of channel trafficking in cRadKO was not pursued in this dissertation; 
however, previous studies have demonstrated that RGK inhibition, including Rad, occurs 
at the cell surface rather than through altering α1 surface expression or trafficking [20, 88, 
183, 282, 319]. A recent study proposed that -AR stimulation causes an increase in CaV1.2 
surface expression by triggering rapid mobilization of CaV1.2-cargo-carrying endosomes 
to the sarcolemma surface; the hypothesis is that channel activity is augmented through 
insertion and recycling of CaV1.2 [320]. It is speculated that when Rad is phosphorylated, 
the dissociation of Rad from CaVβ releases the channel complex and permits trafficking to 
the surface [320]. Studies in heterologous expression systems support this hypothesis, 
demonstrating Rem decreased CaV1.2 surface density by 65%, though inhibition of Rem 
on CaV1.2 was not relieved after -AR stimulation [282, 314]. Therefore, it is possible that 
the absence of Rad promotes modulation of the LTCC simply by permitting the insertion 
of a pool of channels normally lying in reserve for when -ARs are activated. 
Though the mechanisms of LTCC modulation and RGK-mediated inhibition have 
been studied extensively, a conclusive explanation remains elusive.  It is possible that 
regulation by Rad is a combination of the mechanisms described above, or potentially 
dependent on protein-protein interactions with Rad and the LTCC that are currently 




Advances in microscopy techniques and technology, combined with new FRET biosensors 
may allow investigation of LTCC nanodomains, and specific protein-protein interactions 
to better understand how the presence and absence of Rad contributes to LTCC regulation 
[31].  
8.3 Hypertrophic signaling is not exclusively dependent on elevated ICa,L 
A central dogma of calcium cycling is increasing ICa,L inevitably leads to myocyte 
hypertrophy [12, 148, 149, 321-329].  Indeed, overexpression of α1C or CaVβ in transgenic 
mice yields enhanced ICa,L followed by rapid progression to pathological hypertrophy, heart 
failure and death [12, 149, 327]. An early study of global Rad knockout also reported 
increased hypertrophy due to activated CaMKII, without any cardiac functional 
evaluations [181]; Crucial observations from these overexpression models that are 
important to note: the α1C overexpression model exhibited minimal difference in left 
ventricular inner dimensions and in posterior wall thickness compared to non-transgenic 
controls [12]; CaVβ overexpression reported cardiac hypertrophy without functional 
assessment by echo, or indication of activation of CaMKII or calcineurin [330]. The global 
Rad knockout model reported hypertrophy based on hyperphosphorylation of CaMKII, but 
no cardiac functional evaluation [181]. Contrary to these studies, decreased LTCC activity 
also produces severe hypertrophy and remodeling due to calcineurin and CaMKII 
activation [290]. Cardiac-specific Rad deletion exhibited no significant changes in cardiac 
structure compared to CTRL under conditions of elevated ICa,L and enhanced calcium 
handling (Chapter 3, Figures 3.3-3.5; Chapter 5, Figures 5.7,5.8; Chapter 6, Figures 
6.2-6.4); there was also no indication of hyperphosphorylation of phospholamban by 
CaMKII, suggesting CaMKII was not activated in cRadKO (Chapter 3, Figures 3.5,3.9). 
These contradicting results indicate increased ICa,L does not necessarily guarantee 
activation of hypertrophic signaling. 
Cardiac growth can be predicted through a model based on integrated tension 
measured from mean twitch tensions or sarcomere shortening.  A negative score in this 
model forecasts dilated cardiomyopathy, and a positive score indicates potential 




predicting heart remodeling solely on any singular calcium parameter was poor; the model 
had to include mechanical parameters in order to achieve accurate predictions [202].  Based 
on this model, cRadKO approached a WT tension-integral as a consequence of larger 
calcium transient amplitudes (Chapter 3, Figures 3.5,3.6). This could be due to enhanced 
ICa,L kinetics (Chapter 3, Figure 3.3; Chapter 5, Figures 5.2-5.5) and/or due to increased 
expression of SERCA2a (Chapter 3, Figure 3.5). Activation of calcineurin requires a high 
and sustained calcium signal [146]; the acceleration of ICa,L decay in cRadKO may be 
sufficient to prevent activation of calcineurin and hypertrophic signaling even though peak 
ICa,L is increased. Even in conditions of pressure-overload induced heart failure, the 
integrated tension model predicted only modest concentric hypertrophy (Chapter 7, 
Figure 7.10), which is consistent with the slight increase in wall thickness observed in all 
three TAC paradigms of Rad deletion (Chapter 7, Figures 7.1,7.5,7.13). Elevated 
SERCA2a without a mirroring change in phospholamban, as seen in cRadKO, would also 
prevent a high and sustained calcium signal within the cytosol.  This beneficial 
modification would allow enhanced calcium uptake without the need for phosphorylation 
of phospholamban; indeed, this type of regulation displays cardioprotection in conditions 
of high-intensity exercise and advanced heart failure [207-210]. Hypertrophic signaling 
activation therefore is not as straightforward as simply an increase in peak ICa,L; rather, 
enhanced calcium current may be a weak inducer or contributes to hypertrophic signaling 
secondary to chronic stimulation of -ARs.   
An intriguing finding of this work is that attaching an epitope tag, Flag, to Rad caused 
significant alterations to cardiac function and structure (Chapter 6). Many studies have 
utilized transgenic mouse models that express an epitope tag such as Flag to investigate 
LTCC gating properties and binding partners; however, none of these studies report 
functional assessments to demonstrate healthy cardiac function and structure [57-59, 92, 
117, 118, 166, 331]. These types of genetic manipulations have the potential to trigger 
indirect, secondary effects on that confound the direct effects which could cause 
misinterpretations of the results [332].  An example of this were studies recently conducted 
investigating the role of junctophilin-2 (JPH-2) in formation and stabilization of transverse 
tubules.  When all cardiomyocytes are depleted of JPH-2, there was a dramatic loss of 




critical for transverse tubule maturation and preserving cardiac function [333, 334].  
However, loss of transverse tubules is a hallmark feature of pathological remodeling [335]. 
Therefore, the question remains of whether loss of JPH-2 promotes transverse tubule loss 
that then leads to heart failure, or heart failure promotes loss of transverse tubule, causing 
JPH-2 to decrease.  Utilizing a genetic mosaic model to deplete either a low percentage or 
high percentage of JPH-2 within cardiomyocytes demonstrated that low percentage loss of 
JPH-2 yielded minimal transverse tubule disorganization and no disturbances to cardiac 
function; this was only seen in high percentage loss of JPH-2 [332]. This study 
demonstrated JPH-2 does not play as critical of a role in transverse tubule maturation as 
originally demonstrated [332]. This study combined with the results from Rad-Flag 
highlight how direct effects on cardiac gene manipulation may be misinterpreted due to 
confounding, secondary effects, such as heart failure conditions, especially when 
manipulating genes that affect the LTCC. 
8.4 Enhanced ICa,L does not necessarily promote electrical dysfunction 
Experimental and theoretical studies have also identified ICa,L as a critical component 
in arrhythmogenesis due to its central role in action potential duration; specifically, 
reactivation of ICa,L in the late phase of decay induces early afterdepolarizations (EADs) 
that trigger fatal arrhythmias [50, 61-63]. Recent studies have demonstrated that reducing 
the non-inactivating component of ICa,L, known as the pedestal current, can reduce the 
formation of EADs without affecting excitation contraction coupling [50, 61]. This 
suggests a new class of drug action that act as ‘gating modifiers’ to promote subtle changes 
in the biophysical parameters of ICa,L to reduce the late, arrhythmogenic component without 
affecting contractility or action potential duration [62]. A prototype drug that appears to 
achieve this is a drug called roscovitine [62, 126-130, 138]. The work of this dissertation 
supports Rad as another potential ‘gating modifier.’ The absence of Rad reduced the 
pedestal current (Chapter 3, Figure 3.3) and the late component of ICa,L was not 
significantly different between cRadKO and CTRL (Chapter 5, Figures 5.2-5.5). Action 
potential duration and QT interval were not significantly different between cRadKO or 
CTRL (Chapter 5, Figure 5.6), demonstrating that Rad could be a safe ‘gating modifier’ 




(Chapter 5, Figure 5.7,5.8).  In fact, this work establishes that the C-terminus of Rad could 
be the target for a small peptide inhibitor since Rad-Flag A277X also demonstrated 
accelerated inactivation without altering the late component of ICa,L that paralleled cRadKO 
(Chapter 6, Figure 6.2-6.4).  
Another key consideration is potential electrical dysfunction within the sinoatrial 
node. Alterations in sinus node function parallel autonomic imbalance in the ventricles; 
this imbalance is evident in heart failure and can result in sudden cardiac death due to a 
decrease in heart rate variability [336]. Treatment with -AR blockers suggest lowering 
heart rate contributes to survival for patients with heart failure; higher heart rates promote 
arrhythmogenesis and decreased contractility [336]. Contrary to these studies, cRadKO 
exhibited higher intrinsic heart rate without evidence of arrhythmogenesis on the 
background of enhanced ICa,L in sinoatrial cardiomyocytes, and increased contractility in 
the ventricle (SANcm; Chapter 3, Figure 3.3; Chapter 4, Figure 4.4,4.5). These 
paradoxical results suggest that modulated ICa,L may promote balance of autonomic input 
without the required increase in sympathetic drive.  Previous studies indicate there are 
mechanisms that increase and decrease sinus rate in order to preserve autonomic balance 
[336]. In fact, a recent study discovered SANcm undergo a nonfiring mode; the SANcm 
tissue network rhythm is set by the balance between firing and nonfiring cells [337]. Cells 
that are electrically coupled are in a phasic entrainment, and are grouped together either in 
a firing mode, or a nonfiring mode; a firing cell that interacts with a nonfiring cell is called 
tonic entrainment [337]. In tonic entrainment, cells that are in a nonfiring mode 
electronically draw the flow of cations from more depolarized, firing cells via gap 
junctions, thereby creating a bradycardic rhythm [337].  Under sympathetic stimulation, 
cells shift more towards a firing mode in order to accelerate rhythm [337]. In the absence 
of Rad, it is possible that more SANcm could transition to a firing mode, thereby 
accelerating HR and sinus rhythm without necessarily disrupting the balance of nonfiring 
versus firing cells in a pathological manner, as demonstrated by the lack of change in heart 
rate variability. Indeed, this further supports the role of Rad in not only LTCC regulation 
of -AR stimulation, but whole heart regulation by sympathetic stimulation. Taken 




of Rad enhances positive inotropy and positive chronotropy in a manner that follows -AR 
stimulation while still preserving cardiac responsiveness to adrenergic activation. 
8.5 Targeting Rad represents the ideal positive inotrope 
Currently, the ideal, theoretical treatment for heart failure would restore calcium 
handling in a failing heart without activating adrenergic signaling [5]. Depleting the LTCC 
of Rad could serve as a therapeutic target in order to make this ideal treatment a reality.  
First, the absence of Rad enhances calcium handling under basal conditions in a manner 
that preserves β-AR signaling within the cell and at the organ level (Chapter 3, Figures 
3.8-3.10). Enhanced cardiac function is dependent on the presence of Rad in the LTCC 
complex, rather than solely on activating the fight-or-flight response (Chapter 5, Figures 
5.7,5.8), thereby providing a positive inotropic target downstream of adrenergic signaling. 
Unlike studies conducted in global Rad knockout models, cRadKO does not promote 
pathological signaling [181-183] (Chapter 3, Figures 3.3-3.5). In fact, Rad deletion before 
the onset of pressure-overload induced heart failure provides cardiac protection and 
preserves survival (Chapter 7, Figure 7.1). This protection remained even when Rad was 
depleted at the time or four weeks after the induction of pressure-overload (Chapter 7, 
Figures 7.5,7.13-7.17). Calcium handling was still enhanced in cRadKO despite the 
exposure to thoracic aortic constriction surgery (TAC) (Chapter 7, Figures 7.7-7.10), 
though responsiveness to adrenergic stimulation was no longer detectable (Chapter 7, 
Figures 7.11,7.12). These results fit with earlier studies that reported Rad protein is 
reduced in nonischemic heart failure patients, and support the hypothesis that Rad 
contributes to the cardiac compensation in response to heart failure [23, 181].  
Cardiac protection through the depletion of Rad does not extend to all pathological 
signaling seen in heart failure.  When Rad was deleted prior to surgery, fibrosis increased 
significantly compared to Sham, and was not different from CTRL that underwent surgery 
(Chapter 7, Figure 7.3). This is not surprising since others have reported that the absence 
of Rad elevated connective tissue growth factor (CTGF) expression and increased fibrosis; 
however, the difference between that study and cRadKO is that fibrosis was not seen under 




under pressure-overload [24, 198] (Chapter 3, Figure 3.2). However, in response to 
myocardial infarction (MI), global Rad knockout mice displayed less fibrosis development 
compared to WT [184]. This raises an interesting notion – namely, fibrotic signaling and 
protection of cardiac function may not necessarily have a cause-effect relationship [338], 
at least in certain cases. These exceptions may be dependent on the type of injury the heart 
experiences as well as the tissue in which Rad is expressed/depleted. In response to TAC, 
gRad-/- mice displayed increased collagen accumulation and elevated CTGF to promote 
fibrosis [198].  In response to MI, upregulation of inflammatory cytokines and fibrosis 
were both significantly reduced in gRad-/- compared to WT [184]. Because Rad is 
expressed in other tissues, it is possible that gRad-/- undergoes adaptive signaling in 
response to different injuries as part of the cardiac compensatory response.  Further 
investigation is needed to better assess the contributions of Rad to heart function outside 
of cardiac tissue; this may provide insight into how the depletion of Rad in other tissues 
may aid in cardiac protection in specific injuries.  
A major concern with positive inotropes is the energy demanded of the heart in order 
to maintain elevated function [5]. In failing hearts, energy metabolism undergoes 
remodeling that leads to a 30% reduction in concentration of ATP, and ultimately results 
in impaired contractile reserve [339]. Under healthy conditions, calcium activates both 
ATP-consumption and -regeneration [5, 310]. However, calcium uptake is impaired in the 
failing heart, thereby promoting a mismatch between ATP consumption and production [5, 
311]. One mechanism to potentially alleviate this mismatch is increasing expression of 
SERCA2a [5, 207-210]. As stated above, cRadKO results in an increase in SERCA2a 
expression, which may aid in preventing hypertrophic signaling as well as a potential 
metabolic mismatch (Chapter 3, Figure 3.5). However, Rad has also been implicated in 
metabolism.  Expression of Rad negatively correlates with resting metabolic rate in skeletal 
muscle [340]. In cancer cells, Rad inhibited glucose transporter translocation to the plasma 
membrane, which is the first rate-limiting step in glucose metabolism; knockdown of Rad 
enhanced glycolysis [341, 342]. Rad was also found to be a negative regulator of glucose 
uptake in cultured myotubes, adiopocytes, and ovarian cancer cells [178, 200].  From these 
studies and the drastic increase in cardiac function seen in cRadKO, it is very likely that 




these mechanisms remains unclear; however, this understanding is crucial in determining 
how beneficial Rad would be as a positive inotrope target.  
8.6 Future directions 
The work in this dissertation establishes Rad as a central regulator of LTCC activity 
and modulation.  However, there are questions that remain unanswered that encourage 
further investigation of Rad.   
It is clear that modulation the LTCC occurs when Rad is not present, or in close 
proximity of the channel complex.  However, it remains unclear as to where Rad is 
localized upon phosphorylation; it is possible that Rad remains close to the complex 
because of associations with structural proteins within the LTCC-Ryanodine Receptor 
junction like JPH-2 or Speg [343].  It is also possible that Rad is sequestered to a different 
location within the cell, possibly to regulate another mechanism in response to -AR 
stimulation [320].  Future experiments could utilize the Rad-Flag A277X model to 
determine localization within the LTCC or cytosol in response to modulation since results 
from this model resemble a modulated LTCC or Rad-depleted channel. This is especially 
important since Rad is potentially implicated in other critical mechanisms such as channel 
trafficking, channel recycling, and metabolism [178, 200, 320, 340-342]. This may also be 
better suited for a model system that allows the fusion of an epitope tag such as Flag that 
manages to preserve healthy cardiac structure and function; a recent study demonstrated 
biotin-ligase system, BioID, was better suited for studies investigating protein localization 
and protein-protein interactions compared to other knock-in transgenic models [295].  This 
study reported normal cardiac function and structure, though the target protein was JPH-2, 
not a protein with the LTCC complex [295]. The BioID strategy may provide clearer 
insights into Rad localization and important binding partners, especially in regards to 
baseline conditions versus after -AR stimulation. 
The confirmation that the C-terminus of Rad is critical for regulation of LTCC 
activity encourages new targets to focus on understand how Rad inhibits the LTCC.  
Critical binding sites for CaV, 14-3-3, CaM, and negatively charged phospholipids in the 




in binding could help resolve the critical components needed for Rad-mediated inhibition 
of the LTCC. For example, disruption of binding between Rad-CaM may promote channel 
clustering without the need for adrenergic activation.  It is currently unknown how channels 
cluster together in the absence of Rad; this should be explored both in cRadKO and Rad-
Flag A277X. Then, understanding how Rad binding to CaM affects clustering could give 
further insight into how channels cluster together, both at baseline and under modulated 
conditions.  
Phosphorylation sites for PKA and CaMKII are also found on the C-terminus of Rad 
[17, 92, 166, 177, 281]. Mutations of these regulatory sites within the C-terminus could 
provide insight into which are critical for modulation of the LTCC by Rad. For instance, 
mutations at the phosphorylation sites for PKA and/or CaMKII to create phospho-mimetics 
may help elucidate what protein-protein interactions are needed for higher Po, and whether 
this is a CaV-dependent or -independent mechanism [282]. Phospho-mimetics may also 
contribute to understanding of Rad localization within the complex or cytosol under 
modulated conditions, and whether ‘super-clusters’ of LTCCs form without stimulation of 
-ARs. These studies would not only help understand modulation in the ventricle, but also 
the sinoatrial node.   
The effects of the C-terminal deletion of Rad were not investigated in the sinoatrial 
node in this dissertation.  Future studies should investigate whether Rad-Flag A277X 
displays the same ICa,L phenotype and exhibits the same effect on heart rate and heart rate 
variability as cRadKO. The prediction would be that Rad-Flag A277X would be 
indistinguishable from cRadKO in regards to SANcm ICa,L, heart rate, and heart rate 
variability. This would be critical to know if Rad is to serve as a therapeutic target as groups 
begin to develop small peptide inhibitors specifically made to inhibit calcium channels by 
altering the C-termini of RGK proteins [282].  
Another potentially intriguing pursuit of investigation would be to develop a N-
terminal deletion of Rad, and assess how this affects LTCC activity.  The functional 
significant of the N-terminus extension of Rad, or any RGK protein, remains unknown 
[20]. One study removed the N-terminus of Gem and reported reduced activity of the 




and all RGK proteins, contains a binding site for 14-3-3 [166].  This may be a crucial site 
for removal of Rad from the LTCC upon phosphorylation so that the IS6-AID linker can 
be stabilize higher Po [118, 166, 281]. The N-terminus may also contain other key binding 
sites that have yet to be discovered that could help explain how Rad-mediated inhibition 
occurs.   
8.7 Limitations 
A major implication of the studies conducted in this dissertation support Rad as a 
potential therapeutic target for positive inotropy.  However, these studies were limited to 
mouse models; mice have a larger sarcoplasmic reticulum calcium content and greater 
SERCA activity compared to larger species that may accommodate the drastic change in 
ICa,L better than larger animals [257, 268]. Repolarizing currents are also mostly conducted 
via Ito and IKur in mice, while larger species express IKr and IKs which could alter action 
potentials and QT interval in larger species that is not accounted for in mice [268]. It 
therefore is crucial that cardiac-specific Rad deletion be explored in larger animals or in 
model systems that better emulate human cardiac function. 
A critical factor that is unexplored in this dissertation is the effect of Rad deletion on 
other ion channels.  While there is no current evidence to suggest that Rad interacts with 
other channel complexes besides the LTCC, interactions may still exist.  It is also possible 
that other ion channels that are affected by intracellular calcium could experience 
secondary effects due to Rad deletion.  Indeed, it is possible that calcium-activated 
potassium channels could be activated in cRadKO so that balance is maintained in the 
plateau phase of the action potential and QT interval is not prolonged. This knowledge 
would become especially important in understanding the fight-or-flight response since this 
mechanism is conserved across multiple species.   
8.8 Conclusions 
Based on the results of the studies in this dissertation and literature that has been 
published during the course of this work, I speculate that Rad governs CaV1.2 channel 




Rad; this inhibition is relieved under conditions of -AR stimulation due to 
phosphorylation of Rad by PKA that allows different proteins to interact and deplete the 
LTCC of Rad. Because Rad serves as the critical modulator of LTCC in response to 
sympathetic drive, depleting the LTCC of Rad yields a chronically modulated channel. The 
resulting increase in peak ICa,L stimulates a larger calcium induced calcium release from 
the sarcoplasmic reticulum to enhance contraction; this is balanced through enhanced 
inactivation so that hypertrophic signaling is not initiated, nor is the late, arrhythmogenic 
component of ICa,L increased. Therefore, Rad deletion specifically from cardiomyocytes 
could serve as an ideal positive inotrope for heart failure treatment due to the novel 
mechanism to increase ICa,L in a manner that preserves structure, function, and the fight-or-




















List of Abbreviations 
 
AID   α-Interaction Domain 
AKAP15  A-kinase anchoring protein-15 
ANF   Atrial Natriuertic Factor 
ANOVA  Analysis of Variance 
ANS   Autonomic Nervous System 
AP    Action Potential 
APD   Action Potential Duration 
-AR   -Adrenergic Receptor 
BAPTA  1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
BW   Body Weight 
CaM   Calmodulin 
CaMKII  Calmodulin Kinase II 
cAMP   cyclic-AMP 
CDF   Calcium Dependent Facilitation 




CICR   Calcium Induced Calcium Release 
cRadKO  Cardiac-specific Rad Knockout (also known as Rad) 
CTGF   Connective Tissue Growth Factor 
CTNNA3  Catenin Alpha3 
CTRL   Control (also known as Radfl/fl) 
DAD   Delayed Afterdepolarization 
DHP   1,4-dihydropyridine 
dKO   12-Adrenergic Receptor Double Knockout 
EAD   Early Afterdepolarization 
ECG   Electrocardiogram 
EF   Ejection Fraction 
EGTA   Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid 
FDR   False Discovery Rate 
GAPDH  Glyceraldehyde-3-phosphate Dehydrogenase 
GK   Guanylate kinase 
gRAD-/-  Whole Body Rad Deletion 
HCN4   Hyperpolarization-activated Cyclic Nucleotide Gated Channel 4 




HERG   human Ether-à-go-go-Related Gene Potassium Channel 
HF   Heart Failure 
HFrEF   Heart Failure with Reduced Ejection Fraction 
HR   Heart Rate 
HRV   Heart Rate Variability 
HVA   High-voltage-activated 
HW   Heart Weight 
I   Macroscopic Current 
i   Unitary Current Through an Open Pore    
ICa,L   L-type Calcium Current 
ISO   Isoproterenol 
LTCC   L-type Calcium Channel 
LQTS   Long QT Syndrome 
LVA   Low-voltage-activated 
LVAW  Left Ventricular Anterior Wall 
LVID   Left Ventricular Inner Dimension 
LVPW   Left Ventricular Posterior Wall 




MEF2   Myocyte Enhancer Factor 2 
MerCreMer  Tamoxifen-Inducible Cre Recombinase 
MHC   -Myosin Heavy Chain 
MI   Myocardial Infarction 
NCX   Na+/Ca2+ Exchanger 
NFAT   Nuclear Factor of Activated T Cells 
NT   Total Number of Channels 
PCR   Polymerase Chain Reaction 
PDE   Phosphodiesterase 
Pf   Probability that a Given Channel is Available 
PKA   Protein Kinase A 
PKC   Protein Kinase C 
PLN   Phospholamban 
Po   Probability that the Channel will be Open 
qRT   Quantitative Real Time  
QTc   Corrected QT Interval 
RAD   Rad Associated with Diabetes 




Rad   Inducible, Myocardial-Restricted RAD Knockout 
Rad-Flag  Wild-Type 3xFlag-Rad 
Rad-Flag A277X  3xFlag-RadA277X 
RCAN1  Regulator of Calcineurin 1 
RT   Room Temperature 
RyR2   Ryanodine Receptor 2 
r30   Remaining Current 30 ms After Peak 
r150   Remaining Current 150 ms After Peak 
SAN   Sinoatrial Node 
SANcm  Sinoatrial Node Cardiomyocyte 
scRNA-seq  Single-cell RNA-sequencing 
SD   Standard Deviation 
SEM   Standard Error of Mean 
SERCA2a  Sarco/Endoplasmic Reticulum Calcium ATPase 
SH3   SRC Homology 3 
SNS   Sympathetic Nervous System 
SR   Sarcoplasmic Reticulum 




TAC   Transverse Aortic Constriction 
tKO   12-Adrenergic Receptor, Rad Triple Knockout 
TS   Timothy Syndrome 
t-SNE   t-distributed Stochastic Neighbor Embedding 
VGCC   Voltage-Gated Calcium Channel 
VDI   Voltage Dependent Inactivation 
WT   Wild-type
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